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SUMMARY
Prologue and Introduction
Epilepsy is a disease which has struck fear into the hearts of both sufferers and onlookers 
for many centuries. Only in the past hundred years or so has effective medication become 
available, and medical management still relies on a small group of antiepileptic drugs 
(AEDs). These can often abolish seizures, and very frequently diminish their frequency 
such that patients can enjoy a normal life-style. A significant minority of patients, 
however, do not respond satisfactorily. Combining different drugs is complicated by 
their sharing the same side-effect - sedation - which seems more additive than does any 
therapeutic effect. It is for the benefit of these patients with refractory epilepsy that 
research continues, to improve our use of the present AEDs, and to find new drugs which 
might, when used alone or in combination, improve their lot.
Therapeutic Drug Monitoring (TDM)
In Chapter 1, current use of TDM in the epilepsy clinic is analysed. By recording 
physicians’ decisions both before and after serum anticonvulsant concentrations were 
made available at 488 clinic visits, we found that management decisions were affected at 
23% of these consultations. However, physicians did not appear to follow a "target 
concentration strategy" as a high proportion of results (26%) in the "target range" were 
followed by a change in dosage. A drawback with the "target concentration strategy" was 
highlighted by the correlation between carbamazepine concentration and time since 
dosing (P<0.005). The possible benefits of an approach combining clinical and 
biochemical information are discussed.
Cognitive function
In Chapter 2, the effects of many AEDs on mental function are assessed. Deterioration in
24
"cognitive" or "psychomotor" abilities is a generally recognised side-effect of all current 
AEDs. However, most evidence compares patients taking AEDs with healthy volunteers, 
the effect on mental function of the disease itself thus being uncontrolled. Other studies 
show short term deterioration in volunteers given AEDs for a limited period, or in 
patients abruptly taking an increased dose. These respectively fail to allow for any 
beneficial effect which controlling seizures might have on mental function, and the effect 
of tolerance to the drugs’ side-effects.
In EXPT. 2, 66 patients on AED therapy performed a battery of psychomotor function 
tests, and their results were compared with those of 14 untreated epileptic patients and 11 
healthy controls. A clear "step-wise" deterioration in function was seen with reaction 
times, short-term memory, card-sorting, and finger-tapping speeds. Untreated epileptics 
fared worse than controls (P<0.05 - PcO.OOl) but better than treated patients (P<0.05 - 
PcO.Ol). This demonstrated the deliterious effect of epilepsy itself. The drugs may 
aggravate this, though clearly the treated patients had more severe epilepsy. No 
differences were found between the individual drugs.
In EXPT. 3, the effect of tolerance was demonstrated in a small group (n=13) of new 
patients commenced on carbamazepine. After an initial deterioration in reaction time 
(P<0.05) and finger-tapping (PcO.OOl) at one week, these abilities returned to normal by 
twelve weeks, while mean serum concentrations of carbamazepine only fell from 8.5 
mg/L to 7.1 mg/L. The relevance of short-term cognitive deterioration demonstrated in 
many studies is thus brought into question.
Since diurnal variation in serum concentrations has been shown to correlate with 
carbamazepine neurotoxicity, EXPT. 4 tested the pharmacokinetics of a controlled- 
release preparation (Tegretol Retard, CBZ-CR). Eight healthy volunteers took this and
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conventional carbamazepine 200mg bd for two weeks in a double-blind, crossover 
fashion. Serum concentrations "plateaued" for 56h after single dose CBZ-CR, while 
chronic dosing resulted in diurnal fluctuation of only 12% compared with 24% on 
conventional carbamazepine (P<0.025), and produced less rapid changes in concentration 
(P<0.02). Enzyme induction appeared similar with both preparations, but the 
bioavailability of CBZ-CR was possibly slightly lower. The "smoother" pharmacokinetic 
profile of CBZ-CR did not produce a detectable improvement in psychomotor function.
Enzyme induction
Many AEDs (carbamazepine, phenytoin, phenobarbitone) induce an increase in hepatic 
metabolising enzyme activity. This results in accelerated metabolism of the drugs 
themselves, of some other drugs which undergo oxidative metabolism, and of 
endogenous hormones. The clinical implications of this last aspect remain unclear.
In EXPTS. 5 and 6, thyroid and sex hormone concentrations were measured in 54 young 
epileptic men taking a variety of AEDs, and compared with the results in 14 untreated 
epileptics and 16 healthy controls. Falls in total and free thyroxine were confirmed in 
patients taking the inducing drugs carbamazepine and phenytoin. Nine such patients were 
in the "hypothyroid" range, but none had increased TSH concentrations or TSH response 
to TRH stimulation. Sodium valproate (a non-inducer) showed no effect, supporting the 
case for enzyme induction as the mechanism responsible for the phenomenon.
Concentrations of the sex hormone dehydroepiandrosterone sulphate were also reduced 
in induced patients (PcO.OOOl), while sex hormone binding globulin levels were 
increased (PcO.OOOl) causing a tendency for free testosterone to be lowered (P=0.06). 
These effects might help explain the reported hyposexuality in epilepsy. Again, sodium 
valproate showed no effect.
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The keto-analogue of carbamazepine - oxcarbazepine - is reported to have similar 
efficacy to the parent compound, but not to cause enzyme induction. In EXPT. 7, this 
drug was given to eight healthy volunteers, in a dose of 300mg bd for two weeks, and 
various markers of enzyme induction were measured. Half-life of the drug’s active 
metabolite - 10-hydroxy carbazepine - was unaltered. Similarly, antipyrine metabolism, 
6-beta hydroxy cortisol excretion, and endogenous hormone concentrations did not 
change during two weeks therapy. Oxcarbazepine may provide an improvement on 
carbamazepine in patients taking other drugs or those complaining of sexual difficulties.
It is, however, not proven that hormonal changes due to AED therapy affect sexual 
function. A long-term study of sexual function, hormone levels and AED concentrations 
in patients and controls is in progress in our unit. These and other possibly important 
factors, such as education and upbringing, will be correlated.
Calcium antagonists
Calcium influx across the neuronal cellular membrane is essential for intrinsic burst 
firing and the abnormal action potentials at the heart of initiating epileptogenic activity. 
Calcium antagonists inhibit these features in vitro, and are effective in many animal 
models of epilepsy. The dihydropyridines (e.g. nifedipine, nimodipine) have been 
particularly effective, promoting their appraisal as possible adjuvant AEDs.
EXPT. 8 was an open study of nifedipine in twelve epileptic patients given the drug as 
adjuvant therapy for three months. Eight patients completed the study, all of whom 
reported a decrease in seizure frequency compared with the previous three months 
(PcO.Ol). Two hitherto refractory patients remained seizure-free throughout the trial 
period. Since there was no placebo group, however, further investigation was required.
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EXPTS. 9 and 10 were performed on mice, to supply pharmacokinetic data, and to assess 
the relative efficacies of nifedipine and nimodipine, the former drug having been largely 
ignored in previous work. Intraperitoneal injection of the dihydropyridines (6 mg/kg) 
followed by sacrifice of the animals at different time points allowed the estimation of 
half-lives in mouse blood and brain respectively for nifedipine (11.2min, 14.7min) and 
nimodipine (16.7min, 22.4min). Both drugs easily crossed the blood-brain-barrier, 
whether dissolved in alcohol/water (50/50) or suspended in Tween 80.
Using a pentylenetetrazol-induced seizure model, both drugs and carbamazepine were 
shown to be effective, orally and parenterally, in delaying seizure onset. However, 
nifedipine combined with carbamazepine was ineffective, suggesting a possible 
interaction.
EXPT. 11 was a placebo-controlled trial of nifedipine in 22 patients with refractory 
epilepsy. Only in the first of the two months active therapy did nifedipine show a 
significant improvement on placebo (P<0.05). EEG scores were also improved during 
active treatment (P<0.05), but, overall, the results were disappointing. A possible reason 
was the low circulating concentrations of nifedipine - less than half of those considered 
effective in angina. A significant correlation between seizure control and serum levels 
further suggested that the drug might be effective if taken in adequate dosage.
In EXPT. 12, nimodipine also disappointed in a placebo-controlled study in 22 patients. 
Again, circulating concentrations of the drug were low, and might explain its lack of 
efficacy.
An alternative explanation for the drugs’ failure to impress in clinical trials was 
investigated in EXPT. 13. Possible mechanisms of action of established AEDs such as
28
carbamazepine include an effect on adenosine, one of "the brain’s natural 
anticonvulsants". Carbamazepine has been shown to increase adenosine receptors in 
mouse brain. Using a binding assay involving [JH]cyclohexyladenosine as radioligand at 
concentrations of 0.2nM - 29nM, we calculated adenosine receptor numbers and affinity 
in three areas of mouse brain. A slight increase in receptor numbers in the cerebellum of 
mice treated with carbamazepine was confirmed, but the dihydropyridines decreased the 
affinity of the same receptors.
This might be the basis of a deliterious interaction between carbamazepine and the 
dihydropyridines, reducing efficacy in clinical trials. It seems, however, more likely that 
enzyme induction due to concomitant AED therapy decreases the dihydropyridine’s half- 
life and reduces concentrations. Further pharmacokinetic and dose-ranging studies are 
proposed - both in mice and man - for the novel dihydropyridine amlodipine, which has a 
longer half-life (35h) than nifedipine (6h) or nimodipine (2h). Meanwhile, we are 
continuing to assess the possibility that a more subtle interaction - perhaps involving the 
adenosine receptor, or even the dihydropyridine receptor (carbamazepine and other 
AEDs have calcium antagonist activity) - may underlie the relative failure of 
dihydropyridines in the clinical setting. It would be surprising if the calcium antagonists, 
with all their theoretical promise and success in seizure models, did not produce one 
useful antiepileptic drug.
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"RECOVERING SOUL"
Over the course of history the management of epilepsy has probably made use of a 
greater variety of remedies than that of any other disease. This reflects the long-standing 
bewilderment over its likely cause. In many societies, the aetiology of epilepsy has been 
attributed to the work of evil spirits. Indeed, the oldest written account of epilepsy so far 
known - that of a Babylonian treatise discovered on a stone tablet in South Turkey 
[Kinnier Wilson & Reynolds 1990] - is adamant: "If epilepsy falls once upon a 
person....it is the result of possession by a demon or departed spirit" and goes on to 
describe which demons cause which type of seizure. Other societies blamed friendly 
spirits. Hippocrates "et al" (c. 400 B.C.) was the first to ridicule this latter concept of 
"The Sacred Disease" as "a shelter for ignorant and fraudulent practices" [Temkin 
1971a]. His suspicions fell upon the brain where, he felt, an excess of phlegm overspilled 
into the bloodstream. Widespread belief in the epileptogenic effect of attacks by spirits or 
demons, however, was slow to disappear. In Biblical times, it remained the conventional 
wisdom, as witness the Evangelist Mark’s description of "the epileptic demoniac":
there is a spirit of dumbness in him, and when it takes hold of him it 
throws him to the ground, and he foams at the mouth and grinds his teeth 
and goes rigid [Mark 9: 18]
to which Luke adds:
it is slow to leave him, but when it does it leaves the boy worn out
[Luke 9: 37]
The very word "epilepsy" comes from the Greek ’epilambanein’ which means ’to seize’
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or ’to attack’ and such nomenclature continues to the present day, perhaps bringing with 
it an associated stigma.
From earliest days, however, we can also find precise clinical observations, such as the 
Hippocratic mention of convulsions on the contralateral side to skull injuries, or the 
superb description by Lucretius (? 2nd century A.D.) of a tonic-clonic seizure:
As if by stroke of lightning, tumble down 
Before our eyes, and sputter forth and grunt,
Blither, and twist about with sinews taut,
Gasp up in starts, and weary out his limbs
With tossing round......
Until eventually the patient
...Arises reeling, and gradually comes back
To all his senses and recovers soul. [Temkin 1971b]
Since the Ancients variously attributed the disease to demons, phlegms and the phases of 
the moon, it is hardly surprising that the remedies were equally disparate. Dietary 
measures were legion and ranged from abstention from meat to the avoidance of all food 
and drink. Phlebotomy or the drinking of vinegar were other simple measures, while 
more bizarre procedures included the provocation of sneezing last thing at night, or the 
rubbing of affected limbs with the genitals of a seal [Temkin 1971b]. The most direct 
approach was "trephining" - the production of a large hole in the skull, usually by 
cautery. Its versatility clearly suited all aetiologies as it could be used to allow the escape 
of phlegm or vapours - or indeed evil spirits - as required.
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Progress in understanding the "Falling Sickness" [attrib. Paracelsus; cf. Esquirol 1845] 
was slow. Galen’s idea (130-200 A.D.) of "animal spirits" in body tubes was still being 
quoted by Willis in the late 17th century [Stevens 1973]. Social attitudes were also slow 
to progress. Although Aristotle had long-before espoused an association between 
epilepsy and genius (still contemplated to this day cf. Caesar, Petrarch, Napoleon, 
Moliere, Van Gogh, Dostoyevsky), Albich in the 18th century warned "neither talk nor 
bathe with them, since by their mere breath they infect people" [Temkin 1971c].
During the more rational approach of the "Enlightenment" of the 18th and 19th centuries, 
attempts were made to classify epilepsy into idiopathic and secondary epilepsies, whose 
causes ranged from the respectably traumatic to the witnessing of a seizure while 
pregnant [Esquirol 1845]. The association with the moon’s phases was scientifically laid 
to rest by Leuret [Temkin 197Id] notwithstanding today’s interest in catamenial 
epilepsy, which was also noted in the early 18th century by Maisonneuve [Esquirol 
1845].
"Modem epilepsy" may have begun with John Hughlings Jackson, who linked new 
electrophysiological evidence discovered by Fritz & Hitzig in 1870 with clinical 
observations in his "Investigation of Epilepsies" [1873] and defined epilepsy as "the 
name for occasional, sudden, excessive, rapid and local discharges of grey matter." Yet, 
Jackson still claimed "there can be no question that the ligature is a most valuable means 
of arresting such fits" [1873].
Some attempts at scientific evaluation of therapies, however, were proceeding. Around 
1840, Esquirol twice-yearly submitted 30 female patients to a different traditional or 
novel remedy. A fine demonstration of the placebo response ensued:
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"A new medicine invariably suspended the attacks with some, 
for fifteen days; for a month, two months, and even three 
months, with others." [Esquirol 1845]
Nitrate of silver remained the thinking-man’s drug of choice [Pereira 1839] until 1857, 
when the first mention of potassium bromide was made during a paper at a meeting of 
the Royal Medical and Chirurgical Society in London [Sieveking 1857]. Bromide, 
probably the first genuinely effective therapy, was championed by Locock, and was used 
by Hammond in 288 patients, producing an improvement in 243, with total seizure 
control in 91 [Hammond 1871]. The related potassium iodide was used by others, 
including Charcot [Charcot 1881].
Response to the availability of these drugs was perhaps over-enthusiastic. Overdosing 
was common: "As you see, he is broken down in appearance, has large abscesses in his 
neck, and is altogether in a bad condition. But this is better than to have epilepsy." 
(Hammond) [Temkin 197le] This, however, has to be viewed alongside contemporary 
practices. A series of 72 cases of trephining was published as late as 1861, and in 1866 
cliteroidectomy was still being practised by Baker [Duffy 1963]. By the 1880s, however, 
surgery aimed at removing affected parts of the brain was meeting with more 
conventional success. The foundations of modern-day therapy had been laid.
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INTRODUCTION
Classification of epilepsy
Drug treatment of epilepsy is dependent on some degree of classification of the disease. 
The official classification [CCTILAE 1989] is a complicated hotch-potch of syndromes, 
but does acknowledge the major division of epilepsies into generalised seizures 
(generalised tonic-clonic seizures, absences, myoclonic, tonic, clonic) and epilepsies with 
partial or focal seizures (origins in frontal, temporal, parietal and occipital lobes). It is the 
management of generalised tonic-clonic (GTCS) and partial seizures with or without 
secondary generalisation which forms the basis of this thesis on adult epilepsy.
Partial seizures may be simple or complex (where there is loss of awareness) and may 
vary in character, depending on their site of origin in the brain. These are the epilepsies 
most often associated with a preceding "aura" and with other localising features such as 
deja vu phenomena and automatisms. Often, they are "symptomatic" epilepsies 
associated with a single anatomical or functional lesion, but "idiopathic" varieties do 
occur, where investigation may reveal more diffuse localisation of the origin, perhaps 
involving both hemispheres. Partial seizures may progress to secondary generalised 
seizures which can mimic entirely the presentation of a GTCS. Differentiation is best 
attempted by analysis of the initial clinical or encephalographic changes as it is early 
bilateral involvement which characterises the primary GTCS. Most patients presenting at 
the epilepsy clinic can be classified as suffering from generalised seizures alone, from 
partial seizures alone, or from both partial and secondary generalised seizures.
Clinical and pharmacokinetic data on the major anticonvulsants (or antiepileptic drugs - 
AEDs) which were available in 1986 are shown in Tables 1 and 2 [adapted from Brodie 
1990]. It is generally accepted that the three "first-line" drugs from this group are
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carbamazepine, phenytoin and sodium valproate. A case can be made for ethosuximide 
as the drug of choice in childhood absence seizures [Mikati & Browne 1988] (although 
its efficacy is at least equalled by sodium valproate [Sato et al. 1982]), but it has no place 
in the management of other epilepsies.
Primidone (PRIM) has undoubted anticonvulsant activity both in animals [Bogue & 
Carrington 1953] and in patients [Gruber et al. 1957, White et al. 1966] but suffers from 
important drawbacks. These include the presence of phenobarbitone as a major 
metabolite [Butler & Waddell 1956], which makes the anticonvulsant activity of 
primidone itself more difficult to assess. In a recent large controlled trial of 
carbamazepine, phenytoin, phenobarbitone and primidone [Mattson et al. 1985], the last 
was easily the least effective and least-well tolerated drug of the four. From the earliest 
animal studies [Barnes 1960], marked sedation has been recognised as a side-effect of 
primidone.This and other side-effects, such as gastrointestinal intolerance and psychosis, 
often lead to discontinuation of the drug [Mattson et al. 1985]. Physical dependence 
[Frey 1985] and withdrawal seizures [Norton 1970] are also major problems. There is 
thus no place for primidone as a first-line drug in the present-day management of 
epilepsy.
Phenobarbitone (PB), whose anticonvulsant properties were first discovered in 1912 by 
Loewe et al. [Gallagher & Freer 1985], suffers from many of the same drawbacks as 
primidone. It is highly sedative [Schmidt 1985] and can also cause hyperactivity and 
irritability [Consensus Statement 1980]. The long-term sequelae of its undoubted effects 
on higher cortical function [Guest et al. 1970, Consensus Statement 1980] are not yet 
clear. Tolerance occurs [Gallagher & Freer 1985] and withdrawal often provokes
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seizures [Buchthal et al. 1968]. However, it lacks the added complication of a highly 
active metabolite, and was shown in the "Veterans’ study" to be superior to primidone in 
treating secondary generalised seizures with respect to both efficacy and side-effects 
[Mattson et al. 1985]. While it is no longer a first-line drug, many patients continue to be 
well-controlled on phenobarbitone, and the problems of withdrawal often argue against 
stopping the drug entirely. It remains a possible second-line drug, to be considered in 
preference to primidone, and continues to play a major role in antiepileptic therapy in 
developing countries.
The benzodiazepines are the most recent entrants to Tables 1 and 2. Anticonvulsant 
effects were first demonstrated against electroshock and pentylenetetrazol-induced 
seizures in animals in 1960 by Randall and his colleagues. While diazepam remains 
arguably the drug of choice for status epilepticus [Simon 1985], the derivatives clobazam 
and clonazepam are most often used in epilepsy on a chronic basis. Both clonazepam 
[Shakir 1979, Mikkelsen et al. 1981] and clobazam [Allen JW et al. 1983] are effective 
adjuvant therapy in controlled studies, and clobazam in particular has markedly reduced 
sedative properties compared to typical benzodiazepines [Hindmarch & Gudgeon 1980, 
Trimble & Robertson 1986]. However, withdrawal seizures can be a problem [Fialip et 
al. 1987, Allen JW et al 1983] and loss of efficacy after variable periods of time on the 
drug has been widely reported [Trimble & Robertson 1986]. Clobazam is thus a useful 
member of the available group of anticonvulsants, and may have a particular place as 
adjunctive short-term therapy. In catamenial epilepsy, short courses of the drug around 
the time of menstruation have proven effective [Feely et al. 1982].
Phenytoin (PHT) was the first of the three first-line anticonvulsants to come into general 
use [Merrit & Putnam 1938]. Its main advantage at that time over phenobarbitone was its
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activity against partial seizures, which had largely remained refractory to therapy [Jones 
& Wimbish 1985]. It was also obvious clinically that it was a less sedative drug. More 
sophisticated approaches have since suggested that it does cause some impairment of 
psychomotor and cognitive processing [Thompson et al 1981, Andrewes et al 1986]. 
These findings, however, have not been universal, and some studies have shown 
improved mental function in "retarded" epileptic patients [Goldberg & Kurland 1970], or 
"healthy" elderly subjects [Smith & Lowry 1975]. In toxic concentrations, phenytoin can 
cause ataxia, nystagmus, diplopia and vertigo [Reynolds 1989]. Its chronic side-effects 
include hirsutism and gum hyperplasia. It is thus often a cosmetically displeasing drug, 
but it is largely free from life-threatening side-effects. Interference with vitamin D 
metabolism may produce a degree of hypocalcaemia and osteomalacia [Ashworth & 
Horn 1977], while a mild macrocytic anaemia due to folate deficiency may also occur 
[Jones & Wimbish 1985]. Similar problems are found with phenobarbitone [Gallagher & 
Freer 1985]. The risk of the "foetal hydantoin syndrome" [Hanson et al 1976] has 
inhibited the use of phenytoin in pregnancy, but any gain from avoiding the drug has to 
be weighed against possible risks to the foetus from impaired seizure control. Phenytoin 
remains a very useful drug; perhaps less so in young women, but its once-daily dosage 
regimen is often an advantage.
Carbamazepine (CBZ), a drug chemically related to the tricyclic antidepressants, was 
introduced in 1963 [Theobald & Kunz 1963]. Its efficacy was found to be similar to that 
of primidone [Rodin et al 1976], and it has become a major anticonvulsant, particularly 
for partial seizures [Cereghino et al 1974, Troupin et al 1977]. It has generally low 
toxicity, although rashes occur in approximately 5% of patients [Pellock et al 1984] and 
hyponatraemia is a recognised side-effect [Gram & Jensen 1989]. The occasional
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leucopenia and rare aplastic anaemia at one time prompted the use of haematological 
monitoring [Hart & Easton 1982] but this is now largely discarded [Loiseau & Duche 
1989]. As with the other major anticonvulsants, CBZ does have neurological side-effects, 
mainly nausea, headache, dizziness and diplopia. Many of these may in part be 
associated with serum concentrations of the active metabolite carbamazepine-10,11- 
epoxide (CBZ-E) [Patsalos et al 1985, Schoemann et al 1984]. It is arguable that CBZ is 
one of the least sedative of the anticonvulsants [Thompson & Trimble 1982a, Andrewes 
et al 1986] although a definite effect on psychomotor function has been demonstrated in 
both healthy volunteers [Macphee et al 1986a] and patients [Macphee et al 1986b]. It 
may also produce some elevation of mood [Dalby 1975, Loiseau & Duche 1989] 
suggesting usefulness in patients with depression. The success of carbamazepine has led 
to the production of slow-release preparations and derived drugs such as oxcarbazepine, 
the place of which will be considered later.
The antiepileptic properties of sodium valproate (VPA) were first discovered 
accidentally in 1963 when valproic acid was being used in animal studies as a solvent for 
the drugs which were being formally tested [Meunier et al 1963]. As the most recently 
introduced of the major anticonvulsants, VPA has a wide background of successful trials 
in various animal models of epilepsy [Loscher 1985]. Clinical studies confirmed its 
efficacy in GTCS [Gram & Bentsen 1984, Shakir et al 1981] and partial epilepsy [Shakir 
et al 1981] as well as other epilepsies [Gram & Bentsen 1985]. It is a viable alternative to 
CBZ and PHT in both GTCS and partial seizures, while maintaining an advantage over 
them in myoclonic epilepsy and absence attacks [Sato et al 1982, Gram & Bentsen 1985, 
Fariello & Smith 1989]. Side-effects include hair loss, weight gain, and a tremor 
resembling benign essential tremor [Gram & Bentsen 1985]. These problems usually 
resolve with dose reduction or, if necessary, cessation of the drug. More worrying are the 
rare episodes of hepatitis, pancreatitis, thrombocytopenia or coma [Dreifuss 1989].
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Fortunately, the incidence of these serious problems is low, even in children, where the 
overall incidence particularly of hepatitis is increased owing to the occasional patient 
with a metabolic defect [Gram & Bentsen 1985]. It is thus a close choice between VPA 
and ethosuximide for absence seizures, while VPA remains a useful drug of 
comparatively low toxicity in adult patients. It shares with carbamazepine a reputation 
for causing less sedation than some of the other anticonvulsants [Thompson & Trimble 
1981, 1982a]. It is also notable for its lack of enzyme induction, and may be an enzyme 
inhibitor [Kapetanovic & Kupferberg 1980, Koch et al 1981] which could lead to toxicity 
if it is added to longstanding AED therapy [Levy & Koch 1982].
Scope of thesis
I have outlined above the background of the drugs currently used in epilepsy. This thesis 
will approach the problem of improving anticonvulsant therapy in two parts. In the first, 
an investigation will be made of the way in which these drugs are presently used, and of 
their drawbacks, with particular reference to psychomotor impairment and enzyme 
induction. A new formulation (controlled-release carbamazepine - "Tegretol Retard") and 
a new keto-analogue of carbamazepine (oxcarbazepine) will be assessed as we look for 
small but important advances in current therapeutic modalities. In the second part, I shall 
be investigating the potential of a new group of drugs for epilepsy - the calcium 
antagonists - in both clinical and animal studies.
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RECURRENT METHODS
Drug Assays
Assays of the common anticonvulsants CBZ, PHT, VPA and PB were all performed 
using an enzyme-mediated immunoassay technique (EMIT-SYVA, Palo Alto). A 
previously described [Macphee et al 1984] modification of the high performance liquid 
chromatography (h.p.l.c.) method of Meijer [1981] was utilised to measure CBZ-10,11- 
epoxide, and used 5-(p methyl-phenyl)-5-phenyl hydantoin as internal standard.
Unbound CBZ concentrations were assayed by equilibrium dialysis using teflon dialysis 
cells separated by a presoaked semipermeable membrane (Dianorm). Plasma (0.9ml) and
0.13M (0.9ml) phosphate buffer were rotated at 4 r.p.m. for 24h in a water bath at 37 °C. 
Free CBZ concentration was calculated from the following equation:
f = C1(F) /  C1(0) - C1(F)
where f=free fraction; Cl(F)=final concentration of free ligand; and Cl(0)=starting 
concentration of ligand [Macphee et al 1986a]. Antipyrine was measured using a 
modification of the h.p.l.c. method of Shargel [1979] as outlined by Macphee et al 
[1984].
These assays were all performed in the laboratories of the Department of Medicine & 
Therapeutics (previously Department of Medicine), Western Infirmary, unless otherwise 
stated. Blood samples were centrifuged after allowing time for clotting, and the serum 
was stored at -20°C or lower until all of the appropriate samples had been obtained. 
Assays were then performed in batches to offset any slight time-to-time variation in the 
assays.
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Pharmacokinetics
Antipyrine kinetics following oral ingestion of 600mg antipyrine were used as a measure 
of enzyme induction. Patients supplied 5ml samples of saliva for analysis after 0, 3, 5, 8, 
12, 24 and 32 hours. Kinetic parameters were obtained using computer-assisted analysis. 
Antipyrine kinetics were routinely calculated in the laboratory using least-squares 
regression analysis assuming a one-compartmental model. The programme for Apple HE 
microcomputer has been previously outlined [Bimie 1986a]. Kinetics of CBZ and other 
drugs were calculated by myself using a kinetics programme adapted for use on an 
Apricot F10 microcomputer [Bimie 1986b]. Later the statistical and pharmacokinetic 
package "STATIS" [CLYDESOFT] became available and was used for the analysis in 
EXPT 9.
Statistics
In general, statistical comparisons between groups were made using non-parametric tests. 
In some cases, the groups were reasonably large, and parametric testing might be deemed 
appropriate, but as few presumptions as possible have been made. The Wilcoxon rank 
test (or equivalent Mann-Whitney "U" test) has been used in many cases, with "matched- 
pairs" testing of related samples (usually the same patient on different regimens) where 
appropriate. Where more than two groups are being compared, an initial non-parametric 
test of analysis of variance (Kruskal-Wallis or Friedrich’s analysis of variance) has been 
performed to decide whether there is a significant variation between all groups before 
going on to test specific pairs. This makes some allowance for the problems of multiple 
group vs. group analysis, as its failure to demonstrate a significant variance between all 
groups points against going any further with individual testing. This, however, results in 
the test being arguably too conservative, and an effort has been made to discuss the 
ramifications of this where appropriate e.g. EXPT. 8.
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While non-parametric tests are employed, the presentation of data as medians and ranges 
has largely been avoided. Although more logical, such presentation is so rarely employed 
that the reader, in my opinion, does not develope any "feel" for data shown in this 
manner. Therefore, means with standard deviation (SD) or standard errors of mean 
(SEM) are shown for illustrative purposes in most figures where the full data set would 
be inappropriate. Correlations quoted are either Pearson’s product moment correlations 
(r) or Spearmann rank correlations (rs). All statistics were performed by myself either by 
hand or using MINITABS (release 5.1) on an Apricot F10 microcomputer. The methods 
for hand-performed tests, and the choice of test in each situation was determined from 
the monographs of Siegel [1956] and Howell [1985].
Consent
Patients and volunteers gave informed consent to their participation in all of the studies 
and trials; in particular, written consent was obtained for EXPTS. 3, 4 ,7 , 8 ,10 and 11. 
All experiments received approval from the local ethics committee, and animal studies 
were approved by the Home Office.
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PA R T I  
CURRENT PROBLEMS WITH ANTIEPILEPTIC DRUGS
This part will consist of three chapters. In the first, therapeutic drug monitoring (TDM) 
will be discussed and its influence in the epilepsy clinic in the Western Infirmary will be 
assessed. This will also give some demographic data on the patients attending the clinic, 
from whom subjects will be drawn for the later studies. Chapter 2 will discuss the 
ubiquitous side-effect of psychomotor and cognitive impairment with anticonvulsants 
and includes a cross-sectional study in the clinic. The efficiency of a controlled-release 
carbamazepine in "smoothing" diurnal variation of serum concentrations and thus 
possibly reducing sedation will be investigated. In chapter 3, the impact of enzyme 
induction, which is exhibited by many anticonvulsants, on exogenous hormones will be 
assessed, and the claimed lack of enzyme induction with oxcarbazepine will be tested.
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CHAPTER 1 
THERAPEUTIC DRUG MONITORING
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CHAPTER 1
THERA PEU TIC DRUG M ONITORING
INTRODUCTION
The correlation between clinical effects and serum drug concentrations was first 
investigated using antibiotics during the Second World War [Marshall 1940] and was 
later demonstrated with antimalarials [Shannon 1946]. From these beginnings, there has 
evolved a "target concentration strategy" of therapeutic drug monitoring (TDM) [Spector 
et al. 1988] whereby efforts are made to bring serum drug concentrations into a 
predetermined "therapeutic range" for that drug. Indeed, some would include "ensuring 
that plasma concentrations lie within a ’therapeutic’ range" in their definition of TDM 
[Whiting et al 1984]. Vozeh [1987] more simply defines TDM as "(Routine) use of drug 
concentrations to individualise dosage."
The attributes of an appropriate drug are outlined in Table 3. [Spector et al 1988]. The 
"bottom line" is the belief that serum concentrations correlate better with clinical effect 
than does dosage. Of the anticonvulsants, phenytoin best fulfils these criteria, and its 
saturable kinetics, resulting in large concentration increases for relatively small changes 
in dosage [Richens & Warrington 1979], make it particularly suitable for TDM.
However, extrapolation of phenytoin’s suitability to other AEDs has not met with 
universal approval [Chadwick 1987].
Carbamazepine, like phenytoin, has a pharmacological effect generally proportional to 
serum concentration, but this is less true of VPA and the barbiturates [Chadwick 1985, 
Brodie & Feely 1988]. With VPA in particular, accumulation in the brain may be a 
relevant factor [Schobben et al 1980] and plasma concentrations may correlate only with
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TABLE 3 APPROPRIATE DRUG FOR TDM
1. Efficient and relatively inexpensive assay available
2. Interindividual variation in drug absorption, 
elimination and distribution
3. Pharmacokinetic data available
4. Pharmacological effect proportional to serum concentration
5. Narrow therapeutic ratio
6. Constant pharmacological effect over extended time period
7. Therapeutic and toxic ranges well defined
[Adapted from Spector et al 1988]
toxicity and then only crudely [Turnbull et al 1983].
Most controversy, however, is aroused by the question of "well-defined therapeutic and 
toxic ranges" (No. 7). Many would argue that no drug fulfils this criterion, and that 
therapeutic ranges are an oversimplification. We can examine the range (10-20mg/L) of 
the "ideal" drug phenytoin as an example. Buchthal et al [1960] first looked at 12 
patients new to PHT. On constant dosage for "three to four weeks" those with serum 
concentrations below 10 mg/L showed no clinical improvement, while those above did 
better. This rather arbitrary figure was then used as a cut-off point in assessing out­
patients and showed - not surprisingly - that those with levels above this figure were 
better controlled than those below. Lund [1974] also showed that increased 
concentrations correlate with better control, but seizure count was already improving at 
concentrations around 6 mg/L. He also pointed out that an increase from 11.7 to 15 mg/L 
in the group - a change within the therapeutic range - produced an improvement in 
seizure control. Further work has shown complete control of seizures to occur at varying 
levels ranging from 3 to 50 mg/L [Schmidt & Haenel 1984]. It seems likely and logical 
that, with increasing PHT concentrations, more seizures will come under control, and 
that there is no magical figure above which this will occur.
The upper level of the range is even less well formulated. Buchthal et al [1960] gave 10- 
20 mg/L as a vague range where efficacy might be expected, while they found no serious 
neurotoxicity below 30 mg/L (mild symptoms began above 14 mg/L). Lund [1974] also 
found very little toxicity below 25 mg/L, while recently it has been suggested that these 
side-effects tend to appear only at much higher levels [Gannaway & Mawer 1981].
Despite such evidence, the range of 10-20 mg/L has been handed down almost as a sine 
qua non for PHT therapy. While the early studies were clearly useful in providing 
guidelines to the use of PHT, the further stage of treating blood levels as the most
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important aspect of patient management - the "target concentration strategy" - is not 
justified by their observational results. It is doubtful whether the original authors would 
have envisaged such an extrapolation. The argument is further complicated by the 
suggestion of a "therapeutic window" whereby seizures recur above a certain 
concentration of PHT. The initial observation of seizure-like activity in animals given 
high-dose PHT [Gruber et al 1940] was later shown not to be accompanied by 
epileptogenic EEG activity [Bazemore & Zuckermann 1974]. Clinical studies have since 
postulated a "window" [Troupin & Ojemann 1975], but a careful study by Osorio and 
colleagues [1989] has virtually discounted such an occurence, although a small 
proconvulsant action of PHT could not be excluded. This would be in keeping with a 
previous appraisal of increased seizures in "phenytoin-toxic" patients [Stilman & Masdeu 
1985] where one patient did not have epilepsy but suffered seizures following accidental 
ingestion of PHT.
There have been recent expressions of concern over clinicians’ requests for, and 
application of serum drug concentrations in all specialties. Up to 74% of requests have 
been deemed "inappropriate" [Levine et al 1988] while the same epithet has been 
attached to clinicians’ actions following 17-40% [Beardsley et al 1983, Bussey & 
Hoffman 1983] of results. One paper showed that seizure frequency only improved if 
"appropriate" action was taken [Beardsley et al 1983]. This is, in fact, one of the few 
instances where seizure control has been shown to be improved with TDM. However, 
confounding variables which may have resulted in "inappropriate" action were not 
analysed, and it shares with other papers the difficulty of defining "appropriateness". It 
may be necessary for a clinician to check drug concentrations not at steady-state or at an 
unusual time after ingestion. Allowances can be made for such problems clinically, but 
not in the protocol of many of these papers, which tend to be pharmacy-based [Pitterle et 
al 1985, Bussey & Hoffman 1983].
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Nevertheless, there is a growing feeling in many quarters that the measurement of drug 
concentrations may be overdone [Brodie et al 1985, Chadwick 1987] and valuable 
resources misspent [Bussey & Hoffman 1983, Vozeh 1987]. The ready availability of 
drug concentrations may itself encourage clinicians to measure these more frequently 
[Ried et al 1989] and perhaps adopt the strategy of chasing the "therapeutic" range, thus 
treating the anticonvulsant concentration rather than the patient - a policy which can be 
shown to cause unnecessary toxicity [Woo et al 1988]. Unnecessary treatment failure 
may also ensue in inexperienced hands, if drugs are abandoned because they are "in the 
therapeutic range" yet ineffective. Training may be beneficial, and it has recently been 
shown that the introduction of a formal TDM programme can reduce the number of 
requests for drug concentrations [Wing & Duff 1989].
Vozeh [1987] has outlined the difficulties of assessing the cost-effectiveness of TDM. 
Part of the assessment must include an estimate of how often an available drug 
concentration will affect management. This has been investigated with regard to 
anticonvulsants by Marty et al [1981] in a small study which included only 42 patients 
taking either PHT or CBZ. To assess the effect on clinical management in our epilepsy 
clinic, an anticonvulsant assay service was set up on-site. A record was made of the 
physicians’ clinical decisions before and immediately after the result became available. 
No specific instructions or protocol were followed for the adjustment of therapy, to allow 
analysis of the way clinicians would use such a service.
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EXPT. 1 A YEAR OF THERAPEUTIC DRUG MONITORING IN THE 
EPILEPSY CLINIC
AIM
To assess the impact of an on-site TDM service on patient management, and to 
investigate the way in which clinicians make use of such a service.
PATIENTS AND METHODS
The epilepsy service at the Western Infirmary is provided by Clinical Pharmacology. In 
1986, the clinic was manned by a consultant clinical pharmacologist, myself as NHS 
registrar, and a "rotating" medical Senior House Officer. During the year for which data 
are presented (February 1986-87), an average of 22 patients attended the clinic each 
week, four of whom were new referrals. Patients for the study were preselected as 
requiring active management. Indications for monitoring included poor seizure control, 
unwelcome polypharmacy, clinical toxicity, suspect compliance and the recent 
introducion of a new drug.
Of the 1162 patient attendances, 488 (42%) were monitored. A total of 632 drug assays 
were performed (277 carbamazepine, 170 phenytoin, 113 valproate, 72 phenobarbitone) 
in 182 individual patients, most of whom were studied on more than one occasion (one 
visit - 52, two visits - 48, three visits - 33, four visits - 23, five visits - 15, six visits - 4, 
seven visits - 6, eight visits -1). Of these patients, 117 had partial seizures with or without 
secondary generalisation, while 65 reported only generalised tonic-clonic convulsions. 
132 patients received one anticonvulsant, 47 took two, and 3 patients were treated with 
three antiepileptic drugs. These figures include monitored drugs only, and omit the
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benzodiazepines clobazam and clonazepam.
Age, type of epilepsy, dose of anticonvulsant(s), reason for assay, time of last dose and 
of blood sampling were entered for each study patient on a specially designed form prior 
to consultation (Figure 1). A venous blood sample was withdrawn from each patient and 
transferred into a lithium heparin tube for centrifugation and analysis. After the initial 
interview, the clinician recorded his or her management decisions on the same form. 
Anticonvulsant dose(s), addition or substitution of another drug, advice regarding poor 
compliance and time to next appointment were stipulated. The assay result(s) became 
available approximately 15 minutes after venepuncture. The doctor then noted whether 
the result was expected and reviewed his decisions while the patient waited.
Concentrations of CBZ, PHT, VPA and PB were measured using an enzyme 
immunoassay system (EMIT, Syva) and this service was kindly supplied by the Western 
Infirmary Biochemistry Department under the auspices of Prof. Percy-Robb. 
Phenobarbitone alone was assayed in the six patients taking primidone.
Statistics
Comparisons were made using non-parametric statistical tests. Chi-square test was 
employed for assessing the influence of: a) type of seizure on drug taken (PHT or CBZ, 
degrees of freedom = 1); b) concentration category (low, "therapeutic", high) on decision 
to change anticonvulsant dose (df = 2); and c) time-since-dosage on concentration 
category (df = 12). Drug doses and concentrations for different types of epilepsy were 
compared by the Mann Whitney ’U ’ test. Correlations quoted are Spearmann rank 
correlation coefficients.
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FIGURE 1 Proforma for study of therapeutic drug monitoring
RESULTS
Details of anticonvulsant drugs, doses and concentrations are shown in Table 4. 
Carbamazepine was the most commonly prescribed drug and was used in a larger 
proportion of patients suffering from partial (70%) than from primary generalised 
epilepsy (36%, p<0.001). No other drug was associated with a particular seizure type. 
Patients with partial seizures received a higher dose of carbamazepine than those 
experiencing only generalised fits (means 860mg vs 600mg, p<0.005), although 
concentrations did not differ significantly between the groups (8.6 mg/L vs 7.7 mg/L). 
Patients experiencing partial seizures took similar doses of phenytoin (353mg vs 324mg) 
to those with GTCS but concentrations were higher in the former group (16.7 mg/L vs 13 
mg/L, P<0.01). These results are consistent with the accepted wisdom that partial 
seizures are more difficult to control [Brodie & Porter 1990].
A wide range of concentrations at each daily dosage schedule was demonstrated for all 
drugs. This is illustrated for CBZ in Figure 2. The time elapsed since the previous dose 
correlated highly (P<0.001) with the classification of the results into low, "therapeutic" 
and high values (Figure 3). This effect was not seen with phenytoin or valproate. The 
distribution of assay results for each anticonvulsant is shown in Figure 4. Thirty-five per­
cent of all concentrations were categorised as "unexpected" by the examining physician, 
and in 43% of these (19.2% of all results) a change in decision regarding management 
was thought appropriate. In 114 (23.3%) of the 488 patient visits, some alteration of 
management was brought about in response to the assay result (Table 5). The outcome of 
each patient visit, regardless of whether or not the assay result affected management, is 
summarised in Table 6. The proportion of results which were unexpected, or which 
altered management, did not vary significantly between the three clinicians (Table 7).
The tendency for the registrar to anticipate results better than the others was, fortunately,
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TABLE 4 Anticonvulsant doses and plasma concentrations (mean ± SD) in 
182 actively managed epileptic outpatients
Drug Number of Daily Dose Commonest Daily Plasma
Patients (mg) Dose (mg) Concentration
(Monotherapy) (mg/L) (mg/L)
Carbamazepine 106
(69)
743 ±415 800 8.2 ±3 .8
Phenytoin 59
(36)
336 ± 110 300 16.2J :  8.2
Sodium Valproate 44
(22)
1220_± 785 1000 80.9 J :  42
Phenobarbitone 20
(3)
111 ±  45 120 19.0J: 8.9
Primidone 6
(2)
509 ± 220 50 17.8_± 9.0*
* Phenobarbitone measured
TABLE 5 Changes in management following anticonvulsant assay at 
488 patient visits
Increase in drug dosage - 57 (11.7%)
Decrease in drug dosage - 37 (7.5%)
Advice concerning compliance 8 (1.6%)
Addition/discontinuation of drug 3 (0.6%)
Earlier clinic appointment - 45 (9.2%)
Later clinic appointment - 13 (2.7%)
Total visits with one or more changes - 114 (23%)
TABLE 6 Outcome of clinic visit regardless of whether decision changed
No alteration in management - 271 (55%)
Increase in drug dosage - 97 (20%)
Decrease in drug dosage - 73 (15%)
Change in dose of two drug[s] - 15 (3%)
Advice concerning compliance - 12 (2.4%)
Addition of new drugs - 8 (1.6%)
Admission to ward - 8 (1.6%)
Stop current drug(s) - 4 (0.8%)
Total patient visits 488
TABLE 7 Proportion of results which were unexpected and which altered 
management - by grading of clinician
SHO REGISTRAR CONSULTANT
PATIENTS SEEN 90 163 244
UNEXPECTED 38 (42%) 58 (36%) 109 (45%)
RESULTS
MANAGEMENT 24(27%) 27(16%) 56(23%)
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FIGURE 4 Distribution of 632 assays of 4 anticonvulsants. Unshaded areas represent 
results which were followed by a change in dosage. Putative "therapeutic" ranges are 
shown.
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FIGURE 5 Proportion of results below, within and above the "therapeutic" range for 
carbamazepine (4-10 mg/L), phenytoin (10-20 mg/L), sodium valproate (50-100) mg/L 
and phenobarbitone (10-40 mg/L) following the patient’s last clinic visit compared to 
previous visits.
not "statistically significant".
Table 8 displays the assay results according to whether they were below, within or 
above the "therapeutic" ranges for the four anticonvulsants i.e. CBZ 4-10 mg/L (17-42 
umol/L), PHT 10-20 mg/L (40-80 umol/L), VPA 50-100 mg/L (350-700 umol/L) and PB 
10-40 mg/L (40-172 umol/L) [Brodie & Feely 1988]. With both carbamazepine and 
phenytoin, a low result was more likely to be followed by a change in dosage than a 
"therapeutic" (p<0.001, p<0.005) or high (p<0.001, p<0.05) result, but there was no 
difference between the physicians’ responses to "therapeutic" and high results. With 
valproate, the presence of a "therapeutic" range appeared to have even less influence on 
the likelihood of a change in dose which was recommended after 46% of low results, 
after 42% of "therapeutic" levels and after 29% of high concentrations.
Distribution of assay results obtained at the last clinic visit was compared with all 
previous analyses in Figure 5. Only with phenytoin was there a tendency for higher 
numbers of patients to enter the therapeutic range as the year progressed.
DISCUSSION
These data confirmed "interindividual variation in drug absorption, elimination and 
distribution" by showing the wide range of concentrations obtained in patients taking the 
same dose (Figure 2). This is a basic premise for the preferred use of serum 
concentrations over dosage in the monitoring of drug therapy. However, the striking 
relationship between CBZ concentration and time-since-dosing shows how a random 
result could cause confusion, and argues against any rigid adherence to a "therapeutic" 
range for this drug. In many cases, finding a concentration inside or outside the range
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would entirely depend on when the blood sample was taken in relation to the previous 
dose. Sophisticated allowances for such complications are thus necessary if a target 
concentration strategy is to be adopted [Whiting et al 1984].
The receipt of an anticonvulsant concentration was followed by an alteration in patient 
management in 23% of monitored attendances. This was not an automatic consequence 
of the result, as more than half of the "unexpected" results were not followed by a change 
in decision. The "therapeutic" range had a smaller influence on decision-making than 
might be expected. A change in dosage was almost as common after a "therapeutic" level 
(26%) as after a high level (29%). From Figure 4, it would seem that only with phenytoin 
did the clinicians adopt, consciously or otherwise, a "target concentration strategy" 
[Spector et al 1988].
A low result was more likely to precipitate a change in dose (54%) than the other 
categories. A few of these patients had the dosage decreased, as it was decided to 
withdraw the drug. Those who were asymptomatic and seizure-free did not have their 
dose increased. An attempt to bring phenytoin and phenobarbitone from "subtherapeutic" 
to "therapeutic" levels in well patients has been shown to increase neurotoxicity without 
affecting seizure control [Woo et al 1988]. Many partially controlled patients in the 
present study, who would have continued as previously, had their dosage increased after 
a surprisingly low result. The number of patients (8) in whom poor compliance was 
identified appeared lower than might be expected. However, this includes only those 
individuals in whom poor compliance was previously unsuspected and not those known 
to be erratic in taking their medication.
The diagnosis of anticonvulsant neurotoxicity is a clinical one in the majority of affected 
individuals. There was little suggestion from these data that drug concentrations were 
being used to uncover latent sedation or ataxia. In 71% of the "high" concentrations, the
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examining doctor considered the result satisfactory and the dose appropriate for the 
patient. Indeed, of the 55 patients with high results in whom a decision to alter the dose 
was made, an increase was advised at 11 consultations as the patient’s seizure disorder 
was not fully controlled and there was no clinical evidence of toxicity.
Table 4 suggests a move towards earlier appointments as a result of the TDM. This may 
be misleading, however, as the physicians were choosing return appointment dates with 
the knowledge that a result would shortly be available. It is likely that, without TDM, 
clinicians would be requesting earlier appointments in order to see the patient with an 
anticonvulsant level to hand. The clinician’s initial estimate of time to next appointment 
is therefore "assuming that I will soon be in possession of the result I expect". The 
shortened appointment times thus demonstrate the effect of occasional unexpected 
results, rather than of TDM itself.
This study of on-site anticonvulsant monitoring has demonstrated immediate impact on 
clinical management in more than 20% of patient visits - a similar figure to a previous 
small study [Marty et al 1981]. In our clinic, however, we did not seem to follow a 
"target concentration strategy". Clearly, other factors were taken into consideration 
before an alternative anticonvulsant dose was recommended. This more subtle effect of 
drug concentration results on management is incompatible with a "therapeutic range".
Our unit has come to prefer the term "target range" though this also remains far from 
ideal. It does, however, lose some of the inflated "therapeutic" validity which a single 
anticonvulsant measurement cannot possess. Among epilepsy specialists, this might seem 
self-evident, however as recently as 1986, a group of experienced neurologists tackling 
computer-simulated case histories tended to miss ideal treatment regimens owing to a 
tendency to follow "therapeutic ranges" [Ward 1986]. Meanwhile, in general practice and
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general medicine, patients frequently have their drug dosage tailored to achieve 
"therapeutic levels" rather than therapeutic effects. Hopefully, this is changing. A recent 
review states "One needs only to determine the ’therapeutic range’ for the individual 
patient" [Dodson 1989]. The same writer continues "changing an epileptic drug dose 
based only on the drug level is like driving a car looking only at the speedometer". While 
this may be an overstatement, one would hope that the following quotation from a clinic 
letter will become a thing of the past:
"I saw E- for a follow-up visit....I am pleased to find that she is now well and 
symptom-free. I did check a phenytoin level and found this still to be in the toxic 
range. I telephoned and advised that E -’s phenytoin be cut down to lOOmg b.d."
While on-site TDM clearly affects management, does it improve it? Preliminary evidence 
suggests that the number of clinic visits and assays required to optimise control can be 
decreased [Patsalos et al 1987, Wing & Duff 1989] and that seizure control might even 
be improved [Miller et al 1982, Wing & Duff 1989]. However, only small numbers of 
patients have been monitored, and the popular claim that "therapeutic drug monitoring, 
used intelligently, is of indisputable value to the individual epileptic" [Mucklow 1982] is 
not backed up by controlled studies. It can be shown that drug levels can be brought into 
predetermined ranges [Whiting et al 1984] but the further step that this necessarily 
improves the lot of the patient remains a presumption. The present study shows that we 
use TDM only as part of the over-all clinical picture, and this concurs with modem 
thinking [Chadwick 1987]. But perhaps even this needs testing. No-one as yet seems 
willing to face the problems of a proper, blinded, controlled study. Drug assays at our 
own clinic continue, and patients’ future performance with regard to frequency of 
seizures and of attendance will be compared with these baseline data. Results will be 
partially helpful, but will not fully answer the question which began this paragraph.
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CHAPTER 2
PSYCHOMOTOR FUNCTION AND ANTICONVULSANT DRUGS
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CHAPTER 2
PSYCHOM OTOR FUNCTION AND ANTICONVULSANT DRUGS 
INTRODUCTION
While an individual with epilepsy may have normal or above-average cognitive ability, 
epileptic patients as a whole tend to show impairment in memory, learning capacity 
[Hirtz & Nelson 1985] and academic achievement [Seidenberg et al 1986]. Intelligence 
may also be lowered, but that in "non-institutionalised" people with epilepsy usually 
approaches normal [Bourgeois et al 1983]. The relative importance of clinical and 
subclinical seizures [Kasteleijn-Nolst Trenite et al 1988, Siebelink et al 1988], 
underlying cerebral damage, and psychosocial problems is difficult to establish [Smith et 
al 1986, Dodrill 1986]. Anticonvulsant drugs are another complicating factor. Subtle 
changes in "psychometric" or "cognitive" function have been suggested to occur with all 
AEDs. In healthy subjects, limited treatment with phenytoin [Thompson et al 1981], 
carbamazepine [Macphee et al 1986a, Trimble 1987] and sodium valproate [Thompson 
& Trimble 1981] have been shown to impair memory, motor speed and mental 
processing at low dosing.
The relative psychomotor toxicity of the major AEDs when used in therapeutic doses is 
becoming clearer. Sedation with phenobarbitone and primidone was almost universal, so 
the introduction of phenytoin was an obvious improvement [Jones & Wimbish 1985], 
while CBZ was also clearly better than phenobarbitone in children [Schain et al 1977]. 
Recently, more sophisticated testing of psychomotor and cognitive function suggests that 
CBZ is superior to phenytoin [Dodrill & Troupin 1977, Andrewes et al 1986, Smith et al 
1986, Gallassi et al 1988] and confirm both CBZ and phenytoin as improvements on 
barbiturates [Meador et al 1990]. These papers used a variety of tests of memory (digit
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recall, word list and prose memory), motor function (reaction time, finger tapping), 
decision making (choice reaction time) and tracking to investigate the cognitive side- 
effects of these drugs. These tests (of which the relevant ones will be further described 
later) are discussed in the individual papers and in the extensive review of Hindmarch 
[1980]. Using this battery of tests, some subtle differences have emerged, suggesting that 
the superiority of CBZ over PHT is more marked with regard to memory and learning 
[Evans & Gualtieri 1985, Andrewes et al 1986] than with purely motor function [Evans 
& Gualtieri 1985, Dodrill & Troupin 1977].
Studies with VPA have revealed only slight slowing of cognitive processing [Thompson 
& Trimble 1981] or reaction times [Sommerbeck et al 1977] and some workers have 
failed to show any deficit. [Harding et al 1985]. Its superiority to phenobarbitone has 
been confirmed [Vining et al 1987]. The assertion of Evans & Gualtieri [1985] that 
"CBZ appears to have the least harmful neuropsychological consequences of all the 
antiepileptic drugs, with the possible exception of valproic acid" still holds true, and 
these two drugs remain inseparable. One point of general agreement is that 
polypharmacy with more than one AED tends to produce a greater increase in sedative 
side-effects than in anticonvulsant efficacy [Morris et al 1987, Reynolds 1983]. This has 
led to a move towards monotherapy [Shorvon et al 1978, Thompson & Trimble 1982b] 
often producing less toxicity with no loss of effect or even increased efficacy [Shorvon & 
Reynolds 1979, Ludgate et al 1985]. A recent study in mice, however [Bourgeois 1988], 
suggested that this should not be assumed for all AED combinations, and showed that 
while VPA and PB had additive neurotoxic effects, VPA together with CBZ produced 
less problems. Some combinations may have a better therapeutic ratio than others.
Our unit has taken a particular interest in CBZ, as an anticonvulsant which is coming 
more and more into use world-wide. Although it is among the least sedative of the AEDs,
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the evidence for a degree of psychomotor impairment is persuasive. A single dose of 
600mg CBZ causes detrimental changes to many parameters in healthy subjects 
[Macphee et al 1986a], while an additional 400mg at night causes similar problems in 
patients stabilised on the drug [Macphee et al 1986b]. However, these studies only show 
acute effects, and it is possible that tolerance to psychomotor impairment developes. 
Studies have been performed which show impairment with chronic dosage, but here a 
common drawback is the use of normal healthy subjects as the only controls [e.g. Stores 
et al 1978, Tomson et al 1988, Tedeschi et al 1989] so the effect of epilepsy itself is not 
excluded. An attempt to delineate, if not overcome, this problem is made in EXPT 2.
Another aspect of psychomotor impairment with CBZ is the effect of diurnal fluctuation 
of blood concentrations. In our unit, daily fluctuation {(peak - trough 
concentration)/mean concentration x 100%} on twice-daily CBZ has been measured as 
59% [Macphee et al 1987]. This occurs despite an initial half-life of CBZ which exceeds 
24h, since autoinduction of metabolism lowers the half-life to approximately 12h with 
monotherapy, and further with polypharmacy [Eichelbaum et al 1985]. Hoppener and his 
colleagues [1980] found a similar degree of fluctuation and showed that neurological 
side-effects which did not relate to morning blood concentrations could be shown to 
correlate with fluctuating levels. The findings of Riva et al in 1984 were similar, while 
recent sophisticated analysis of saccadic eye movements [Tedeschi et al 1989] have 
confirmed the correlation. Hoppener suggested that thrice-daily dosing of CBZ should be 
mandatory to help reduce fluctuation, but this may reduce compliance. Riva thought his 
findings "should stimulate the pharmaceutical industry toward the development of CBZ 
preparations with more desirable pharmacokinetic properties." A controlled-release 
preparation might diminish side-effects, allow higher steady-state concentrations and 
improve compliance by allowing twice-daily dosage for all patients. The 
pharmacokinetics of such a preparation are assessed in this chapter.
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EXPT. 2 PSYCHOMOTOR FUNCTION IN EPILEPSY PATIENTS AND 
CONTROLS
AIM
Using a battery of psychomotor and cognitive function tests, to compare the performance 
of epilepsy patients on therapy with that of untreated patients and healthy controls.
MATERIALS AND METHODS
This study was well under way before my arrival in the unit. Patients were recruited by 
Drs Brodie and Macphee. Psychomotor testing was performed by E. McPhail, and an 
alternative view of the data forms part of her MSc thesis.
Sixty-six patients with GTCS or complex partial epilepsy took part (Table 9). Patients 
exhibiting neurological deficit or poor control were excluded, and no patient was studied 
within 48 hours of a seizure. None had reported more than two seizures per month over 
the previous three months. Fifty-four patients were taking a single anticonvulsant (Table 
10) and 12 took two or more AEDs. Drug dosage had remained unaltered for the 
previous three months in all patients, and none was taking any other drug known to 
impair psychomotor function. All of the polypharmacy group took CBZ (mean daily 
dose 920 mg, mean daily concentration 7.5 mg/L) together with one or more additional 
AED (3 each PHT and PB; 2 primidone, VPA and clobazam; 1 clonazepam). A 10 ml 
venous blood sample was taken into a heparinised tube at the time of testing for 
measurement of circulating anticonvulsant concentrations.
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TABLE 9 Clinical details of control subjects and treated and untreated
epileptic patients undergoing psychomotor function testing
Group n Male Female Age Duration of
(years) disease (years) 
(range) (range)
Controls 11 4 7 26.4 + 5.1 SD 
(22-39)
-
Untreated 14 7 7 26.6 + 3.2 SD 
(16-41)
3.7 + 5 
(0.25 - 14)
Treated 66 35 31 26.3 + 7.5 SD 
(13-45)
9 + 8.5 
(0.5 - 36)
TABLE 10 Drugs taken as monotherapy bv treated enileptic patients undergoing 
psychomotor testing
Drug No. of 
patients
Mean dose 
(mg/day) (range)
Mean concentration 
(mg/L) (range)
Target range 
(mg/L)
Carbamazepine 30 720 (200-2000) 7.9 (3.1 - 14) 4 -  10
Phenytoin 15 360 (200-500) 18 (6.3 - 32.2) 10-20
Sodium valproate 9 1350 (400-3000) 56 (30- 117) 50 - 100
TABLE 11 Distribution of centrencephalic and focal EEG findings
Localised Centrencephalic
Carbamazepine 17 6
Phenytoin 7 2
Valproate 2 6
Polypharmacy 7 3
Untreated 2 5
Fourteen patients who had been diagnosed as having epilepsy on the basis of more than 
one witnessed seizure, but who had been prescribed no anticonvulsant therapy for at least 
three months, were included as the untreated group. A further 11 age-matched healthy 
subjects were recruited from the staff of the Western Infirmary to act as controls. All but 
four epileptic patients had an electroencephalogram (EEG) result available. Thirty-five 
showed a lateral focus, 22 showed "centrencephalic" epilepsy, 7 were normal, 6 showed 
indeterminate "slowing" and 5 had some other abnormality. The distribution of localised 
and centrencephalic epilepsy among the treatment groups is shown in Table 11.
Psychomotor Testing
Psychomotor testing was performed at the same time (1400h-1600h) and in the same 
lighting conditions with all patients. They performed two initial complete runs to allow 
acclimatisation to the requirements of the series prior to completing the tests on a further 
three occasions. A mean value was obtained for each test. The tests employed are 
outlined below.
1. Critical Flicker Fusion Threshold (CFFT) was carried out using the Leeds 
Psychomotor Tester and involved the patients’ appraisal of the frequency above which 
flickering diodes appeared as a constant light. The frequency at which the light 
"changed" was noted in three tests of increasing frequency (CFFTi) and of decreasing 
frquency (CFFTd). The mean of both tests was also calculated (CFFTm). This test 
assesses "integrative function", the aspect of coordination of sensory and motor function 
which is least affected by personality and motivation. CFFT is considered the best way of 
assessing drug-induced changes in this modality [Hindmarch 1980].
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2. Choice Reaction Time (CRT), also performed with the Leeds Psychomotor Tester, 
measured the patient’s reaction time in recognising a flash from one of six lights and 
touching one of six buttons equidistant from his index finger to extinguish it. A mean of 
thirty tests was recorded for recognition time (the time to lift the finger from its starting 
point - CRT1), movement time (CRT2) and total reaction time (CRT). This test assesses 
sensorimotor performance [Hindmarch 1980].
3. "Simple Simon" memory game involved the use of a commercially produced toy (M & 
B Games) which generates a randomised colour sequence of increasing length which the 
subject is asked to repeat. This tests short-term memory in a fashion similar to the digit- 
span technique [Wechsler 1972] but has no bias due to variable numeracy of patients and 
control subjects or the investigator’s intonation of number sequences.
4. Finger tapping rate, using the index finger of the dominant hand, was determined over 
60 seconds on an electronic calculator keyboard set in constant addition mode. This is a 
measure of pure motor function of the simple "ballistic" type [Hindmarch 1980].
5. Card sorting of a shuffled pack of conventional playing cards into aces, kings etc. on a 
table-top was employed as an over-all assessment of cognitive function - an "excellent 
example of a performance task which embraces sensory, motor and central components" 
[Hindmarch 1980].
Assays and statistics
All plasma concentrations of CBZ, PHT and VPA were measured immediately by 
enzyme immunoassay (Emit Syva). Comparisons between patient groups were made 
using the Mann-Whitney ’U ’ test. Correlations between age, duration of epilepsy and 
AED concentrations with psychomotor performance were obtained using the Spearmann
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ranking procedure.
RESULTS
The mean and ranges for the performances of all tests in each group are shown, along 
with significance testing, in Table 12. Means (+ 2SEM) are shown graphically for the 
three components of choice reaction time in Figure 6, and of the other discriminatory 
tests in Figure 7. The untreated epileptic patients performed less well than control 
subjects in CRT1, CRT2, Simple Simon sequencing and card sorting. Their performance, 
however, was superior to treated patients in the same tests (except for CRT2 and finger 
tapping). There were highly significant differences between the healthy controls and 
treated patients for all tests with the exception of CFFT which did not distinguish 
between any of the groups.
No significant difference in psychomotor performance between the patients making up 
the four different treatment groups (CBZ, PHT, VPA, polypharmacy) was found for any 
test (Figures 8 & 9 show the results for CRT1 and finger tapping). There was no 
significant correlation between drug concentration and performance in any test for any of 
the monotherapy groups. Similarly, circulating CBZ (Fig 10; n=29, rs=0.1), PHT (n=15, 
rs=0.06) and VPA (n=9, rs=0.04) correlated poorly with an "overall ability score" 
obtained by summing the ranks in the four discriminating tests (CRT, SS, CS, finger 
tapping) and listing the patients in order of decreasing performance. The 14 monotherapy 
patients above the "target" ranges performed no differently from the 39 within or below 
the range for each drug (Fig. 11). There was no overt association between overall ability 
score and age (rs=0.08) or duration of epilepsy (rs=0.15) in the treated patient group.
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TABLE 12 Mean performance (and range) of subject groups in each psychomotor test
Controls U ntreated
epileptics
Treated
epileptics
CFFTj (Hz) 28.5 28.4 27.5
(21-31.6) (24.7-31.5) (18.9-38.4)
CFFTd (Hz) 31 29 29.2
(26.6-38.6) (24.3-34.5) (20.8-40.9)
CFFTm (Hz) 29.8 28.7 28.4
(25.6-34.7) (24.4-32.4) (22.3-36.7)
CRTj(s) 0.36 0.44c 0.52de
(0.31-0.41) (0.33-0.60) (0.35-1.0)
CRT2(s) 0.18 0.28a 0.27d
(0.12-0.23) (0.14-0.47) (0.13-0.48)
CRT (s) 0.53 0.72b 0.78d
(0.44-0.64) (0.46-1.1) (0.54-1.5)
SS (sequence length) 10.4 7.6a 6.9de
(7-17) (5-11) (4-11)
CS (s) 50.1 63.l b 7 5.1df
(36-62) (44-91) (46-117)
FT taps/minute 370 344a 302de
(310-425) (239-476) (140-413)
CFFT = Critical flicker threshold (i = increasing, d = decreasing, m = mean)
CRT = Choice reaction time (1 = recognition, 2 = movement)
SS = ‘Simple Simon’ memory game
CS = Card sorting
FT = Finger tapping
Comparisons were made using the Mann-Whitney U test 
Controls versus untreated patients: a = P<0.05, b = PcO.Ol,c = PcO.OOl 
Controls versus treated patients: d = PcO.OOl 
Untreated versus treated patients : e = P<0.05,f = PcO.Ol
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F1GURE 6 Choice reaction time and its two components in controls, untreated 
patients and treated patients. Values are mean + 2 SEM Significant differences were 
found between controls and untreated patients for all tests (P<0.05 - P<0.001), but only 
recognition time shows a difference between treated and untreated patients (P<0.05).
CARD SORTNG
SECONDS
80-
g* Q W
LENGTH 
OF SEQUENCE
16
1 2 -
8 -
SiMPLE SIMON FINGER TAPPHG
TAPS/MlNLfTE 
400-
QCO
200-
B , *  Mig*
FIGURE 7 Card sorting, Simple Simon sequences and finger tapping rates in the 
three groups. Values are mean + 2SEM. Controls differ from untreated patients in all 
tests (P<0.05 - P<0.01), while treated patients show further deterioration in performance 
in all tests (P<0.05-P<0.01).
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FIGURE 12 Recognition (CRT1) and card sorting times in patients with a localised 
EEG abnormality, and those with centrencephalic epilepsy.
Patients with centrencephalic epilepsy (n=22) demonstrated longer CRT1 (P<0.02) and 
card-sorting times (P<0.01) than those with discrete left- or right-sided EEG 
abnormalities (n=35; Figure 12). No significant differences in anticonvulsant 
concentrations were found between these two groups.
DISCUSSION
This study demonstrates impaired psychomotor/cognitive function as measured by three 
simple tests (CRT, "Simple Simon", card sorting) in epileptic patients on no medication 
compared with age-matched controls. A further reduction in function in these 
assessments (plus finger tapping) was apparent in a larger group of patients on chronic 
anticonvulsant medication. Although IQ, educational status and work experience were 
not considered, it is unlikely that these would have an important influence on the 
performance of these simple tests.
Young patients with good control were chosen to reduce the possible detrimental effect 
of age and of seizure activity on performance. These findings suggest that both epilepsy 
itself and AEDs contribute to the impairment of psychomotor/cognitive function. The 
failure of the CFFT to discriminate between the groups may be due to the lack of any 
"normal value" for this test, whose most useful function is to document serial changes in 
performance. A study published since this work was performed also failed to show any 
difference in CFFT between CBZ-treated patients and controls [Tomson et al 1988]. 
Meanwhile an American study performed about the same time did show a poorer 
performance at finger tapping, CRT1 and some other tests in untreated epileptic patients 
compared to controls [Smith et al 1986]. In the present study, the epilepsy in the 
untreated group was undoubtedly less severe than in the patients on drug therapy, so the 
study only goes some way towards separating the deliterious effects of AEDs and
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epilepsy itself. What it does do is convincingly demonstrate the difference between 
untreated patients and the normal population, and promote caution in interpreting 
comparisons with healthy controls seen in other studies.
Another interesting feature is the lack of difference between untreated and treated 
patients with regard to the "movement phase" (CRT2) of the choice reaction time. Both 
groups are clearly worse than controls, but there is no further deterioration with 
treatment, in contrast to the effects on recognition time (CRT1). Perhaps we are seeing a 
degree of divergence between the neurotoxic effects of the drugs and of epilepsy itself.
The failure to demonstrate the "pecking-order" of psychomotor effects with the different 
AEDs is perhaps not surprising. Inter-subject variability may lead to the missing of 
effects in individual patients. These results also emphasise the subtlety of any differences 
between the drugs. Only since this work was completed have large studies with multiple 
testing [Vining et al 1987, Gallassi et al 1988, Gallassi et al 1990] or crossover designs 
[Meador et al 1990] shown convincing differences. The studies by Gallassi and his 
colleagues are probably the best evidence for psychomotor impairment with chronic 
carbamazepine and valproate treatment, as they show the detrimental effects gradually 
resolving following drug withdrawal.
The poorer performance in recognition and card sorting times in patients with 
centrencephalic epilepsy compared with those having focal EEG abnormalities was 
unexpected, particularly since a disproportionate number of the centrencephalic 
epilepsies were in what we would expect to be the "better" groups - VPA and untreated.
It is generally accepted that patients with temporal lobe foci have poorer memories 
[Delaney et al 1980], reduced attention span [Stores et al 1978] and mental slowing 
[Halstead 1957]. Generalised spike-wave activity on the EEG has also been associated
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with decreased intellectual performance [Goode et al 1970]. The present findings are at 
variance with this general trend.
The poor correlation between psychomotor impairment and anticonvulsant 
concentrations over a wide range of values was of interest. The suggestion that 
impairment is not confined to those patients at or above the upper limit of the target 
ranges is perfectly compatible with a previous finding that toxicity relates to 
concentration in the individual patient [Macphee et al 1986b]. The fact that this does not 
hold on a population basis supports our own view of TDM which came through in the 
previous chapter. Each individual has his or her own "therapeutic" and "toxic" ranges, 
and the population studies should be seen only as a guideline.
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EXPT. 3 PSYCHOMOTOR FUNCTION IN NEW PATIENTS GIVEN 
CARBAMAZEPINE PROSPECTIVELY - A BRIEF REPORT
AIM
To assess prospectively the effect on psychomotor function of starting and continuing 
AEDs in patients recently diagnosed as having epilepsy.
METHODS
The previous experiment addressed the major problem with long-term studies - healthy 
subjects as sole controls. Short-term studies with volunteers have shown psychomotor 
impairment with CBZ [Macphee et al 1986a]. To ascertain the relevance of this to 
chronic dosage I began seeing new patients before and after they commenced CBZ 
200mg b.d. or VPA 200mg t.d.s. Psychomotor testing was performed as in the previous 
study (except that a more conventional digit recall test [Weschler 1972] was substituted 
for the ’Simple Simon’ test) at 0, 1, 2, 4 and 12 weeks. A visual analogue scale ’alertness 
score’ was also included, where a patient marked a 10cm. line which ranged from "wide 
awake" to "almost asleep". Tests were always performed between 1330h and 1500h, and 
blood was obtained for measurement of serum anticonvulsant concentrations. Dose of 
drug was increased if previous level was below "target range".
Recruitment was slow and a range of problems including variable compliance resulted in 
a high drop-out rate. The study was discontinued when the Unit commenced a trial of a 
novel anticonvulsant in new patients. At this stage, there were insufficient data on 
patients taking VPA for meaningful analysis, but satisfactory longitudinal results from 13
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patients taking CBZ were available for paired comparisons (Wilcoxon-rank).
RESULTS
Critical Flicker Fusion Threshold, digit recall and card sorting showed no significant 
changes from baseline at any time point. Total CRT (Fig. 13) increased after one week of 
CBZ (P<0.05) then returned to baseline levels. Finger-tapping similarly decreased after 
one week (PcO.OOl) before gradually recovering (Fig. 13). Figure 13 also shows the 
slight drop in serum CBZ concentrations over the twelve weeks.
DISCUSSION
It was impossible to study the planned number of patients for this study, and the 
information to be gained from it is therefore limited. It does seem to demonstrate, 
however, the development of tolerance to the detrimental effects of CBZ, as shown with 
finger tapping and CRT. A previous report of impaired CRT at one month with CBZ 
[Smith et al 1986] may have missed a subsequent improvement. Enzyme induction, with 
lowering of serum concentrations of CBZ, may play a part in the improvement, and the 
increased dosage in two patients, although almost maintaining "mean" concentrations, 
may not be adequate compensation. However, patients’ subjective complaints suggested 
that maximum sedation took place in the first few days - before steady-state levels are 
reached. Unfortunately such alacrity of tolerance was not expected, and psychomotor 
tests were performed at the attainment of steady-state (one week), perhaps missing the 
initial effects. Such tolerance would explain the difference between the obvious 
psychomotor effects of CBZ in volunteer studies [Macphee et al 1986a] and the more
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FIGURE 13 Changes in total CRT and finger tapping rate in 13 patients taking 
carbamazepine for 12 weeks. Values are mean + SD. Both CRT (P<0.05) and finger 
tapping (P<0.001) deteriorate after one week, but recover to previous levels.
subtle impairment in patients taking the drugs long-term [Andrewes et al 1986, Aman et 
al 1990].
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EXPT. 4 CONVENTIONAL AND CONTROLLED-RELEASE 
CARBAMAZEPINE IN HEALTHY SUBJECTS
AIM
To compare the pharmacokinetics of a controlled-release preparation of carbamezepine 
(Tegretol Retard, Ciba-Geigy, CBZ-CR) and conventional carbamazepine (Tegretol, 
CBZ-C).
METHODS
Eight healthy volunteers (seven male, one female; aged 25-47 years) took part in a 
double-blind, balanced cross-over study. No concurrent medication was taken during the 
study. A minimum wash-out period of one month was considered adequate between the 
two legs, each of which lasted three weeks, as enzyme induction has previously been 
found to abate two weeks after discontinuing CBZ [Rapeport et al 1983]
Single Dose
Following a single 400mg dose of CBZ-C or CBZ-CR, blood was drawn 0, 2, 4, 6, 8, 10, 
14, 24, 32, 48 and 56h later for measurement of circulating CBZ, free CBZ and CBZ- 
10,11-epoxide (CBZ-E) concentrations. Psychomotor function tests were performed just 
prior to CBZ ingestion and lOh later, equivalent to the expected time to peak 
concentration [Evans & Gaultieri 1985]. Baseline antipyrine kinetics were also assessed 
48h before CBZ ingestion.
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Chronic dosing
Subjects took 200mg of the appropriate preparation at 0900h and 2100h daily for two 
weeks finishing with the 29th dose at 0900h on the 15th day. Tablet counting ensured 
compliance. Blood was withdrawn for drug analysis after the first and fifteenth (eighth 
day) doses at 0, 2, 4, 6, 8, 10 and 12h for "dosage interval" concentrations and again after 
the 29th dose (15th day) at times similar to those employed in the single-dose phase.
Psychomotor function tests were performed on days 1, 8 and 15 of each leg at 0, 3, 6 and 
lOh after the morning dose. The tests used were the same as those in EXPT. 3.
Antipyrine kinetics were repeated on the eighth and fifteenth days of CBZ 
administration.
Assays, Kinetics and Statistics
Blood samples were centrifuged immediately after withdrawal and the serum was stored 
at -20°C for batch analysis. Total and free CBZ, CBZ-E and antipyrine were assayed as 
outlined in the Recurrent Methods section of the introduction to this thesis.
Antipyrine and CBZ kinetic parameters were also performed as outlined earlier. Diurnal 
fluctuation was defined as the difference between maximum and minimum 
concentrations expressed as a percentage of the mean [Riva et al 1984]. Comparative 
statistics were performed with the Wilcoxon matched-pairs signed-ranks test and 
confidence intervals were calculated using the Mann-Whitney confidence interval test.
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RESULTS
Pharmacokinetics
Following a single dose of CBZ-CR, CBZ concentrations plateaued around 60% of the 
peak obtained with CBZ-C (Figure 14). Steady-state concentrations were slightly lower 
with CBZ-CR at 29 days (Figs. 15, 16) but this difference was not statistically significant 
with respect to either trough or average concentrations. Free CBZ levels followed a 
similar pattern to total CBZ (Fig. 17). The percentage protein binding was the same with 
both preparations, the mean (SD) values at each time point after the 29th dose ranging 
from 73.9 (4.5)% to 75.2 (2.4)% on CBZ-C and from 74.4 (2.7)% to 75.7 (2)% on CBZ- 
CR. CBZ-E levels on CBZ-CR were lower than on CBZ-C but not significantly so (Fig. 
18).
Bioavailability
The area under the concentration-time curve for a dosage interval (AUC 0-12h) was 
calculated following the 15th and 29th doses (Fig. 19). After the 15th dose, mean results 
(SD) were CBZ-C 84 (17) mgh/L and CBZ-CR 85 (15) mgh/L (95% confidence interval 
{Cl} for the difference +16 to -20). After the 29th dose, the AUC values were 80 (16) 
mgh/L and 75 (16) mgh/L respectively (95% Cl for difference +23 to -12).
Fluctuation
Diurnal fluctuation of CBZ concentrations around the mean at steady-state (Fig. 20) was 
significantly less with CBZ-CR (12%) than with CBZ-C (24%, P<0.025, 95% Cl 
difference +4% to +18%). The maximum increase in concentration in any 2h period is 
shown for each individual subject on the two preparations in Fig. 21. This was also lower 
with CBZ-CR (P<0.02). Decreased fluctuation of free CBZ and epoxide concentrations
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FIGURE 14 Mean serum drug concentration-time curves (+ SEM) following a single 
400mg dose o f carbamazepine in eight subjects receiving conventional and controlled- 
release (sustained-release) preparations.
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FIGURE 15 Mean diurnal serum drue concentration-time curves (+ SEM) in eight 
subjects after 1st, 15th and 29th dose of conventional and controlled-release 
carbamazepine.
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FIGURE 16 Mean serum drug concentration-time curves (+ SEM) in eight subjects 
following the 29th dose of 200mg twice daily conventional or controlled-release 
carbamazepine.
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FIGURE 17 Mean diurnal serum drug concentration-time curves (+ SEM) of free 
carbamazepine in eight subjects following 15th and 29th dose of conventional and 
controlled-release carbamazepine.
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FIGURE 18 Mean diurnal concentration-time curves (+ SEM) of serum 
carbamazepine-10,11 -epoxide in eight subjects following 15th and 29th 200mg dose of 
conventional (e-e)and controlled-release (o-o) carbamazepine.
120
100
80
60
1 5 th  d o s e  
CBZ-C CBZ-CR
< i
2 9 t h  d o s e  
CBZ-C CBZ-CR
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dose of 200mg twice daily conventional (CBZ-C) and controlled-release (CBZ-LK) 
carbamazepine. Vertical bars represent mean + SEM
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(CBZ) in eight subjects during dosing with 200mg twice daily of conventional and 
controlled-release (sustained-release) preparations. Vertical bars represent mean + SEM.
MAXIMUM CHANGE IN CARBAMAZEPINE CONCENTRATION OVER
SUCCESSIVE 2 HOURLY PERIODS FOLLOWING 29th DOSE 
CARBAMAZEPINE CARBAMAZEPINE
CONCENTRATION
(mgAJ1-20
Qcbnveotionol
S u sta in e d —M w m
fX0.02
- 1-5
1-0-
- 0-50 -5 -
0J L0
F 6A EB 0 H
INDIVIDUAL SUBJECTS
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release) preparations.
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36% [Hoppener et al 1980], 41% [Riva et al 1984] and 59% [Macphee et al 1987]. Our 
measure (24%) may be lower because of the strict adherence to a twice daily schedule by 
healthy volunteers. The controlled-release preparation showed an improvement (12%) on 
even this figure and thisshould have a beneficial effect on side-effects associated with 
large swings in blood drug concentration [Hoppener et al 1980, Riva et al 1984, Tomson 
1984]. Anecdotally, many patients complain of maximum drowsiness and diplopia 30- 
120 minutes after ingestion of CBZ [Macphee et al 1986b] i.e. before peak drug 
concentrations are achieved. Our volunteers followed a similar pattern. This suggests that 
a rapid increase in concentration may be important in initiating the mild neurotoxic 
effects associated with the drug. If this is the case, the smaller increments shown with 
CBZ-CR (Fig. 21) may be as relevant as the reduction in peak concentration or 
fluctuation.
The contribution of CBZ-E to the psychotropic side-effects of CBZ is uncertain. The 
epoxide is at least as potent as CBZ in seizure models [Faigle et al 1977] and trigeminal 
neuralgia [Tomson & Bertilsson 1984]. Collaborative work we have carried out with RA 
Gillham (Psychology Department, Southern General Hospital, Glasgow) suggests a 
better correlation of psychomotor impairment with serum epoxide concentrations than 
with CBZ itself [Gillham et al 1988]. In that study, we found that 7 separate measures of 
mental performance (including performance IQ, CRT1, CRT2, finger tapping and 
backward digit span) showed deterioration which correlated with CBZ-E concentrations 
(range of r = 0.299 - 0.610), while only 4 correlated with CBZ concentrations.
The decreased half-life of CBZ following CBZ therapy confirms previous reports that 
CBZ induces its own metabolism [Eichelbaum et al 1975, Rapeport et al 1983]. Since it 
is not known, however, whether the extent of induction is a function of peak, trough or 
"average" drug concentrations, it is of interest to note that the mean half-life of CBZ 
following CBZ-CR (24.4h) was similar to that found with CBZ-C (23.2h). The effect of
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CBZ-CR on antipyrine clearance was more impressive than that of conventional CBZ 
against baseline, but there were no significant differences when the two preparations 
were compared directly.
The AUC over a dosage interval at steady state was 1% lower with CBZ-CR. Although 
this was not a statistically significant decrease, we cannot exclude the possibility that the 
bioavailability of CBZ-CR may be slightly less than that of CBZ-C. A further study in 
our unit suggests that this may, in fact, be the case [McKee et al 1991]. This difference 
would not explain the reduced fluctuation, which was calculated as a percentage of the 
serum values. Increased induction with CBZ-CR is a further possible reason for 
decreased AUC, particularly since the AUCs after dose 15 were similar on the two 
preparations. No significant differences in CBZ half-life or antipyrine induction were 
found to support this suggestion.
The diurnal pattern of unbound CBZ resembled that of total CBZ, protein binding being 
similar with both formulations. Epoxide concentrations seemed "tighter" and at a lower 
level with CBZ-CR than CBZ-C. However, these differences did not reach conventional 
significance levels - possibly owing to the small numbers in the study. The smaller error 
bars with CBZ-CR in Figure 18 reflect the significantly reduced variation in CBZ-E 
concentration between individuals on this preparation, rather than reduced diurnal 
fluctuation.
Psychomotor testing failed to reveal differences between the two preparations. As with 
EXPT. 3, variability of these tests would work against disclosing differences in small 
numbers of healthy volunteers taking a relatively low dose. Subjective complaints 
suggested that symptoms were not experienced at times of peak concentration but much 
earlier. The timing of psychomotor testing at lOh post-dosing may thus have been less
77
than optimal. Tolerance to the psychomotor effects may be occurring before serum levels 
have peaked following the first dose!
This study demonstrated Tegretol Retard to be a true controlled-release preparation 
which reduced diurnal fluctuation of CBZ levels. Bioavailability is perhaps reduced, but 
enzyme induction is at least as marked as with conventional CBZ. Psychomotor testing 
again may have been mistimed, as the peak impairment did not seem to correspond with 
peak serum concentrations.
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CONCLUSION CHAPTER 2
The problem of psychomotor impairment in epilepsy remains a complex one. As we saw 
in EXPT. 2, even relatively mild epilepsy, not requiring therapy, is associated with a 
significant degree of psychomotor impairment. A further deterioration in patients taking 
AEDs gave some evidence for a separate effect from the drugs themselves, but clearly 
these patients also have more severe epilepsy. The detrimental effects of AEDs in 
epileptic patients have largely been extrapolated from studies in healthy controls [e.g. 
Thompson et al 1980, Thompson & Trimble 1981, Macphee et al 1986a], but these are of 
necessity short-term studies. Other studies of patients themselves - where extra doses are 
given - [Macphee et al 1986b] also show a deterioration in performance, but these are 
also short-term, and as we see from EXPT 3, such changes may well return towards 
normal after some weeks.
Our collaborative study with psychologists [Gillham et al 1988] showed only minimal 
effects by CBZ on a wide range of psychomotor and cognitive tests, except when it was 
used in combination with another AED. All things considered, the evidence for marked 
cognitive impairment caused by the disease is much more convincing than that against 
the AEDs. Perhaps clinicians can take solace from the idea that the impairment caused by 
AEDs is outweighed by benefits in the same modalities due to a decrease in number of 
seizures - a known independent cause of psychomotor impairment [Seidenberg et al 
1986]. A transient drowsiness 30-90 minutes following dosing with CBZ may be a small 
price to pay for an improvement in seizure frequency. Long-term damage is a genuine 
possibility however, though difficult to prove. Anecdotally, patients do very often 
complain in the clinic of memory deterioration. We have recently performed 
sophisticated psychological testing of 84 patients receiving monotherapy with CBZ (35), 
VPA (30), PHT (19) and 26 untreated patients [Gillham et al 1990]. Differences were 
subtle, but the phenytoin patients had poorer memory while the CBZ patients had slightly
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impaired motor function. Interestingly, the VPA group were significantly better than 
those taking other drugs in these modalities. The results are in keeping with suggestions 
that different AEDs affect different modalities of mental function - PHT having more 
effect on memory and cognitive function, while CBZ may impair pure motor abilities 
[Andrewes et al 1986]. Whether phenytoin is more likely to cause long-term memory 
problems is unproven. The findings may also constitute early evidence that VPA may 
prove to be slightly less neurotoxic than CBZ.
The transient drowsiness following CBZ dosing may be open to amelioration using CBZ- 
CR. EXPT. 4 failed to prove this with regard to psychomotor testings, but did 
demonstrate pharmacokinetics which would appear much more favourable than those of 
CBZ-C. A recent study [Aldenkamp et al 1987] had the opposite emphasis, and while 
failing to show the pharmacokinetic effects in such detail, did demonstrate improved 
cognitive function with CBZ-CR compared with CBZ-C. A study of patients using a 
double-dummy technique with conventional CBZ is in progress in the unit to confirm 
this.
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CHAPTER 3
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CHAPTER 3
ENZYME INDUCTION AND ANTICONVULSANT DRUGS
INTRODUCTION
Induction
The elimination of many anticonvulsants is largely dependent on metabolism by the 
family of monooxygenase enzymes in the liver. For example, carbamazepine is oxidised 
to carbamazepine-10,11-epoxide (CBZ-E), an active metabolite which is further 
enzymatically converted to 10,11 -dihydro- 10,11-dihydroxy-carbamazepine (CBZ trans- 
diol, cf Figure 25). As with many drugs, the mixed-function oxygenases, the terminal 
electron acceptor of which is cytochrome P-450, are of paramount importance in the 
biotransformation of anticonvulsants [Park 1982].
The activity of these enzymes can be assessed in various ways. The most common 
method is to measure the pharmacokinetics of the outmoded analgesic antipyrine. This 
drug is rapidly absorbed after oral ingestion, and is metabolised almost completely in the 
liver by the mixed function oxygenase system [Boobis et al 1981]. Pharmacokinetics can 
be calculated using either plasma or saliva concentrations. Increasing clearance and 
shortening elimination half-life can both give a good indication of enhanced mixed 
oxygenase activity due to induction [Park 1982]. Another method of detecting changes in 
an individual’s monooxygenase enzyme activity is to measure the 24h urinary excretion 
of 6 beta-hydroxy cortisol which is increased by inducing drugs [Park 1981]. This minor 
metabolite of cortisol is formed in the liver by enzymes associated specifically with 
cytochrome P450 [Park 1982]. This entirely non-invasive technique can be used in 
children, where it has been shown to correlate with antipyrine clearance in young 
epileptic patients given CBZ [Ohnhaus & Park 1979].
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FIGURE 25 Metabolism of carbamazepine and oxcarbazepine.
Using such techniques, various workers have produced overwhelming evidence that PB 
[Burstein & Klaiber 1965, Ohnhaus & Park 1979, Vessell & Page 1969], PHT [Werk et 
al 1964, Petruch et al 1974] and CBZ [Moreland et al 1982, Rapeport et al 1983] can all 
induce hepatic enzymes, while this does not appear to be the case with VPA [Perucca et 
al 1984]. One possible consequence of this induction is accelerated metabolism of the 
drugs themselves ("autoinduction") with, for example, a resultant decrease in CBZ half- 
life [Eichelbaum et al 1975] reducing steady-state levels and necessitating an increase in 
dosage [Macphee & Brodie 1985]. Similarly, the dosage of concurrent medication also 
metabolised by the same enzyme system may require to be increased if an AED such as 
CBZ is added to the regimen. The most notable example is the oestrogen-containing 
contraceptive pill, where the introduction of an anticonvulsant has been shown to cause 
breakthrough bleeding and contraceptive failure [Orme 1982, Mattson & Cramer 1985]. 
On the other hand, the addition of an enzyme-inhibiting drug to a regimen containing e.g. 
CBZ can offset the effect of enzyme induction, thus causing an abrupt rise in CBZ levels 
and consequent toxicity. This may occur with VPA [Levy & Koch 1982] or with other 
commonly used enzyme inhibitors such as cimetidine [Macphee et al 1984] or verapamil 
[Macphee et al 1986c].
Hyposexuality
A controversial aspect of enzyme induction is the possible effect of AEDs on 
endogenous hormones, and the part they may play in the hyposexuality which has been 
recognised in epilepsy patients since 1954, when Gastaut & Collomb described a group 
of 36 patients with temporal lobe epilepsy (TLE), of whom 26 they considered as having 
absent or reduced sexual activity. The nature and prevalence of this hyposexuality has 
since been under investigation. Most studies find a decrease in sexual potency rather than
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libido [Saunders & Rawson 1970, Pritchard 1980], though either may be present alone 
[Saunders & Rawson 1970]. A particular association with TLE was further championed 
by Hierons & Saunders [1966] and others [Kolarsky et al 1967, Pritchard 1980, Herzog 
et al 1986]. Many of these studies are presented in a way which makes it difficult to 
decide whether control groups with other epilepsy syndromes were considered. However, 
Saunders & Rawson [1970] simply interviewed 100 epileptic patients of whom 33 had 
TLE. Twelve patients had a "sexual disorder" and all of these were in the TLE group. It 
has since been argued that not only might TLE cause an endocrine disorder, but that the 
endocrine abnormalities themselves may predispose patients to epileptic seizures 
[Herzog 1989].
Many studies have also shown that earlier onset epilepsy is more likely to be associated 
with hyposexuality [Gastaut & Collomb 1954, Taylor 1969] with only one in 
disagreement [Pritchard 1980].
Hyposexuality and Induction
The role of antiepileptic drugs and induction in this hyposexuality is unclear. Circulating 
concentrations of sex-hormone binding globulin (SHBG) have been found to be 
markedly increased by AEDs [Victor et al 1977, Toone et al 1980]. Total testosterone is 
usually normal [Toone et al 1984, Rodin et al 1984] or increased [Toone et al 1982], but 
free testosterone is lowered [Dana-Haeri et al 1982, Toone et al 1983]. Luteinising 
hormone is raised [Toone et al 1980, Rodin et al 1984]. Toone [1985] has enumerated 
various possible sequences for these changes, favouring an increased metabolism of free 
testosterone as the first step, but also mentioning the possible roles of: a) increased 
SHBG; b) decreased testosterone synthesis due to a direct toxic effect on the testes; c) a 
failure of central mechanisms in response to reduced free testosterone. In this chapter, the 
effects of the drugs on young epileptic men will be investigated. EXPT 5. separates the
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patients taking different AEDs, to investigate the possibility that the non-inducing drug 
VPA has different effects from the others. An untreated epilepsy group is also included 
and compared to healthy controls. A likely sequence for the hormonal changes is more 
fully discussed in the conclusion to this chapter.
Thyroid function
The effect of AEDs on thyroid function has also come under scrutiny. Depression of 
thyroid hormones was first reported with PHT in 1961 [Oppenheimer et al 1961]. Both 
PHT and CBZ have since been found to be associated with a reduction in total (T4) and 
free (FT4) thyroxine [Liewendahl et al 1978, Heyma et al 1977, Yeo et al 1978]. 
Triiodothyronine (T3) has been less consistently found to be decreased, and this may 
reflect changes of a smaller magnitude [Smith & Surks 1984]. Again, enzyme induction 
may be involved [Larsen et al 1970], although failures to reproduce the effect with the 
inducers primidone [Liewendahl et al 1978] and phenobarbitone [Yeo et al 1978] are 
perhaps surprising. Some support for the inductive mechanism is gained from the 
evidence that the inducing antibiotic rifampicin lowers T4 concentrations [Ohnhaus & 
Studer 1983]. Again, this chapter compares the non-inducing VPA with other AEDs to 
further assess the case for this mechanism.
Oxcarbazepine
Attempts to modify the structure of CBZ to reduce side-effects have produced 
oxcarbazepine (OXC), the 10-keto analogue (Figure 25). It has similar anticonvulsant 
efficacy to CBZ in animal models [Baltzer & Schmutz 1977] and in clinical trials 
[Houtkooper et al 1987, Reinikainen et al 1987, Dam et al 1989]. Psychomotor 
impairment was decreased in these clinical studies, and rashes were less frequent than
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with CBZ in one [Dam et al 1989]. Hyponatremia may, however, be at least as common 
with OXC as with CBZ [Nielson et al 1988].
The metabolism of OXC differs markedly from that of CBZ. While CBZ is oxidised to 
CBZ-10,11-epoxide, OXC is immune to oxidative attack (Fig. 25) and is instead reduced 
to 10-hydroxy-carbazepine (10-OH-CZ). Indeed it is the anticonvulsant properties of this 
metabolite which account for the drug’s pharmacological actions [Schutz et al. 1986], as 
OXC itself is only briefly present in the circulation [Theisohn & Heimann 1982, Kramer 
et al 1985]. As a consequence of this variation in metabolic profile, OXC may lack the 
enzyme-inducing properties of CBZ [Kramer et al 1985] and this postulation is tested 
later in this chapter (EXP 7).
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EXPTS. 5 & 6 THYROID AND SEX HORMONES IN YOUNG EPILEPTIC MEN 
RECEIVING LONG-TERM ANTIEPILEPTIC MEDICATION
AIM
To determine sex hormone and thyroid hormone profiles in epileptic patients, and assess 
the effect of enzyme induction and epilepsy itself by including a group taking the non­
inducing AED sodium valproate, and an "untreated epilepsy" control group.
PATIENTS AND METHODS
Fifty-four patients taking CBZ, PHT, VPA or a combination of drugs including either 
CBZ or PHT (POLY) were recruited (Table 14). All were compliant as judged by 
consistent AED concentrations at out-patient attendances. No other drugs were being 
prescribed, and no patient was known to abuse alcohol. Treatment had been unaltered for 
at least three months, and no patient had suffered a seizure in the previous 48h. For 
comparison, 14 untreated epileptics and 16 unmedicated members of laboratory and 
medical staff were included as controls.
Following a 30 minute supine rest, 40 ml blood was withdrawn through an indwelling 
cannula. Samples were centrifuged, and serum (hormone assays) and plasma (AED 
assays) were stored at 20°C until batch analysis. "Sex hormones" assayed included 
testosterone (T), sex-hormone binding globulin (SHBG), dehydroepiandrosterone 
sulphate (DHAS), androstenedione (AND), luteinising hormone (LH), follicle 
stimulating hormone (FSH) and prolactin (PRL). Thyroid function tests consisted of 
serum thyroxine (T4), free thyroxine (FT4), triiodothyronine (T3) and thyrotropin (TSH).
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TABLE 14 Mean and SD of age, seizure type, and AED concentration in all patient 
groups and in controls
Group Age
(yr)
Seizure type AED concentration
(mg/L)
Healthy subjects 
(n = 26)
31(7) - -
Untreated epileptic patients 
(n = 14)
28 (8) 8 CPS + SG 
6 GTCS
-
CBZ 
(n = 18)
29 (7) 11 CPS + SG 
7 GTCS
9.8 (4.1)
PHT
(n = 13)
32 (8) 5 CPS + SG 
8 GTCS
17.4 (12.7)
VPA 
(n = 10)
23 (5) 3 CPS + SG 
7 GTCS
75.6 (34.7)
Combination therapy 
(n = 12)
36 (7) 9 CPS + SG 
3 GTCS
11.5(3) CBZ, n = 8 
17.6 (6.9) PHT, n = 5 
24.8 (15.8) PB, n = 8 
64, 55 VPA, n = 2
AED, antiepileptic drug; CPS, complex partial seizures; SG, secondary generalisation;
GTCS, generalised tonic-clonic seizures; CBZ, carbamazepine; PHT, phenytoin; VPA, valproate
A subgroup of 6 controls, 7 untreated patients and 33 treated patients (11 receiving CBZ, 
9 PHT, 6 VPA and 7 POLY) underwent a combined pituitary stimulation/TRH test. After 
a supine rest and baseline measurements through an indwelling cannula, an intravenous 
injection of 100 ug. LHRH and 200 ug. TRH was administered. Further venous blood 
samples were obtained after 20 and 60 minutes for LH, FSH, PRL and TSH. These 
procedures were performed by Dr. GJA Macphee.
Assays
Hormone assays were performed by radioimmunoassay as previously described [Connell 
et al 1984a, Connell et al 1984b]. SHBG was determined by a modification of the 
method of Rosner [1972]. All had a mean interassay coefficient of variation of less than 
10%. None of the AEDs or their metabolites was known to interfere with any of the 
assays. Free testosterone (FT) was derived from the formula: FT (pM) = total T x % free 
T x 1000/100, where % free T = -2.38 log jq (SHBG nM) + 6.11. This correlates very 
closely with free testosterone [Nanjee & Wheeler 1985].
Kinetics and Statistics
Areas under the concentration-time curve (AUC) for individual hormones following 
pituitary stimulation were calculated by the trapezoidal rule. Although means are given, 
all comparative statistics were non-parametric. Initial Kruskal-Wallis of the six groups 
was followed up by the Mann-Whitney ’U ’ test in positive cases. As well as analysing 
the differences between the six groups of subjects, the untreated epileptics and healthy 
controls were amalgamated for comparison with the VPA-treated group and those 
receiving one or more enzyme-inducing AED. Correlation coefficients were obtained by 
the Spearman ranking procedure.
RESULTS
Sex Hormones
The individual results of all subjects for each measurement are shown in Figure 26 (a)- 
(h). Three measurements (SHBG, H=30.4, PcO.OOl; DHAS, H=16.8, P<0.005; PRL,
H=11.1, P<0.05) showed significant variation between the six subject groups. SHBG was 
increased in the CBZ (P<0.05), PHT (PcO.OOOl) and POLY (PcO.OOOl) groups, and 
DHAS was significantly decreased by the same drugs, relative both to controls (all 
PcO.OOl) and to the VPA group (P<0.02, PcO.Ol, P<0.05). PRL was increased only in 
the CBZ group (P<0.005). In no measurement did the VPA group differ from either set 
of controls, nor did the untreated patients differ from the healthy controls. The results are 
summarised (means(SD)} in Table 15. Some individual group results - such as the 
polypharmacy LH and FT, and the untreated patients’ androstenedione - seemed altered, 
but the Kruskal-Wallis for all groups did not reach significant levels for these hormones. 
Amalgamation of the untreated patients and controls (n=30) and comparison with VPA 
(n=10) and induced patients (n=44) confirmed a marked increase in SHBG (PcO.OOOl) in 
induced patients vs. controls and a decrease in DHAS vs. both controls (PcO.OOOl) and 
VPA patients (Pc0.005). A decrease in free testosterone in the induced group just failed 
to reach statistical significance (P=0.06).
Circulating AED concentrations were correlated with hormonal values for CBZ and PHT 
monotherapy patients. The only significant value obtained was an inverse relationship 
between CBZ and free testosterone (rs = -0.54, Pc0.05; Fig. 27)
Results for the LHRH/TRH stimulation test are shown in Table 16. The A U C s q _^q  were 
similar to controls in all patient groups for LH and FSH. For PRL, it was greater in the 
CBZ group only (Pc0.05).
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TABLE 15 Mean (SD) sex hormone and binding globulin concentrations in 
93 subjects
Norm Untreated CBZ PHT VPA POLYPHARM 
n = (26) (14) (18) (13) (10) (12)
LH 4.9 6.1 7.2 8.3 7.6 11.5
(U/L) (2.8) (2.6) (3.6) (7) (7.8) (10.3)
FSH 4.2 5.3 4.2 7.8 3.1 7.5
(U/L) (2.1) (6.4) (3.1) (10.1) (1.5) (8.1)
* PROLACTIN 136 207 380 199 227 190
(U/L) (83) (159) (299) (95) (218) (191)
TESTOSTERONE 15.4 21.7 16.6 22.6 17.3 17.4
(nmol/L) (4) (20.3) (8) (11.1) (5.8) (3.6)
FREE
TESTOSTERONE 452 538 430 426 443 339
(pmol/L) (121) (256) (229) (184) (174) (96)
**SHBG 22.9 28.3 31.1 61.2 32.9 55.8
(nmol/L) (2) (6.2) (2.9) (17.2) (6.2) (6.9)
***DHAS 7.4 7.7 3.1 1.9 5.9 2.6
(umol/L) (4.1) (2.9) (1.9) (1.8) (3.7) (2.6)
A’ENEDIONE 5.8 8.2 6.1 9.3 8.2 6.8
(nmol/L) (2.4) (1.7) (1.8) (9.3) (3.3) (2.6)
* P<0.00 ** PcO.Ol *** P<0.005
TABLE 16 Areas (mean ± SD) under concentration-time surve (0-60 min) for LH, 
FSH and PRL following combined gonadatrophin and TRH stimulation 
in 33 male epileptic patients receiving CBZ. PHT, VPA, or combination 
treatment and in 13 drug-free controls
Area under the concentration-time curve 
(0-60 min)
Group
LH
(U/L/min)
FSH
(U/L/min)
PRL
(U/L/min)
Controls 1,771 499 42,100
(n = 13) ±  563 ±  290 ±  18,200
CBZ 1,449 498 62,900 a
(n = 11) + 644 ±  430 ±  22,700
PHT 1,682 692 46,400
(n = 9) ±  801 ± 672 ±  21,900
VPA 1,530 372 43,900
(n = 6) + 688 ± 130 ±  18,400
Polypharmacy 1,829 721 60,928
(n = 7) ±  718 ±  914 ±  45,130
LH - Luteinising hormone
FSH - Follicle Stimulating hormone
PRL - Prolactin
TRH - Thyrotropin-releasing hormone
a P< 0.05 vs. controls, statistics obtained by Student’s t test for unpaired values.
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FIGURE 27 Correlation of serum carbamazepine concentrations and calculated free 
testosterone levels in 18 male epileptic patients receiving the drug as monotherapy.
Thyroid Hormones
Thyroid function test results were not available on five of the control group (leaving 
n=l 1). A summary of the data in the six groups is shown in Table 17. TRH test results 
are presented as the percentage rise of TSH to the peak from baseline. Individual data 
measurements for controls, patients receiving VPA monotherapy, and those on inducing 
drugs are shown in Fig. 28.
Nine of the T4 estimations in the patients receiving enzyme-inducing AEDs (2 CBZ, 4 
PHT, 3 POLY) were below the reference range for the assay (55-144 nmol/L), the lowest 
being 28 nmol/L. None of the subjects who were not taking inducing drugs was below 
this range. Five subjects had free T4 concentrations below 10 pmol/L. Again, all were on 
inducing drugs (1 CBZ, 1 PHT, 3 POLY). No patient in the study had abnormal high 
basal or stimulated TSH concentrations.
Kruskal-Wallis analysis showed differences in T4 when the subjects were divided into 
either six groups (H=25.9, P<0.0005) or three groups (H=24.8, P<0.0005). Patients on 
inducing drugs had lower circulating T4 concentrations than both controls (PcO.OOl) and 
patients taking VPA (PcO.OOl). Significance testing for the individuals taking inducers 
against the three other groups is shown in Table 17. Valproate patients had slightly 
higher T4 concentrations than controls (95% Cl +28 to -8 nmol/L), but the difference 
was not statistically significant.
Differences were also present in the FT4 results among the six groups (Pc0.005) or the 
three groups (Pc0.005). FT4 concentrations in induced patients were lower than in either 
controls (Pc0.05) or VPA-treated patients (Pc0.002). The latter again had slightly, but 
not "significantly", higher levels than controls (95% Cl +5 to 0 pmol/L).
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FIGURE 28 Thyroid hoimone and thyrotropin (TSH) concentrations in controls, in 
patients receiving sodium valproate (VPA) monotherapy, and in those taking enzyme- 
inducing AEDs either singly or in combination. Vertical bars are mean (+SEM). Total 
and free thyroxine were lower in the inducer group than in controls (P<0.001, P<0.05) 
and VPA patients (P<0.001, P<0.002). Mann-Whitney ’U ’ test
No significant correlation was found between circulating CBZ or PHT concentrations 
and T4 or FT4 concentrations in the monotherapy patients. There were no significant 
variations in the six or three groups for T3 or basal TSH. The PHT patients had lower 
concentrations of T3 and TSH than both controls and the other drug groups using simple 
Mann-Whitney testing, but the non-significant Kruskal-Wallis test suggests, as with 
some of the sex hormones, that this could be due to the compounding effect of multiple 
analyses. None of the TRH tests performed gave results suggestive of hypothyroidism. 
All of the tests gave normal rises of TSH (> 100%) and there were no important 
differences between the groups.
DISCUSSION 
Sex Hormones
The similarity between untreated and healthy subjects suggests that epilepsy per se did 
not affect the hormone profile. Hypothalamic-pituitary function may be affected by ictal 
activity through limbic structures [Mattson & Cramer 1985], but all patients were studied 
following a 48h seizure-free period, and any central hormonal dysfunction provoked by 
complex partial seizures is known to reverse within hours [Pritchard et al 1983]. The 
"untreated epileptics" control group is not ideal, as they have less severe epilepsy, but the 
ideal group of patients with regular untreated seizures over a long period is, of course, 
unachievable.
Total T concentrations were unaltered in all drug groups, in keeping with many previous 
and subsequent reports [Dana-Haeri et al 1982, Toone et al 1984, Rodin et al 1984, 
Isojarvi et al 1989b], although others have shown an increase [Toone et al. 1982, Isojarvi 
et al 1990]. There was, however a trend towards a decrease in free T in induced patients
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(P=0.06) and it is this active unbound fraction [Anderson 1974] which some workers 
have found to be decreased in patients with reduced sexual drive [Toone et al 1983]. This 
finding appears to be confirmed by later work [Toone et al 1984, Fenwick et al 1985], 
but these papers quote the same data. Other workers have found both free and total T to 
relate to the volunteered symptoms of low sexual drive [Rodin et al 1984] or decreased 
nocturnal erections [Fenwick et al 1986]. While any alteration in free T was marginal in 
the present study, definite changes occurred with SHBG, DHAS and PRL.
The increased SHBG would be expected to influence FT, but there was only a borderline 
decrease (P = 0.06) seen and only when all of the induced patients’ results were 
amalgamated. This would suggest at least some normal functioning of the pituitary 
response to low FT levels, which would normally increase testosterone production by 
releasing LH. The increased LH concentrations in the induced groups just failed to reach 
significant levels (Mann-W P<0.02, but Kruskal-Wallis not significant) but are consistent 
with a response, while LHRH stimulation tests also suggested that the hypothalamic- 
pituitary axis was intact. However, the slight fall in FT may suggest that homeostatic 
mechanisms are not working to normal capacity. There may be an inability of the 
testicular Leydig cells to increase synthesis further. Healthy subjects treated with CBZ 
have shown an initial fall in free T which was fully compensated after three weeks of 
therapy [Connell et al 1984a]. A failure of homeostasis in epileptic patients could arise 
through a direct toxic effect of AEDs on the testes as suggested by Toone [1985]. 
Alternatively, inducing drugs may stress the individual’s homeostatic responses by 
increasing SHBG and accelerating testosterone metabolism, while the eventual outcome 
is dependent on each person’s homeostatic mechanisms - some of which may be 
relatively deficient as a normal variant, rather than due to epilepsy. This might explain 
why some patients complain of sexual problems while others do not, and why population 
studies such as this only find marginal changes in mean values of free T.
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DHAS is a major androgenic steroid secreted principally by the adrenal gland [Bentley 
1980a]. Its increased release in boys at the age of 9-10 has been described as a posiible 
"adrenarche" initiating puberty [Ducharme & Collu 1982]. Low levels have been 
associated with increased mortality in older men [Barrett-Connor et al 1986], although its 
precise function as a sex hormone is unknown. Our results show a marked reduction in 
DHAS in all groups receiving enzyme-inducing AEDs. These findings confirm earlier 
reports of reduced DHAS in healthy male subjects treated with CBZ [Connell et al 
1984a] and in male and female epileptic patients receiving CBZ and PHT [Levesque et al 
1986]. Why DHAS should be more obviously affected than other hormones is unclear, 
but it may simply be a manifestation of unequal effects on different enzymes. 
Pregnenolone and progesterone are metabolised to DHAS and androstenedione 
respectively via 17alpha-hydroxypregnenolone or 17alpha-hydroxyprogesterone. All 
steps are interchangeable and androstenedione may be further reversibly transposed to 
testosterone [Bentley 1980a]. It is easy to see how varying degrees of enzyme induction 
might result in differential effects on hormone levels. Alternatively, the negative 
feedback response may be more sensitive to changes in other hormones e.g. testosterone.
Prolactin concentrations may also be of some importance, since hyperprolactinaemia is 
associated with impotence [Cooper 1986] and hypogonadism [Bentley 1980b]. Elevation 
of PRL may occur in epilepsy for some hours following generalised [Trimble 1978] or 
partial seizures [Pritchard et al 1983, Rao et al 1989]. It has been suggested that baseline 
levels may be increased in patients taking multiple AEDs [Toone et al 1983] or CBZ 
alone [Franceschi et al 1984, Rodin et al 1984], but other papers have reported no 
difference [Isojarvi et al 1988] or even a decrease in baseline levels [Isojarvi et al 1989a]. 
LHRH/TSH stimulation has failed to show differences, except in female patients at 2 
hours [Dana-Haeri et al 1984], although metoclopramide stimulation may demonstrate 
more convincingly an increased PRL response in CBZ-, PHT- and PB-treated patients 
[Franceschi et al 1984]. Since the present study, Isojarvi and his co-workers first found
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no enhancement of PRL response to metoclopramide in patients taking CBZ [1989a], 
then found such an enhancement in similar studies [1989b, 1990]. This last report also 
showed a low baseline PRL in patients taking PHT. The changes appear worryingly 
inconsistent, but the present study conforms to the general trend for CBZ to be the AED 
most likely to affect PRL levels, which may suggest that this drug has a differential effect 
on dopaminergic function. An alternative mechanism, suggested by Isojarvi et al [1989a] 
is by way of the changes in thyroid hormones, which are also known to affect PRL 
responses [Yamaji 1974].
The effect of AEDs on central endocrine function is unclear. Impaired LH response to 
LHRH stimulation has been noted in treated epileptics already known to have sexual 
hypofunction [Spark et al. 1984] and Masala and his co-workers have shown impairment 
of LH response with PB [1980] but not with VPA [1981]. However, an exaggerated 
response to LHRH - consistent with primary gonadal dysfunction - has been shown with 
PHT but not CBZ [Dana-Haeri et al. 1984]. The present study showed adequate 
responses in all drug groups - even polypharmacy - and does not implicate a clinically 
relevant alteration in pituitary responsiveness being caused by AEDs.
Thyroid Hormones
While the incidence of clinical hypothyroidism due to anticonvulsants can be counted on 
anecdotal fingers [Aanderud & Standjord 1980, Blackshear et al 1983], depression of T4, 
FT4 and T3, in the absence of changes in TSH, is well documented [Liewendahl et al. 
1978, Aanderud et al. 1981, Connell et al. 1984b]. Our results, with the inclusion of an 
untreated epilepsy group, confirm that this is an effect of CBZ and PHT and is not 
associated with the disease itself. Nine (20%) and five (11%) of the patients receiving 
enzyme-inducing drugs had "hypothyroid" total T4 and FT4 concentrations respectively,
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while no subjects in the other groups were thus affected. T3 concentrations were not 
shown to be altered, but we may have failed to pick up an effect smaller than that on T4 
and FT4. The statistical analysis of individual groups in Table 17 are shown as calculated 
without a correction factor, and demonstrate that the differences between inducers, VPA, 
and controls are not produced by any one drug.
The lack of response of TSH to the lowered T4 concentrations remains unexplained. The 
pituitary-mediated negative feedback system can be provoked by either T4 or T3. 
Although the initiating steps may be T3-dependent, T4 conversion within the pituitary 
may supply T3 for this mechanism [Larsen 1982]. None of the 9 patients with 
"hypothyroid" T4 concentrations had an inappropriate TSH response (range 0.8-2.7 
mU/L). This may be a consequence of normal T3 concentrations, although an influence 
of CBZ and PHT on pituitary feedback cannot be excluded. Phenytoin has been shown to 
depress TSH response to TRH in both hypothyroid patients and animals [Surks et al. 
1983]. However, if this effect is important, it is perhaps surprising that more patients do 
not become clinically hypothyroid.
The role of enzyme induction in the lowering of T4 and FT4 is unclear. Following the 
initial observation that PHT reduced serum protein bound iodine [Oppenheimer et al. 
1961] it was shown that PHT displaced T4 from thyroxine binding globulin [Wolff et al. 
1961, Oppenheimer et al. 1962,] and this was assumed to be the mechanism. However, 
methods developed for the estimation of FT4 showed that the free fraction was not 
increased and thus both total and free thyroxine were reduced [Chin & Schussler 1968], 
suggesting that the decrease in globulin binding could not be the whole story. Enhanced 
clearance of T4 was put forward as a possible mechanism [Larsen et al. 1970]. Although 
T4 is normally metabolised by mono-iodination to T3 or reverse T3 - processes not 
normally susceptible to induction by AEDs - it may also undergo deamination and 
decarboxylation [Chopra et al. 1978], of which the former at least can be catalysed by the
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P450 system and will thus be inducible [Park 1982], Induction of this "wastage pathway" 
may increase its relative importance to T4 breakdown. In support of this suggestion, it 
has been shown that isolated livers from PHT-treated rats exhibit accelerated metabolism 
of T4 [Mendoza et al. 1966]. An alternative theory put forward by Rao et al [1987], is of 
interest in view of the second part of this thesis concerning itself with calcium 
antagonists. Since one of these drugs, flunarizine, causes similar changes in T4 to those 
described above, they suggest that interference with calmodulin transport of thyroid 
hormones may be the basis of the effect. There is, however, little supportive evidence.
Recent studies have shown little [Haidukewych & Rodin 1987] or no effect [Connacher 
et al. 1987] with VPA on thyroid hormones. The first of these papers suggested a 
possible small decrease in hormone levels caused by VPA monotherapy, but 
comparisons were made with standard reference ranges rather than specific control 
groups. The present study included healthy and untreated controls, and the confidence 
intervals appear to exclude the possibility that VPA lowers T4 and FT4, and may even 
suggest that VPA increases T4 concentrations, which would be consistent with previous 
indications of a small inhibitory effect on oxidative metabolism [Levy & Koch 1982].
This study demonstrates a wide range of effects of AEDs on sex and thyroid hormones. 
The most striking overall finding is the disparity between the effects of VPA and those of 
the other AEDs, which supports the case for enzyme induction as the basis for all of the 
changes seen. A recent study [Isojarvi et al 1990] has suggested changes in serum 
oestradiol, LH and FSH in males taking VPA, but the patients were markedly younger 
than the controls, and this may have influenced the results. The cumulative evidence is 
against any significant effect with VPA. While the clinical relevance is uncertain, VPA 
may be preferrable to other AEDs in the occasional case of hypothyroidism [Aanderud & 
Strandjord 1980] or in male patients reporting sexual dysfunction. An analogue of CBZ
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which does not induce enzymes could present another appealing option, so the reports of 
oxcarbazepine being such a drug required serious consideration and investigation.
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EXPT. 7 OXCARBAZEPINE AND ENZYME INDUCTION
AIM
To investigate the enzyme-inducing properties of oxcarbazepine in healthy subjects by 
assessing the effect of two weeks’ therapy on concentrations of the active metabolite 10- 
OH-CZ, and on other endogenous and exogenous substances metabolised by inducible 
pathways.
MATERIALS AND METHODS
Eight healthy male volunteers (aged 22-43 years, weight 70-89kg.) took part in a study of 
similar design to EXPT. 4. The study was performed in two stages.
Single dose
After an overnight fast, 300mg of OXC was ingested at 09.00h and blood drawn from an 
ante-cubital vein 0, 1,2, 3, 4, 6, 8, 10, 12, 24, 32,48, 56,72 and 96h later for 
measurement of serum OXC, its major metabolite 10-OH-CZ and a further metabolic 
product 10,ll-dihydrotrans-10,ll-dihydroxy-carbamazepine (trans-diol).
Chronic Dosing
After a washout period of 7 days, subjects commenced taking OXC 300mg. at 9.00h and 
21.00h. daily for two weeks finishing with the 29th. dose at 9.00h. on the 15th. day.
Blood was drawn for trough (pre-dosing) serum concentrations of the three chemical 
moieties before doses 1, 2, 3, 4, 5 ,7 , 15, 21, 23 and 29. After dose 29, serial blood
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samples were taken as in the single dose stage.
Induction Markers
Antipyrine kinetics were assessed at least 48h before the single dose stage ("baseline"), 
on days 8 and 15 of chronic dosing, and two weeks after OXC was discontinued ("post­
study"). Urinary excretion of 6 beta-hydroxycortisol in a 24h sample was measured at 
baseline, on days 8 and 15, and post-study as were serum concentrations of Testosterone 
(T), Androstenedione (AND), Dehydroepiandrosterone (DHAS), Luteinising Hormone 
(LH), Follicle Stimulating Hormone (FSH) and Sex Hormone Binding Globulin (SHBG). 
Free androgen index (FAI) was calculated from the expression (TxlOO/SHBG)%.
Routine biochemical tests were performed at baseline and on day 15.
Assays
Blood samples were centrifuged after withdrawal and the serum stored at -20°C  for batch 
analysis. The concentrations of OXC and its metabolites were determined using the 
h.p.l.c. method of Kumps [1984] as we found that antipyrine did not interfere with this 
assay. The limit o f quantitation was 0.05ug/ml for all three compounds, and the % 
coefficients of intra-assay variation for OXC, 10-OH-CZ and trans-diol were 5.4%, 4% 
and 4.1% respectively. A sample chromatogram of two runs of "prepared standard" 
concentrations is shown in figure 29. This shows the measurement of trans-diol, 10-OH- 
CZ and OXC in concentrations of 2 ,1 0  and 1 mg/L respectively, then 1.5,7.5 and 0.75 
mg/L.
Antipyrine concentrations in saliva were measured using h.p.l.c. as previously described 
[MacPhee et al. 1984]. Serum T, AND, DHAS, FSH, LH and PRL were determined by
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FIGURE 29 Chromatogram (h.p.l.c.) from simultaneous assay of trans-diol, 10-OH- 
CZ and oxcarbazepine itself. Assays are of standard preparations. In the top assay, these 
are of 2,10,  and 1 mg/L respectively. The lower assay is of 1.5,7.5 and 0.75 mg/L 
standards.
standard radioimmunoassay [Connell et al. 1984a] and SHBG was analysed using a 
commercial immunofluorimetric assay (DELFIA, Pharmacia Ltd.). Urinary 6 beta- 
hydroxycortisol was measured by a specific radioimmunoassay method [Park 1978]. 
Thyroid hormone assays were performed by radioimmunoassay [Connell et al 1984b]. 
All hormone assays were kindly performed by Dr. GH Beastall o f the Biochemistry 
Department, Glasgow Royal Infirmary. Mean interassay coefficients of variation for sex 
hormone assays were all between 5-10%, and for T4:6.5%, T3:5.9%, free T4:6.3% and 
TSH:8.9%.
Kinetics and Statistics
Kinetic parameters were calculated as described earlier. Trough concentrations during 
chronic dosing were predicted from the single-dose data using superposition [Gibaldi & 
Perrier, 1982] and compared with actual values.
The Wilcoxon matched-pairs signed-ranks test was used for direct comparisons, and 
Friedman two-way analysis o f variance was employed for more than two groups.
RESULTS
OXC and metabolites
The concentration-time curves for OXC and 10-OH-CZ following single-dose OXC, 
using the mean of eight results at each time point, are shown in figure 30. Trans-diol 
levels were largely undetectable. The comparable curves following the 29th. dose are 
given in figure 31. All subjects demonstrated a higher AUC(0-12h) at steady state (mean 
± SEM, 100 + 15 mg.h/L) for 10-OH-CZ than the equivalent AUC(O-infinity) following
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FIGURE 30 Concentration-time curves of oxcarbazepine and its metabolite 10-OH-CZ 
following 300mg oxcarbazepine by mouth in eight subjects ($ mean +SEM).
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FIGURE 31 Concentration-time curves of oxcarbazepine and its metabolites 10-OH- 
CZ and trans-diol following the 29th dose of oxcarbazepine 300mg b.cL ($ mean +SEM).
10-OH CARBAZEPINE 
HALF—UFE 
(hours)
1 6 0 -
1 2 0 -
8 0 -
4 0 -
Single 29th Dose
FIGURE 32 Half-life o f 10-OH-CZ in eight subjects following single dose 300mg 
oxcarbazepine or after two weeks therapy (<£ mean +SEM).
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FIGURE 34 Individual antipyrine half-life values in eight subjects before, during (day 
8 and day 15) and two weeks after two weeks therapy with oxcarbazepine 300mg b.d.
single dose (65 + 15 mg.h/L, P<0.005). An increase was also seen for OXC (14.1 + 6.4 
mg.h/L vs. 8.0 + 5.7mg.h/L) but these figures are less reliable owing to the small number 
of points on many curves. Elimination half-life of 10-OH-CZ was not significantly 
altered at day 15 from the baseline (Figure 32. 95% Cl change -2.9 to +5h).
Mean predicted trough concentrations (+SD) from single-dose data and means of actual 
results are shown in Figure 33. Each individual subject had higher measured than 
predicted values at all steady-state time points.
Markers of Induction
Antipyrine half-life (95% Cl change, -2.7 to +3.1h) and clearance (95% Cl change, -0.1 
to +0.29 ml/kg.min) and 6-beta OH-cortisol excretion (95% Cl change, -151 to +197 
ug/24h) were not altered by chronic dosing with OXC (Table 18). Individual antipyrine 
half-life results at all time points are shown in Figure 34. The hormone and SHBG levels 
showed no significant changes during OXC treatment (Table 19) although DHAS and 
FAI both showed a possible "rebound" increase post-study. The 95% CIs for the changes 
in hormones and binding protein between baseline and day 15 were: T (-5.9 to +2.3 
nmol/L), SHBG (-9.6 to +5.6 nmol/L), AND (-4.1 to +4.5 nmol/L), DHAS (-3.1 to +1.9 
umol/L), FAI (-14.9 to +10.7%), FSH (-2.3 to +5.6 U/L), LH (-1.7 to +3.6 U/L) and PRL 
(-19 to +44 mU/L).
DISCUSSION
The clinical use of carbamazepine may be complicated by its enzyme-inducing 
properties. In the present study its analogue, OXC, was found to be devoid of any auto-
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TABLE 18 Antipyrine kinetics and urinary 6-beta hydroxycortisol excretion
before, during and after two weeks’ treatment with oxcarbazepine in 
8 male subjects
BASELINE DAY 8 DAY 15 POST-STUDY
Antipyrine half-life 10.6 10.3 10.4 9.3
(h) (3.3) (3.0) (1.7) (3.0)
Antipyrine clearance 0.88 0.86 0.98 0.96
(ml/kg.min) (0.20) (0.20) (0.15) (0.23)
6-beta hydroxycortisol 221 300 250 232
(ug/24h) (180) (129) (149) (129)
Values are mean (SD)
TABLE 19 Mean (SD) circulating hormones, sex hormone binding globulin 
concentrations and free androgen index before, during and after 
two weeks’ treatment with oxcarbazepine in 8 male subjects
BASELINE DAY 8 DAY 15 POST-STUDY
Testosterone (nmol/L) 14.3
(3.8)
Sex hormone binding 24.9
globulin (nmol/L) (7.5)
Androstenedione 7.3
(nmol/L) (3.7)
Dehydroepiandrosterone 8.3
sulphate (umol/L) (2.6)
Free androgen index (%) 58.8
(10.5)
Luteinising hormone 6.3
(U/L) (2.2)
Follicle stimulating 3.2
hormone (U/L) (2.7)
+Prolactin (mU/L) 118
(28)
13.3 12.6 13.9
(2.4) (3.8) (2.4)
25.4 22.9 22.4
(9.1) (6.6) (7.2)
5.3** 7.5# 6.7
(2.8) (4.2) (2.2)
8.1 7.7 9.9##
(2.5) (2.0) (2.3)
56.1 56.6 65.4##
(16.6) (13.0) (15.3)
7.2 7.2 8.1*
(1.7) (2.7) (2.5)
4.2** 4.6 3.7*
(3.0) (4.1) (2.7)
170** 131 186**
(41) (28) (64)
Friedman’s analysis o f variance + P<0.05 Wilcoxon matched pairs
* P<0.05 vs baseline 
** P<0.01 vs baseline
# P<0.05 vs day 8 
##P<0.05 vs day 15
inducing effects, as the half-life of the active metabolite remained unchanged after two 
weeks’ administration - a time period sufficient for near-maximum induction by 
equivalent doses of CBZ [Rapeport et al. 1983, Mikati et al. 1989]. The confidence 
interval "excludes" a fall o f 26% as opposed to the reduction in CBZ half-life of 40% in 
EXPT. 4 and of 38% in a similar previous report [Rapeport et al. 1983].
The standard markers of cytochrome P450 induction - antipyrine metabolism and 6-beta 
hydroxycortisol excretion [Roots et al. 1979, Park 1982, Rimmer et al. 1986] - were also 
unaffected by OXC therapy. Confidence intervals were against the likelihood of a 
reduction of 25% in antipyrine half-life (previous falls with CBZ - 35% in EXPT. 4, 33% 
[Connell et al. 1984a]); an increase of 33% in antipyrine clearance (CBZ - 39% [Connell 
et al. 1984a]), or a rise in 6 beta-hydroxycortisol excretion of 79% (CBZ - 178% 
[Rapeport et al. 1983]). These differences are illustrated graphically in Figures 35 & 36, 
while the effect o f CBZ on hormone and binding protein concentrations is compared with 
that of OXC in Figure 37. The 95% CIs of the hormone measurements in the present 
study approximate the magnitude of changes previously shown with CBZ in SHBG, FAI 
and DHAS [Connell et al. 1984a], so changes of this magnitude were almost "excluded" 
at the 5% level. Thus, there was no evidence of OXC accelerating its own metabolism or 
that of any of the other indices of induction.
After two w eeks’ treatment with OXC, the dosage interval AUC of 10-OH-CZ was 
significantly larger than that to infinity following a single dose, and the observed steady- 
state concentration profile was also higher than predicted. Nevertheless, the time to reach 
steady-state was not affected, and the AUC ratio of 10-OH-CZ:OXC (where calculable) 
showed no overall change after repeated dosing. The elimination half-life of OXC (where 
calculable) was also unaffected by repeated dosing, suggesting a lack of autoinduction.
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FIGURE 35 Effect o f two weeks* oxcarbazepine on the half-life o f its major 
metabolite 10-OH-CZ compared with the previously shown (EXPT. 4) effect of two 
weeks’ carbamazepine on its own half-life. Mean +SEM. ** P<0.01.
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FIGURE 36 Comparison o f effects o f two weeks’ oxcarbazepine ( • - • )  or 
carbamazepine (o~o) on antipyrine half-life (cf. EXPT. 4) and 6-beta hydroxycortisol 
excretion (cf. Connell et al 1984). ** P<0.01.
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FIGURE 37 Comparison o f effects o f two weeks’ oxcarbazepine (•—•)  on sex 
hormones and binding globulin with previously shown (cf. Connell et al 1984, Macphee 
ct al 1984) effects of carbamazepine (o--o). Mean +SEM. * P<0.05.
The higher than predicted steady-state values require some comment. Recent work by the 
pharmaceutical company, Ciba-Geigy, has shown a 17% increase in the systemic 
availability of 10-OH-CZ when OXC is given after a meal [P Lloyd, personal 
communication]. Absorption of OXC itself may be slowed after a meal. In the present 
study, the single-dose and steady-state profiles were determined in fasted subjects, while 
steady-state trough levels were generally monitored under non-fasting conditions. This 
may account, at least in part, for the observed increase in serum levels of 10-OH-CZ. 
Another possible explanation is a putative "biphasic" elimination half-life for 10-OH-CZ. 
It has been suggested that the metabolism of OXC is saturable and so the elimination 
half-life may be prolonged at higher concentrations [Theisohn & Heimann 1982]. This 
could explain our findings, although analysis of the individual concentration-time curves 
showed only two which might better fit a biphasic model. The situation, therefore, 
remains unclear.
Of the hormonal measurements, only serum prolactin concentrations varied significantly 
during the study (Friedman’s two-way analysis of variance, P<0.05). This difference is 
likely to be due to the use of indwelling cannulae for obtaining blood samples only for 
baseline and day 15 samples, which were the days when multiple sampling was 
performed. While none of the other hormones showed significant variation, it would be 
imprecise to ignore the trends for a rebound increase in AND, DHAS and FAI after an 
initial small fall and the trend for an increase in LH, since they are at variance with our 
hypothesis o f lack of induction with OXC. These trends would be "statistically 
significant" if direct W ilcoxon tests were performed without the initial assessment by 
analysis of variance. Thus, while this may well be an effect of multiple analysis, we have 
not excluded some slight alteration of endogenous hormone metabolism caused by OXC.
If these small falls and rebound increases are indeed occurring, they could be due to 
increased LH, the negative feedback mechanism which would be expected to normalise
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hormone values [Bentley 1980a] but which appeared inactive in a previous study with 
CBZ [Connell et al. 1984a]. This would suggest either that an unexplained rise in LH has 
occurred, or that a small fall in hormone levels is being caused by OXC. It is conceivable 
that, since T, AND, and DHAS are reduced as their first step in metabolism [Bentley 
1980a], OXC - which is also reduced - might induce this pathway. This would explain a 
small effect on steroid metabolism, but no effect on the metabolism of 10-OH-CZ or that 
of markers of oxidative induction. A minor degree of induction by the OXC metabolite, 
10-OH-CZ [Wagner & Scmid 1987], is another possible cause of a change in steroid 
metabolism, as the P450 cytochrome enzyme system is involved [Bentley 1980a] but this 
would not account for the discrepancy with other markers of oxidative metabolism. 
Significant induction of reducing enzymes is rare and unlikely to be of clinical 
significance [Bachur 1976].
Overall, we found no evidence of any major inducing effect of OXC on its own 
metabolism or those of other endogenous or exogenous markers of oxidation. By 
necessity, the dose of OXC was low and we cannot exclude at this stage a small 
induction effect in patients receiving a higher dose of the drug, as has very recently been 
suggested [Patsalos et al. 1990], however the difference between OXC and CBZ is 
obvious (Figures 35, 36, 37). OXC is a compound with similar anticonvulsant efficacy to 
CBZ, but which appears to have improved patient tolerability both with regard to allergic 
reactions and psychomotor impairment [Houtkooper et al. 1987, Reinikainen et al. 1987, 
Dam et al. 1989]. The latter potential advantage may be due to its lack of an epoxide 
metabolite, the role of which in the neurotoxic side-effects associated with CBZ has 
already been mentioned [Patsalos et al. 1985, Gillham et al. 1988].
It is this difference in metabolism which may also be responsible for the lack of 
monooxygenase induction with OXC demonstrated in the present study. This may give
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OXC an advantage over CBZ in patients taking other drugs, particularly the 
contraceptive pill. However, a specific study to determine the effect of OXC on the 
metabolism and efficacy of oestrogen-containig contraceptives is indicated before we 
assume that no interaction exists.
It should be noted that the dosage of concomitant drugs will also require reappraisal if 
OXC is substituted for CBZ, as toxic concentraions of other AEDs could occur. As we 
have seen, the effect of enzyme induction on endogenous hormones remains unclear, and 
any elucidation of its importance may enhance the case of OXC as a possible first-line 
AED. Its place in the therapeutic armamentarium is as yet uncertain, but this should be 
clarified when OXC comes into more widespread use.
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CONCLUSION CHAPTER 3
The problem of hyposexuality in epilepsy, and the relative importances of the treatment 
and the disease itself, remains a complex one. Perhaps it is significant that we have 
found, in EXPT 5, no change in the sex hormones in untreated epilepsy patients. Could 
hyposexuality be caused entirely by AEDs? While it may be argued that these are less 
severely affected patients, it is interesting to contrast the results of EXPT. 2, where a 
similar group o f untreated epileptics had obvious psychomotor impairment compared 
with controls. Other workers have only rarely included untreated patients in their studies, 
and those who have done so, tend to find no differences between such a group and 
controls with regard to DHAS [Levesque et al 1986, Isojarvi et al 19 8 8 ,1989a], T, FT, 
SHBG, LH and FSH [Isojarvi et al 19 8 8 ,1989a]. Perhaps it is also significant that the 
concept of hyposexuality in epilepsy was not widely recognised until 1954 [Gastaut & 
Collomb] with very little mention of such problems in the pre-anticonvulsant era. Indeed, 
hypersexuality was considered as the norm, leading to such attempted treatments as 
clitoroidectomy and castration well into the nineteenth century [Duffy 1963]. Potassium 
bromide was first considered by Locock as a possible anticonvulsant because of its 
libido-reducing properties [Sieveking 1857].
It might, however, be too simplistic to suggest that hyposexuality in epilepsy is entirely 
due to the use of anticonvulsants. The early associations of hyposexuality with temporal 
lobe epilepsy, while not rigidly controlled, remain persuasive e.g. the finding by Hierons 
& Saunders [1966] o f 15 cases of impotence - all amongst their TLE patients. They 
included a patient on no therapy, and Saunders & Rawson [1970] cite two further such 
cases. However, these were all severe cases of epilepsy following trauma. W hile the 
temporal lobe may have some part to play in sexual problems, it may be the underlying 
brain damage which was important in these patients, rather than the epilepsy itself. In the
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normal epileptic population, it is more likely that social adaptation [Taylor 1969] and 
AED usage are the major factors in causing an increased incidence of hyposexuality. 
Certainly, the evidence for an intrinsic problem is less convincing than that with 
psychomotor impairment.
If drugs are to blame, enzyme induction may play an important part, though general 
sedative effects of AEDs may also contribute to the problem. It is clear that these 
anticonvulsants do alter hormone concentrations, although the mechanism - or order of 
events - is uncertain. An increase in SHBG is the most consistent finding in all of the 
studies performed, including EXPT. 5. It seems unlikely that this is a secondary 
phenomenon to an enzyme-induced fall in FT, as Toone suggests [1984], which leads to 
a "rise in LH with consequent increase in testosterone synthesis and so to an increase in 
bound testosterone and FT; and second to a rise in SHBG which in turn leads to a further 
increase in bound testosterone and to a fall in FT". It seems illogical that the homeostatic 
mechanisms compensating for a fall in FT should, with no other defect, result in a further 
lowering of FT.
Since studies which find no real change in total testosterone still find a markedly 
increased SHBG [Dana-Haeri et al 1982, EXPT. 5, Isojarvi et al 1989b], it is more likely 
that increased production of SHBG by the liver [Bentley 1980b] is a direct effect of 
enzyme induction. Free testosterone becomes decreased, and there is an LH response in 
an attempt to increase production of testosterone in the Leydig cells. The effectiveness of 
this feedback mechanism will obviously be hindered by an increase in T metabolism, and 
it may well be that the variation in findings with total and free testosterone is simply a 
reflection of the heterogeneity of patients’ relevant homeostatic abilities. Under the stress 
of enzyme-inducing AEDs, some patients’ mechanisms will cope, and some will not. In 
EXPT 5, while we failed to show a significant decrease in FT on AEDs, it should be
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noted that 8 subjects had FT levels below 220pmol/L (6.6mg/dL) - and all of these were 
in the induced groups (3 CBZ, 3PHT, 2 polypharmacy). This level of FT has been 
described as a cut-off point below which patients tend to exhibit hyposexuality which 
improves with oral testosterone undecoanate therapy [Carani et al 1990]. These FT 
findings, although not "statistically significant" may represent clinically important 
findings in individual patients.
It appears, therefore, that any global assessment of epileptic patients will find evidence of 
hyposexuality, and evidence of hormonal changes. However, attempts to be more precise 
- looking at individual drugs or trying to relate hyposexuality to AED concentration - 
may fail simply because there is an intermediate variable factor, perhaps the patient’s 
own homeostatic mechanisms, which dilutes the association. Some workers have 
managed to show, for instance, a positive correlation between CBZ concentration and 
PRL levels, and between low sexual drive and low FT, but have failed to take this a stage 
further and relate AED dosage or concentration with sexual function [Toone et al 1983].
A large scale study, looking at AED concentrations, hormone concentrations and a 
measure of sexual function is required, using groups of untreated patients, patients on 
different drugs, and controls.
Sexual function study
We have now designed and commenced such a study, where the patients’ marital status, 
religion, social class, education and employment status are all recorded. The measure of 
sexual function used was the "sexual experience scale" (SES) as designed and validated 
by Frenken & Vennix [1981] at the University of Utrecht. Patients were recruited from 
the clinic, and controls from medical, laboratory and nursing staff, and from the patients’ 
relatives, friends and spouses. Subjects answered questions in private using a video 
screen and user-friendly software prepared for an Apple II microcomputer. The questions 
are either o f a yes/no variety, or allow answers on a three- to five-point scale between
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two extremes. They fall into four different categories, and are designed to give an 
indication of the following aspects of sexual behaviour:
SES 1. Adherence to Restrictive Morality
21 Questions: possible score 21-105.
High score = "high morality".
Example:
Q. It is acceptable that an engaged couple have sex together...
A. Completely agree...slightly agree...neither agree nor disagree... 
...slightly disagree...completely disagree
SES 2. Allowance of Psvchosexual Stimulation
15 Questions: possible score 15-67.
Low score = high allowance of stimulation.
Example:
Q. I find watching a T.V. show with lots of nudity...
A. Very pleasant...fairly pleasant...a little pleasant...
...fairly unpleasant...very unpleasant.
SES 3. Attraction to Physical Sexual Stimulation ("sexual motivation")
29 Questions: possible score 29-144 
Low score = high sexual motivation.
Example:
Q. I find lengthy and extensive petting...
A. Very pleasant...fairly pleasant...a little pleasant...
...fairly unpleasant...very unpleasant
1 09
SES 4. Attraction to Marriage
18 Questions; possible score 18-93 
High score = high attraction to marriage.
Example:
Q. Are you satisfied with the affection and love your wife shows?
A. Not satisfied...could be better...completely satisfied
Scores for all questions in each category are summated to give an overall score for that 
category. Results may be divided into classifications - e.g. with regard to sexual 
motivation (SES3): "Appetitive" = 29-60, "Apathy" = 61-71, and "Aversion" =72-144. In 
this preliminary analysis, only the precise scores have been utilised.
Subjects supplied a venous blood sample for assay of sex hormones and anticonvulsant 
concentrations where appropriate. Antipyrine kinetics were also assessed in as many 
subjects as possible. These procedures were performed as previously outlined.
This is a long-term study with various facets, and has been conducted by Peter Milligan 
(pharmacist), Violet McKay (pharmacist), Jacqueline Blacklaw (research assistant),
Carol Read (research assistant), Dr. Paul McKee and myself. The study is ongoing and 
involves male and female epileptic and healthy subjects. I have performed an interim 
analysis at various stages on males and females, the results of the first 50 males and 
females having been used as part of the M.Sc. theses of the first two named above. I will 
confine myself here to the data of the first 213 male subjects, of whom 96 have hormone 
assay results available (Table 20). This number is still too small for some comparisons, 
e.g. between individual drug groups, but much interesting information is already 
available.
11 0
TA
BL
E 
20 
D
et
ai
ls 
an
d 
me
an
 
(S
D)
 S
ex
ua
l 
Ex
pe
ri
en
ce
 
Sc
ale
 
sc
or
es
 
of 
21
3 
su
bj
ec
ts
M3C/5 
U 
0/ s  o
6 L._ o 
Z K
3
E
3
wo
C S
VO o
C S
< S  CO C S  ^
C S  ©  c*> H -' ©C S
VO
vdvo
wo
oovo ONr-
vo
o\
VO
CO _  v o  _  CO
cd 2  ov £  —<*
tj- w  C- wo cs
r*
o
wo
CS ^  — VO CO
WO cs
wor t vd/X  rH
i s *C O  —
O W 8r*s *55Z  V3 u
CO C v woCS wo cscs
SESM  WZ  c« voCO O vCO
wo
C O
cs^t O n
cs
cs ON
s  ^
wC/3
4> C S
wo
*n —
WO £  
WO w
vo ^
WO 2 2
wo C-
oo
wo
wo
00 S;
wo O
cs
o
wo
ov
B
u .2
a - i
fa w
cs wo CO wo wo
B2 ftM  ®X)s<
cs
cs
cs
oocs
r-
o
CO
cs
CO ON
cs ©
co C-
00
C O NO
00
cd
C O VO
o
z 00C O C O cs 00C S wo cswo
§co
u
^  C/3<D u•3
p H
c d
d  8
3cd
s
P h
3
>
1
u
B
2Soc<DXJPh
UI
• rH
la
’o
g
£ S
E
S
j: 
hig
h 
sc
or
e 
= 
‘h
ig
h’ 
m
or
al
ity
. 
SE
S2 
: h
igh
 
sc
or
e 
= 
low
 
al
lo
w
an
ce
 
ps
yc
ho
se
xu
al
 s
tim
ul
at
io
n
SE
S3 
: h
igh
 
sc
or
e 
= 
low
 
al
lo
w
an
ce
 
ph
ys
ic
al
 s
ex
ua
l 
st
im
ul
at
io
n.
 
SE
S4 
: h
igh
 
sc
or
e 
= 
hig
h 
at
tra
ct
io
n 
to 
m
ar
ria
ge
The most striking immediate finding further complicates the explanations of 
hyposexuality in epilepsy, as sufferers were shown to adhere to a more restrictive moral 
code than non-epileptics (P=0.0051). This might help explain their decreased affinity for 
psychosexual stimulation (P=0.0019) and physical stimulation (P=0.005), since a high 
morality was independently associated with low psychosexual (PcO.OOl) and physical 
sexual (P<0.001) appetite. The reasons for the "higher moral values" among epileptics 
may include a tendency for patients to spend more time under the "parental wing", or 
their decreased likelihood of going on to further education (PcO.OOl). The significance 
here is that, within the normal group (P<0.05) and within the epileptic group (PcO.OOOl), 
further education was independently associated with a lowered morality and a 
(?consequent) increase in psychosexual appetite (e.g. in epilepsy patients; P=0.0006). If 
we make allowance for this effect by studying further educated subjects in isolation, the 
difference in morality between epileptic and non-epileptic subjects becomes non­
significant and all but disappears, but a trend to decreased physical appetite in epileptic 
patients (P=0.08) remains. Meanwhile, among subjects who have no further education, 
there is a definite decrease in sexual motivation among epileptics (P<0.01).
Other influential factors include religious affiliation (strong, moderate, weak) which 
affected morality (PcO.OOl) and allowance of psychosexual stimulation (PcO.Ol). It was 
also shown that untreated epileptic patients were less attracted to psychosexual 
stimulation than healthy controls (P=0.027), so it would appear that social conditioning 
or the disease itself must have some bearing on the hyposexuality, which cannot be an 
effect exclusively of the AEDs.
With regard to the hormone assay results, the drugs had similar effects to those in EXPT. 
5, except that the CBZ effect on circulating PRL was not shown. The correlation of 
hormone concentrations with sexual function showed an interesting association between 
a raised SHBG and lowered physical appetite (r=0.498, PcO.Ol; Fig 38). The derived free
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androgen index (r= -0.454, P<0.005) and freeT (r= -0.377, P<0.05) were also shown to 
correlate negatively with SES3 (i.e. positively with physical sexual appetite; Figures 39, 
40).
So far, no significant differences have been seen between the drug groups, but one 
instance of making the link between drug, hormones and sexual function has been 
demonstrated. Free CBZ concentrations are inversely related to psychosexual appetite 
(r=0.633, P<0.02; Figure 41).
Clearly, when this database is complete, a substantial amount of information will be 
available, but it will require careful analysis. I have been able only to give a small 
preview of this, but what we can see is a further group of confounding factors - morality, 
education, social and religious background - which might influence sexuality among 
epileptic patients. Further education and separation from family ties seems to induce a 
more liberal morality, so, as a group, epileptic subjects may be relatively sexually 
inhibited.
It would appear that drugs are only one factor in the problem, although it may be true 
that they are more important than the physiological effects of the disease itself. While 
information from this massive study will hopefully prove the case, there is accumulating 
evidence that enzyme induction is a likely mechanism for the contribution of AEDs to 
altered sexuality in epileptic patients. It would seem appropriate, therefore, to use VPA in 
patients who complain of, or may suffer from, such problems. The advent of 
oxcarbazepine as a non-inducing "equivalent" of CBZ may give the clinician another 
valuable option.
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FIGURE 38 Correlation o f Sex Hormone Binding Globulin concentrations and 
increasing SES3 scores (i.e. high SHBG, low sexual motivation) in 36 male subjects.
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FIGURE 41 Correlation o f serum free carbamazepine concentrations with increasing 
SES3 scores (i.e. high free carbamazepine levels, low sexual motivation) in 13 male 
epileptic patients.
PA R T 2
T H E  PO SSIB LE R O L E  O F C A LCIU M  ANTAG ONISTS
The theoretical basis for the use of calcium antagonists in epilepsy will be discussed. 
Two drugs in the dihydropyridine group, nifedipine and nimodipine, are investigated. A 
preliminary open study of nifedipine (EXPT. 8) is followed by a pharmacokinetic 
assessment of these drugs in mice (EXPTS. 9 & 10). Further placebo-controlled studies 
of these drugs are presented (EXPTS. 11 & 12). The possible relevance of adenosine 
receptors is investigated using a radioligand binding assay in EXPT. 13. The present 
outlook and future avenues of research for these drugs are then discussed.
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CHAPTER 4
CALCIUM ANTAG ONISTS AND EPIL E PSY
INTRODUCTION
In the first part of this thesis, I have demonstrated that many AEDs share the same side- 
effects - in particular psychomotor impairment and the effects of enzyme induction. 
Improvements in these factors with such drugs as slow-release CBZ and oxcarbazepine 
represent small steps forward in the treatment of epilepsy. However, a new drug, or 
group of drugs, which lacked the most important of these side-effects - concentration- 
dependent sedation - could presage a leap forward in epilepsy management. One possible 
such group of drugs is the calcium antagonists (CAs).
There are arguably more calcium antagonist drugs than there are AEDs. Verapamil was 
first investigated by Fleckenstein in 1964 [Fleckenstein 1977], and was used in 
cardiovascular disease for many years as a presumed "beta-adrenergic receptor 
antagonist" [Greenberg 1987] based on the finding that beta-agonists enhance calcium 
influx [Reuter 1965]. In 1977, however, Fleckenstein confirmed his initial suspicions that 
a direct action on calcium channels was the likely mode of action. By this time, 
nifedipine and diltiazem had appeared, heralding a shower of "me-too" drugs for use in 
angina and hypertension.
Classifications of the calcium antagonists are complex and may utilise pharmacological 
or clinical parameters [Vanhoutte & Paoletti 1987], but structurally the main groups at 
the time of starting this work were: the 1, 4-dihydropyridines (nifedipine, nimodipine, 
nicardipine, nitrendipine), the phenylalkylamines (verapamil, methoxyverapamil), the 
diphenylalkylamines (flunarizine) and the benzothiazepines (diltiazem) (Figures 42, 43).
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FIGURE 42 Dihydropyridine drugs. Nifedipine and nimodipine are calcium channel 
antagonists, while BAY K 8644 is a calcium agonist. Note similarities in structure o f  
nifedipine and BAY K 8644.
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FIGURE 43 Other calcium antagonists including a phenylalkylamine (verapamil), a 
diphenylalkylamine (flunarizine) and a benzothiazepine (diltiazem).
Of these, only nifedipine, verapamil and diltiazem were being used to any great extent in 
this country. Indeed, these three were the only CAs available for clinical use in the USA 
[Greenberg 1987]. However, other drugs, including neuroleptics such as pimozide and 
thioridazine, were also known to have marked calcium antagonist properties [Snyder & 
Reynolds 1985].
The CAs have their effects on "calcium channels" - proteins spanning the cell membrane 
which, when "open", allow passive passage of the Ca++ ion from the mM extra-cellular 
concentrations to the nM intracellular concentrations [Greenberg 1987]. Other cations, 
such as Ba++ and Na+ may also pass through the open channels, while others such as 
Cd++, M n++ and M g++ may block the entry of Ca++.
The channels themselves may be opened by changes in membrane potential such as that 
which occurs with depolarisation ("voltage-dependent calcium channels" - VDCCs) or by 
occupation of associated receptors ("receptor-dependent" or "ligand-gated" channels).
The VDCCs may be classified into at least three different types. Long lasting (L) 
channels are activated by strong depolarisations, are resistant to inactivation, but are 
sensitive to blockage by Cd++. Transient (T) channels are activated by weak 
depolarisation, readily inactivate and are less sensitive to Cd++. A second transient 
channel (N) which shares the L-channel characteristics with regard to depolarisation and 
Cd‘f + blockage also exists [Greenberg 1987]. Calcium antagonist drugs (CAs) seem to 
exert their effects on the VDCCs, in particular the "L-channels" which produce a long- 
lasting inward calcium current [Greenberg 1987, Himing et al 1988, Meyer 1989].
The VDCCs are almost ubiquitous in the body, being present in smooth, cardiac and 
skeletal muscle, and various other sites including neurones [Hagiwara & Byerly 1981]. 
The movement o f calcium ions into axons during stimulation of neurones was first
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shown by Hodgkin & Keynes in 1957. Studies with frog ganglion cells in a sodium-free 
medium soon demonstrated that depolarisation potentials could occur without N a+ influx 
[Koketsu et al 1959a] but not without calcium [Koketsu et al 1959b]. The presence of 
VDCCs in the brain has led to the study of calcium antagonists in various neurological 
disorders [Raeburn & Gonzales 1988, Delumeau et al 1989]. Animal [Little et al 1986] 
and clinical [Koppi et al 1987] studies have suggested that they may relieve alcohol 
withdrawal symptoms. Schizophrenia has also been reported to improve with verapamil, 
though in an uncontrolled trial [Tourjman et al 1987] which has not been confirmed 
[Scheperlem & Koster 1987, Grebb et al 1986]. The gradual realisation that CAs may 
have a role to play in anticonvulsant therapy has resulted from a variety of observations 
which suggest that calcium influx across the neuronal membrane might play a part in the 
initiation and propagation of seizures.
Cellular Events in Epilepsy
The initiation of epileptogenic activity in the neurone is thought to concern the "intrinsic 
bursting" or "sustained repetitive firing" which may occur in normal invertebrate or 
vertebrate neurones and correlates with the excitability state of the neurone [MacDonald 
& McLean 1986, DeLorenzo 1988]. This can occur in isolated neurones, and may be due 
to a rapid repolarisation of the cell membrane caused by an outward K + current which is 
activated by the slower inward Ca++ current [Prince 1985, Hotson & Prince 1980]. 
Intrinsic bursting is inhibited by all AEDs active in GTCS and partial seizures 
[MacDonald & McLean 1986]. Similar burst-firing can be induced in e.g. hippocampal 
neurones by proconvulsants such as PTZ [Bingmann & Speckmann 1986] and penicillin 
[Wong & Prince 1979] and may lead to synchronous burst firing of multiple neurones. 
Synchronous bursting is almost certainly synapse-mediated [Meyer 1989] and thus 
calcium-dependent since the synaptosomal release of excitatory neurotransmitters is 
dependent on calcium influx [Katz & Miledi 1969] and not simply depolarisation
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[Zucker & Lando 1986]. This action of calcium is probably mediated by a 
calcium/calmodulin-dependent kinase which inactivates an inhibitor of transmitter 
release by protein phosphorylation [DeLorenzo & Freedman 1977, Llinas et al 1985].
Normal intrinsic bursting does not usually precipitate synchronous burst firing. One 
possible cause of progression is a loss of inhibitory mechanisms (inhibitory post-synaptic 
potentials) which are GABA-mediated and are blocked in experimental models by 
proconvulsants such as penicillin [Prince 1985]. In man, it is possible that clinical 
epilepsy may occur when inhibiting fibres are damaged - perhaps preferentially by 
hypoxia [Sloper et al 1980]. Other possibilities include a decrease in electrical stability, 
as has been shown to occur in damaged neurones in crayfish [Kunada & Wine 1981] and 
cats [Kuno & Llinas 1970]. Whatever the reasons, the occurrence of "excessive repetitive 
discharge of neurones" has been described recently by Meyer as "the basic dysfunction at 
the cellular level (in clinical epilepsy)" [Meyer 1989]. The resemblance of this to 
Hughlings Jackson’s description, so many years ago, of epilepsy as an "excessive 
synchronous discharge of nerve cells" [Jackson 1870] is striking.
Synchronous bursting may be the end-stage response of "stimulated" neurones, or it may 
progress to produce paroxysmal depolarising shifts (PDSs) which are abnormal, long- 
duration action potentials long recognised to be associated with the initiation of seizure 
activity [Goldensshon & Purpura 1963]. The PDS is the individual neurone’s 
synchronised part of a large extracellular field potential which appears as the interictal 
"spike" on EEG tracings [Matsumoto & Marsan 1964].
It has been established that the PDS is calcium-dependent [Wong & Prince 1979], as is 
the associated burst firing in hippocampal neurones [Schwartzkroin & Slawsky 1977] 
which has been likened to the burst-firing of pacemaker cells, another calcium-dependent
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phenomenon [Thompson & Smith 1976]. Application of various calcium channel 
blockers can inhibit burst firing [Bingmann & Speckmann 1989] and depress the 
amplitude and frequency of PDSs in hippocampal slices [Bingmann & Speckmann 1989] 
and in anaesthetised rats [Witte et al 1987, Speckmann et al 1986], while systemic 
administration of calcium antagonists e.g. by intracerebroventricular perfusion can 
depress interictal discharges [Walden & Speckmann 1988]. Conversely, the calcium 
agonist BAY K 8644 [Schramm et al 1983], a dihydropyridine which resembles 
nifedipine structurally (Fig. 42) can be shown to exhibit the opposite effects. It increases 
calcium influx in neurones [Walden & Speckmann 1987] and has been shown to enhance 
PDS activity in experiments similar to the above [Walden et al 1986], thus further 
confirming the importance of calcium influx and suggesting an anticonvulsant role for 
calcium antagonists.
The overall effect of calcium influx during epileptogenesis can be measured as a fall in 
extra-cellular calcium during chemical or electrical-induced seizures in the cortex o f the 
cat [Heinemann & Louvel 1983, Heinemann et al 1977]. The decrease is in the order of 
0.45-0.55 mM [Heinemann & Louvel 1983, Pumain et al 1983], a fall o f almost 50%. It 
occurs just prior to the onset of burst firing, and accompanies intracellular accumulation 
of calcium in the mitochondria [Griffiths et al 1983].
Calcium Antagonism in AEDs
Further circumstantial evidence for the importance of calcium’s role has come from 
investigation of conventional AEDs which has revealed that many of them have calcium 
antagonist properties. Sohn & Ferrendelli [1976] and later Ferendelli & Daniels- 
McQueen [1982] showed that phenytoin decreased synaptosomal uptake of calcium. The 
latter paper found similar results with CBZ which has since been shown to inhibit 
transmitter release by this mechanism [Crowder & Bradford 1987]. Benzodiazepines also
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inhibit calcium uptake [Leslie et al 1980] perhaps via a specific receptor [Taft & 
DeLorenzo 1984]. Actions of these drugs, however, may differ from those of 
conventional CAs. Phenytoin appears to act on more transient ("T") calcium channels 
than those affected by CAs [Twombly et al 1988], while some of the BZs’ calcium 
antagonist activity may stem from inhibition of the intracellular calcium/calmodulin- 
dependent protein kinase [DeLorenzo et al 1981] rather than an effect on the calcium 
channels themselves. The relevance of these actions to the anticonvulsant properties of 
these drugs is not clear, but certainly the effects of the AEDs are not fully explained by 
other mechanisms. As an example, the relative binding of different BZs to the BZ central 
receptor correlates well with their relative anxiolytic properties and their inhibition of 
PTZ seizures, but not with the inhibition of electroshock seizures [Taft & DeLorenzo
1987]. It is possible that at least part of the action of established AEDs is due to calcium 
antagonism.
Animal Seizure M odels
Studies of calcium antagonists in various animal models of epilepsy have furthered their 
case as possible AEDs. Flunarizine and cinnarizine were the first CAs to successfully 
inhibit electroshock seizures [Desmedt et al 1975] and pentylenetetrazol-induced seizures 
[Desmedt et al 1976] in rodents. Flunarizine was also found to be effective against 
seizures produced by direct application of D.L.-allylglycine onto rat cortex [Ashton & 
Wauquier 1979a], and in the more sophisticated model of "amygdaloid kindled" seizures 
- where regular subclinical electroshocks eventually "sensitise" the amygdala to produce 
seizures following very small shocks - in both rats [Ashton & W auquier 1979b] and dogs 
[Wauquier et al 1979]. More recently, De Sarro et al [1986] tested flunarizine in models 
as diverse as audiogenic seizures in DBA/2 mice and photosensitive seizures in baboons. 
They found it to be effective, as did Pohl & Mares [1987] using a PTZ model. In the
1 1 9
latter study, only the tonic phase of major seizures was obviously decreased, a finding 
they describe as identical to previous results they had achieved with CBZ and PHT.
While Verapamil has occasionally shown some anticonvulsant activity [Walden & 
Speckmann 1988], it has proven ineffective in many studies [Meyer et al 1986a, De 
Sarro et al 1988, Wong & Rahwan 1989], and it is the dihydropyridines which have 
shown promise similar to that of flunarizine. Nimodipine was first noted by Meyer and 
his colleagues to inhibit ischaemic seizures in the white New Zealand rabbit [1986a]. 
Since nimodipine also improved cortical blood flow in ischaemic regions, they embarked 
on further experiments using other seizure models in the rabbit to determine whether 
nimodipine indeed had a separate anticonvulsant action [Meyer et al 1986a, M eyer et al 
1986b, Meyer et al 1987]. These confirmed its efficacy in ischaemic, reperfusion and 
electroshock-induced seizures, and also in those induced by bicuculline and PTZ. Other 
workers had shown similar results in cefazolin-induced seizures [Morocutti et al 1986] 
and audiogenic seizures [De Sarro et al 1988]. This last paper of De Sarro is one of a 
number to show a proconvulsant effect with the calcium agonist Bay K 8644 [Shelton et 
al 1987, Dolin et al 1988].
Further confirmatory studies have been published during the work of the present thesis 
using PTZ [Dolin et al 1988, O ’Neill & Bolger 1989], electroshock seizures [Meyer et al 
1990] and kainic acid-induced seizures [Paczynski et al 1990]. Wong and Rahwan 
[1989] found nifedipine to be ineffective vs. maximal electroshock seizures but effective 
against PTZ seizures and inferred that the drug might only be active in "petit mal" 
attacks, since the standard PTZ threshold test [Krall et al 1978] has been suggested to be 
specific for drugs active against absence seizures. Various alterations in this test 
however, as discussed by Meldrum [1986] can change this supposed specificity either by 
varying the technique [Kent & W ebster 1983] or the strain of mouse [Sugaya et al.
1986]. Since the method of W ong & Rahwan was not that of the "threshold test", their
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inference is perhaps over-specific.
Clinical Trials
In the face of the above evidence, it is perhaps surprising that clinical trials of calcium 
antagonists in epilepsy remain in their infancy. At the time of commencing this thesis, 
only flunarizine had been tested in patients. Declerk & W auquier initially reported some 
success in mentally retarded patients in trials performed in the late 1970s [Declerk & 
Wauquier 1980]. A double-blind placebo-controlled study by Overweg et al [1984] 
showed "a modest but statistically significant" fall in seizure frequency in 33 patients, 7 
of whom had a seizure reduction of more than 50%. Blood levels of flunarizine were 
found to be rather low (enzyme induction by concomitant AEDs), and an open dose- 
ranging study followed [Binnie et al 1985] where 16 out of 47 patients had a 50% drop in 
seizures. The incidence of side-effects was acceptable, although 15 patients complained 
of drowsiness and one of these required withdrawal from the study. These, plus a further 
report from the same group [Overweg et al 1986], were the main reports in the English 
literature of trials with flunarizine. Work was in progress in Europe and Japan, and was 
reported at various clinical meetings. A recent review by Binnie [1989] recounts the 
marked success of many open trials, where overall, 74 of 197 (38%) patients achieved a 
50% reduction in seizure frequency; and the promise of early crossover studies in which, 
again taken together, 30 (21%) patients improved by 50% on flunarizine, but only 6 (4%) 
on placebo.
Although the incidence of side-effects in the above studies was not particularly high, 
flunarizine is known to cause neurological abnormalities, including Parkinsonism and 
depression [Chouza et al 1986, Micheli et al 1987], and it seemed a logical step to 
consider other calcium antagonists as candidates for clinical trials. This is particularly
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true since flunarizine has numerous actions including antihistaminic, antiserotonergic and 
antidopaminergic activity [Brodie 1990]. It also has an effect on sodium channels [Binnie 
1989] similar to that of CBZ and PHT [Willow & Catterall 1982]. All of this leads to 
doubts over the importance of calcium antagonism in flunarizine’s anticonvulsant 
activity [Binnie 1989].
Before the work of this thesis began, preliminary investigations with verapamil 
[Macphee et al 1986c] and diltiazem [Brodie & Macphee 1986] had been undertaken in 
our unit, but both these drugs were found to inhibit the metabolism of CBZ - which many 
patients were taking concurrently - thus increasing serum concentrations of CBZ and 
causing toxicity. The accumulating evidence for the efficacy of the dihydropyridines in 
animal models of epilepsy supported this group of drugs as an ideal choice for further 
investigation as possible AEDs.
In this chapter, the dihydropyridines nifedipine and nimodipine will be investigated. The 
former drug has received little attention in the epilepsy literature which has focussed 
more on its less well-recognised alternative. The reasons for this may be partly 
psychological - the avoidance of a drug established in other spheres - or perhaps even 
commercial, since the pharmaceutical companies may have little incentive to promote 
new research with an inexpensive drug now out of patent. Other considerations may have 
had more influence. Nifedipine, a less lipophilic drug than nimodipine, was not 
recognised to cross the blood-brain-barrier (BBB), and in 1986 flunarizine was still being 
quoted as the only calcium antagonist "known to enter the brain" [Overweg et al 1986]. 
However, nimodipine had been shown to cross the BBB in the gerbil [Heffez et al 1985], 
and was found to relax cerebral vessels more than nifedipine [Towart 1981] and increase 
both cerebral and coronary blood flow [Haws et al 1983]. It was also shown in animal 
EEG studies to possess psychotropic properties of a "mood-elevator" type [Itil et al
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1984]. These findings may have led to its presumed superiority as a neurologically active 
drug. We decided to investigate these drugs, both clinically and in an animal model of 
epilepsy. Pharmacokinetic studies were also undertaken, in particular to assess the 
penetration of nifedipine into the brain.
The first study (EXPT 8) is an open clinical trial of nifedipine, performed to exclude any 
effect of this drug on the metabolism of CBZ, and to assess in an uncontrolled fashion, 
the possibility of its having anticonvulsant efficacy. Chronologically, the next studies 
performed were in mice (EXPTS 9 & 10) where blood and brain levels of nimodipine 
and nifedipine were measured at different time points after intraperitoneal (i.p.) injection, 
thus assessing blood and brain "half-lives" and BBB penetration. A PTZ seizure model 
was also utilised to compare anticonvulsant efficacy of the two drugs with each other at 
different dosages, and when used alone or in combination with CBZ. Finally, two 
placebo-controlled studies, one of each drug, were designed. One (of nimodipine) was 
performed by m yself in the Western Infirmary, and the other (nifedipine) was designed 
in the Unit and performed in Lingfield Residential School. The implications of the 
disparity between the results of animal and clinical studies are discussed in the 
conclusion, with reference to the recent literature and future possibilities. The last study 
concerns a possible alternative mechanism for the antiepileptic properties of calcium 
antagonists and for any interaction with other AEDs - their effects on adenosine 
receptors.
Calcium Antagonists and Adenosine Receptors
Such is the complexity of neurologically active drugs, and such the magnitude of 
empirical drug use, that the theoretical basis for CAs in epilepsy outlined above may not 
be taken for granted, even if the drugs should prove successful. The tradition of empirical
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usage of drugs with later attempts to discover mechanisms of action is well established, 
and only recently have "designer drugs" with specific actions such as vigabatrin (gamma- 
vinyl GABA, a GABA transaminase inhibitor [Jung et al 1977]) come to the fore 
[Editorial 1989]. Thus, while workers investigate possible mechanisms of action for such 
drugs as CBZ, we find the CAs being drawn into the argument. One such area is the 
effect of AEDs on adenosine - "the brain’s natural anticonvulsant" [Dragunow & Faull
1988] - and its receptors.
Analogues of adenosine show anti-seizure activity [Rosen & Berman 1987] while 
antagonists have proconvulsant effects [Dragunow & Robertson 1987]. Paradoxically, 
CBZ is thought to be an adenosine antagonist [Lewin & Bleck 1977, Marangos et al
1987]. It inhibits adenosine binding to the A j receptor [Marangos et al 1983, Skerritt et
Q
al 1982] which responds to low concentrations (10“°M ) of adenosine and is likely to 
mediate its neurodepressant effects [Reddington 1982]. Part o f the paradox may be 
explained by carbamazepine’s specificity for inhibiting binding to the A^ receptor, while 
other adenosine antagonists with strikingly dissimilar (proconvulsant) pharmacological 
effects (e.g. caffeine) affect both A^ and A 2  receptors [Clark & Post 1989]. Furthermore, 
chronic dosing with CBZ has been reported to increase brain receptor numbers 
[Marangos et al. 1985], while similar adenosine receptor "upregulation" with 
theophylline [Choi et al 1988, Sanders & Murray 1988] has been associated with 
increased tolerance to proconvulsants [Sanders & Murray 1989]. Theophylline, 
meanwhile, interferes with the anticonvulsant activity of CBZ [Skerritt et al 1983b], 
futher complicating the picture. It may be that the acute effects of these drugs differ, 
while their chronic effects on receptor numbers may protect against seizures.
Calcium antagonists have been shown to inhibit binding to adenosine receptors [Murphy 
& Snyder 1982, Cheung et al 1987, Morgan et al 1987, Hu et al 1987] and share some 
pharmacological properties with adenosine [Morgan et al 1987] which also inhibits
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calcium influx in the heart [Harder et al 1979] and synaptosomes [Ribeiro et al 1979]. 
The dihydropyridines appear to be the most active CAs at the adenosine receptor 
[Murphy & Snyder 1982, Hu et al 1987], although differences occur within the group, 
since only nifedipine inhibits adenosine agonist (cyclohexyladenosine) binding, whereas 
they all interfere with antagonist (diethylphenylxanthine) binding [Morgan et al 1987].
Thus, some authors have suggested that adenosine interactions may play a part in the 
anticonvulsant effects of CBZ [Skerritt et al 1983a, Marangos et al 1985] or even the 
CAs [Morgan et al 1987]. Alternatively, the effects on adenosine receptors may be an 
incidental finding, or a secondary response to anticonvulsant effects mediated by a 
separate mechanism. In the final experiment of this thesis, a binding assay for adenosine 
A j receptors is established, and the effect of chronic dosing with CBZ and CAs on these 
receptors in mice is assessed.
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EXPT. 8 NIFEDIPINE IN EPILEPSY - A PILOT STUDY
AIM
To ensure that nifedipine does not interfere with the metabolism of established AEDs, 
while assessing the possibility that it possesses anti-epileptic properties.
PATIENTS AND METHODS
Twelve patients agreed to take part in the study, and their clinical details are shown in 
Table 21. All had intractable epilepsy, and had attended the epilepsy clinic for more than 
a year, where they routinely completed monthly "seizure frequency" charts. No patient 
had any alteration in anticonvulsant medication during the previous three months.
Each patient was admitted to the Gardiner Institute for a total of 14 days. Erect and 
supine blood pressure (in duplicate) was measured 4-hourly. Anticonvulsant drugs were 
continued in unchanged dosage and their concentrations monitored. Blood for CBZ and 
VPA assay was drawn at 0800h ("trough"), 1 lOOh ("peak") and 1600h for three 
consecutive days before nifedipine was commenced, and on days 1, 2, 3, 5 ,7  and 10 of 
nifedipine therapy. Concentrations of PHT and PB, whose elimination half-lives exceed 
24h, were obtained once daily. The mid-afternoon measurement was repeated as an 
outpatient at 2 and 4 months. Patients were treated with a standard nifedipine dose, 
namely 20mg thrice daily, in addition to their existing anti-epileptic therapy. Blood 
samples were centrifuged immediately and the serum stored at -20°C for batch analysis 
as in previous experiments.
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TABLE 21 EXPT.8 Clinical details of patients in study
Age Type of epilepsy Duration
(years)
EEG
abnormality
Anticonvulsants Outcome
FEMALES
1 28 Complex partial 
Secondary generalised
25 (L) Fronto- 
temporal
Carbamazepine Completed
2 33 Complex partial 31 (R) Temporal Carbamazepine Completed
3 58 Generalised
tonic-clonic
42 Centrencephalic Sodium valproate 
Phenobarbitone
Completed
4 33 Complex partial 19 Centrencephalic Carbamazepine Completed
5 38 Complex partial 
Secondary generalised
25 (R) Fronto- 
temporal
Carbamazepine
Phenobarbitone
Completed
6 20 Complex partial 
Secondary generalised
5 Centrencephalic Carbamazepine Completed
7 36 Complex partial 2 (L) Fronto- 
temporal
Carbamazepine 10 days - * 
headache
8 25 Complex partial 
Secondary generalised
7 None Phenytoin 6 days - * 
headache
MALES
9 32 Complex partial 
Secondary generalised
8 (R) Temporal Carbamazepine Completed
10 24 Complex partial 
Secondary generalised
16 (L) Fronto- 
temporal
Carbamazepine Completed
11 28 Complex partial 
Secondary generalised
22 (R) Temporal Phenytoin Non- * 
compliance
12 36 Complex partial 
Secondary generalised
26 (R) + (L) 
Temporal
Carbamazepine 6 weeks - * 
stopped drugs
* Patients who withdrew from the study
NAME:
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Please mark: X MAJOR 0 MINOR
TOTAL MAJOR = TOTAL MINOR =
Treatment
Date Drugs Dose 6 8 10 12 2 4 6 ‘8 10 12
NOTE: A major seizure is  one when you f a l l  down and shake a ll over. Other names for
i t  are grand mal and generalised seizure.
A minor seizure is  an absence event, a funny feeling  or a sta rin g  tu rn . Other 
names include p e t i t  mal and p a r tia l se izure .
FIGURE 44 Seizure chart used by patients to record own seizures. Identical or similar 
chart used in EXPTS. 8,11,12.
To assess the possible efficacy of nifedipine as an anticonvulsant, the patients completed 
seizure frequency charts for the three months before nifedipine was commenced. These 
were compared with those obtained for the next three months. In these charts, each 
generalised tonic-clonic and partial seizure was recorded separately each day by the 
patient and his/her family on a time grid divided into 2h segments (Figure 44).
Alterations in CBZ and CBZ-E concentrations and blood pressure measurements were 
compared using Student’s t-test, with a calculation of 95% confidence intervals for the 
difference between pre- and post-nifedipine values. Seizure frequency before and after 
nifedipine introduction was examined using Wilcoxon matched pairs test for non- 
parametric data. Confidence intervals were also calculated for the differences in seizure 
frequency, assuming suitability for parametric analysis.
RESULTS
Patients 7 and 8 withdrew from the study after 10 and 6 days respectively because of 
headache and light-headedness, a possible consequence of the vasodilatory properties of 
nifedipine. Blood pressure, however, did not appear to be reduced in these patients, nor 
was it significantly affected in the group as a whole (Figure 45). Patient 11 was 
withdrawn because of non-compliance with drug therapy and seizure chart completion, 
and patient 12 spontaneously stopped taking all medication after 6 weeks. Thus, nine 
patients completed one month on nifedipine, and eight completed all three months of the 
trial.
In the nine patients on CBZ, trough, peak and mid-afternoon concentrations did not 
significantly change from baseline in the first 10 days of nifedipine therapy. The mean
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TABLE 22 Mean (± SD) concentrations of total and free carbamazepine (CBZ),
carbamazepine 10,11 epoxide (CBZ-E) and % unbound CBZ before and 
after seven days after introduction of nifedipine in 9 patients 
with intractable epilepsy
BEFORE AFTER 95% Confidence 
Intervals of chang<
TOTAL CBZ 
(mg/L)
12.4 ± 3 .0 12.6 ± 2 .7 (-2 .6 -+ 3 .1 )
FREE CBZ 
(mg/L)
2.49 ± 0 .5 2.68 ± 0 .5 (-0.32 - +0.7)
FREE CBZ
(%)
23.9 ± 2 .1 24.4 ±  2.5 (-1.8 - +2.9)
CBZ-E
(mg/L)
2.2 ±  1.2 2.0 ± 1 .6 (-1 .72-+ 1 .4)
FIGURE 45 Mean (+2SEM) systolic and diastolic blood pressure in 12 patients on 
three days before and six days after commencing nifedipine retard 20mg b.d.
CAMAMAZEPWE
CONCENTRATION
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q^Y S MONTHS
FIGURE 46 Mean (+2SEM) mid-afternoon carbamazepine concentrations for three 
days before and 10 days after nifedipine introduction in nine patients, and two and four 
months later in six patients.
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mid-afternoon levels are shown in Figure 46 to demonstrate the lack of any long term 
effect in those continuing nifedipine for up to 4 months. Similarly, unbound CBZ and 
extent of protein binding together with CBZ-E levels appeared unaffected by NIF 
administration (Table 22). The 95% confidence interval demonstrates that NIF is very 
unlikely to increase CBZ concentration by as much as 0.74 mg/L (6 %). No overt effect 
on circulating levels was seen in the 3 patients receiving other anticonvulsants.
Seizure frequency was significantly less at 1 and 3 months after commencing NIF 
compared to the previous months (both P<0.01; Figures 47 a & b). To demonstrate 
whether these results were affected by the withdrawal of patients who were doing badly, 
the one-month comparison was repeated on an "intention-to-treat" basis and the 
difference remained significant (P<0.02). Insufficient data was available from the 
patients who withdrew or defaulted for such analysis at 3 months. Confidence intervals 
for the change in seizure frequency suggest a decrease of 5-19 (23-36%) after one month, 
and a reduction of 7-16 seizures (25-57%) per month at 3 months.
Five and 4 patients at 1 and 3 months respectively reported a >50% fall in seizures while 
7 had a >25% reduction at both time points. All patients who claimed benefit requested 
to continue taking NIF when the study was completed. Two patients remained seizure- 
free for the whole 3 months - for the first time in many years. One of these (patient 2) 
was still seizure-free one year later, while the other (patient 3) suffered a recurrence 
under unusual circumstances after 4 months of NIF therapy.
Case Report
Mrs. G.Y., a 58 year old lady, suffered from GTCS from the age of sixteen. Serial EEGs 
showed slow-wave activity in both hemispheres with a likely origin in centrencephalic 
structures; CT scanning of brain was normal. All major anticonvulsants singly and in
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FIGURE 48 Schematic history o f patient 3, showing the monthly seizure frequency in 
late 1985 and 1986, and the daily incidence of seizures in September 1986. The temporal 
relationships to nifedipine and calcium therapy are shown.
combination over the years had only partly controlled her seizure disorder. At the time of 
starting NIF (April 1986) she was taking VPA 500mg four times daily (serum level 129 
mg/L) and phenobarbitone 60mg twice daily (serum level 20.9 mg/L), and was 
documenting 5-15 seizures per month.
For more than 5 months after commencing NIF, the patient remained seizure-free. On 
September 2nd, she was prescribed calcium supplements (Sandocal) by her general 
practitioner for treatment of low back pain, attributed to vertebral fractures due to 
osteoporosis. On September 6 th, she had her first seizure since starting NIF therapy, 
which was followed by 13 more over the next 2  days (Figure 48). Sandocal was 
immediately discontinued and the patient became seizure-free for a further 4 months 
before her seizures gradually returned.
DISCUSSION
Both verapamil [Macphee et al 1986c] and diltiazem [Brodie & Macphee 1986] had 
previously been found to inhibit CBZ metabolism and increase serum concentrations of 
this drug. Both CAs were subsequently shown to impair the elimination of antipyrine, 
while NIF did not [Bauer et al 1986]. The results of the present study demonstrate that 
NIF does not substantially affect circulating concentrations of CBZ or of its active 
metabolite, either acutely or in the long term, making it a more realistic adjuvant therapy 
for intractable epilepsy.
The significant fall in seizure frequency with nifedipine was encouraging. This study did 
not control for the placebo effect of giving a new drug nor for that of a short hospital 
admission, but the improvement in control, particularly in the two patients who became
12 9
seizure-free, supports an anticonvulsant action for this calcium antagonist. The 
recurrence of seizures in the patient taking calcium supplements was not anticipated.
This may have been a coincidence, although the chronology of events was quite striking. 
The results of this study marked out nifedipine as a possible anticonvulsant which 
required placebo-controlled evaluation, with measurements of circulating concentrations.
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EXPT. 9+10 NIFEDIPINE AND NIMODIPINE IN MICE: BLOOD AND BRAIN 
PHARMACOKINETICS AND EFFICACY AGAINST PENTYLENE­
TETRAZOL-INDUCED SEIZURES
AIM
To outline the pharmacokinetic parameters of NIF and NIM in mouse blood and brain, 
and to assess their efficacy vs. PTZ-induced seizures when used alone or in combination 
with CBZ.
METHODS
Male CF1 mice were obtained from Bantin & Kingman, Hull, weight 20g. 
Pharmacokinetic and acute efficacy studies were performed in animals weighing 30g, 
while those receiving chronic dosing weighed 30-35g at time of testing.
Materials
Nifedipine and nimodipine for intraperitoneal (i.p.) injection were freshly prepared as 1 
mg/ml concentrations in 50/50 ethanol/water under sodium light. CBZ was made up as a 
2 mg/ml solution in the same solvent by first dissolving it in the alcohol phase. The 
ethanol/water vehicle was also used as a control injection, as ethanol itself has an 
anticonvulsant effect in many seizure models [Mello et al 1990].
For EXPT. 9B, nifedipine and nimodipine were suspended in Tween 80 
(polyoxyethylene sorbitan mono-oleate, Sigma) 0.5% in distilled water at a concentration 
of 18.5 g/L.
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Pentylenetetrazol was prepared as a 0.85% solution in 0.9% saline and kept at 37°C. A 
0.01 ml/g dose (85 mg/kg body weight), which will produce convulsions in 97% of mice 
[Swinyard & Woodhead 1982], was used.
H.p.l.c. calibration
Stock solutions of NIF, NIM and internal standard (nitrendipine) 100 mg/L in methanol 
were stored at -20°C and were stable for several months. Internal standards were 
produced by diluting stock solutions in 50/50 ethanol/water. A calibration curve was 
constructed for both drugs in the range 0.2 - 5 ug/ml and was found to be linear (r=0.95). 
Limit of detection was 10 ng/ml in a 100 ul sample. A recording integrator compared 
peak area ratios of calcium antagonist and internal standard. When assaying 
homogenised brain samples, the individual brain weights were incorporated into the 
calculation to give these results as ug/g wet weight. Ether did not interfere with the assay. 
A Hewlett-Packard 1084B Liquid Chromatograph was used, and all steps were 
performed under sodium light, as the dihydropyridines rapidly break down under other 
artificial light sources or sunlight.
Sample Preparation
For drug assays, 100 uL of blood were sonicated before adding 300uL 1M NaOH and 
200uL internal standard (2 ug/ml nitrendipine). Extraction was performed with 
hexane/diethylether (50/50) in a vortex mixer for one minute before centrifugation for 10 
minutes at 2,000 rpm. The organic phase was transferred to a clean test-tube and 
evaporated to dryness at 40°C  under nitrogen, prior to reconstitution with 
methanol/water (70/30). Mouse brain was prepared, after weighing, by homogenising in
I.5ml 1M NaOH. 200uL internal standard were added and extraction proceeded as
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above. All these procedures were carried out under sodium light by the technical staff in 
the Department of Medicine (and Therapeutics) laboratories.
Pharmacokinetic Studies
EXPERIMENT 9A:
Mice were injected i.p. with 6  mg/kg NIF or NIM (alcohol/water). The animals were 
sacrificed by overdosing with ether after 1, 5, 10, 20, 30 or 60 minutes. A truncal blood 
sample was obtained and the brain perfused with 0.9% saline by injection following 
double puncture of the heart before decapitation and removal.
EXPERIMENT 9B:
Mice were injected i.p. with 60mg/Kg NIF or NIM (Tween). The animals were sacrificed 
after 30, 45, 60, 90 or 120 minutes. As this experiment was designed simply to confirm 
that the drugs entered the brain regardless of whether an alcohol vehicle was used, only 
three animals were included in each group. Blood and brain samples were obtained as 
above.
PTZ seizure inhibition
EXPERIMENT 10A:
Mice (30g) were injected s.c. with a 97% convulsive dose of PTZ 10 minutes after i.p. 
administration of control solvent, NIF 3.3 mg/kg, NIM 3.3 mg/kg or CBZ 6.7 mg/kg.
Each mouse was observed in isolation for features of the various components of PTZ 
seizures in rodents [Pohl & Mares 1987]. The time to the first clonic jerk was recorded as
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the seizure latency since, in preliminary experiments, it was consistent and was affected 
by CBZ - a feature not present in many other approaches to PTZ seizures [Meldrum
1986]. Recordings were made by one observer who was unaware of each animal’s 
treatment.
EXPERIMENT 10B:
Since NIF has been suggested as an adjunctive therapy, a separate experiment was 
performed using pre-treatment with i.p. control, NIF, CBZ, or NIF in combination with 
CBZ in the same doses as above.
EXPERIMENT IOC:
The effect of different doses of NIF and NIM given by mouth on PTZ-seizures was 
investigated. All animals were fed a powdered diet (Beekay Feed No. 42, Banton & 
Kingman, Hull) and housed in separate cages. Groups of 5 test animals received daily 
doses of lm g (33 mg/kg), 2mg (67 mg/kg) or 4mg (133 mg/kg) nifedipine or nimodipine 
for 2 weeks. Ten mice served as controls. One animal taking nimodipine died. All 
surviving mice gained weight. PTZ seizures were provoked and observed as previously 
desribed.
Statistics
An estimation of the elimination half-life of the CAs (alcohol/water) in blood and brain 
was obtained using the mean values at each time point with the STATIS2 statistical 
package (Clydesoft). A measurement of error was achieved using Jackknife analysis 
[Miller 1974] and 9 5 % confidence intervals are shown.
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Comparisons of seizure latency between groups of animals were made using the Kruskal- 
Wallis test to determine if significant differences were present, with follow-up Mann- 
Whitney "U" testing to define these differences. Pearson’s product moment correlation 
coefficients are quoted.
RESULTS
Pharmacokinetics
EXPERIMENT 9A:
Both NIF and NIM readily crossed the blood-brain-barrier. Time courses of blood and 
brain concentrations of each CA are shown in figures 49 and 50, with each point the 
mean of at least 6  results. Estimates of pharmacokinetic parameters were made from the 
mean data and are shown in Table 23. The blood kinetics of NIM best fitted an 
intravenous model, while the behaviour o f NIM in the brain and NIF in both blood and 
brain fitted an oral absorption model. The data at 1 minute were omitted from the half- 
life calculation. A correlation between blood and brain levels was seen at most time 
points (Figures 51 & 52) with an overall correlation of r = 0.701 (P<0.001) for NIF and r 
= 0.572 (PcO.OOl) for NIM.
EXPERIMENT 9B:
Concentration-time curves in blood and brain for the Tween preparations are shown in 
figures 53 and 54. As expected, absorption was prolonged and erratic, and no attempt at 
calculating pharmacokinetic parameters was made. Clearly, however, both drugs crossed 
the BBB. Nifedipine brain and blood concentrations were positively correlated (P<0.02,
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TABLE 23 Pharmacokinetic parameters of nifedipine and nimodipine in 
mouse blood and brain
ELIMINATION HALF-LIFE  
(min)
(Blood) (Brain)
AREA UNDER CURV  
(ug.min/ml) 
(Blood) (Brain)
NIFEDIPINE 11.2 14.7 69.8 71.1
±4.0 ±2.4 ±12.8 ±19.4
NIMODIPINE 16.7 22.4 3.34 10.6
±8.8 ±7.2 ±2.2 ±3.0
Results + 95% confidence limits
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FIGURE 49 Concentration-time curves of mouse blood ( • - • ,  ug/ml) and brain (o-o , 
ug/g) concentrations of nifedipine after i.p. 6 mg/kg nifedipine (alcohol/water). Vertical 
bars represent +SEM.
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FIGURE 50 Concentration-time curves of mouse blood (• - • , ug/ml) and brain (o-o , 
ug/g) concentrations of nimodipine after i.p. 6mg/kg nimodipine (alcohol/water). 
Vertical bars represent +SEM.
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FIGURE 51 Nifedipine concentration in mouse blood and brain at stated times 
following i.p. 6 mg/kg nifedipine (alcohol/water).
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FIGURE 52 Nimodipine concentration in mouse blood and brain at stated times 
following i.p. 6  mg/kg nimodipine (alcohol/water).
p g /m i*  
pg/g •
Blood Mw>n*SEM 
iBrain M oon*S 04
14-
Q-
4 -
2 -
fO OOX 45 60
MNUTES
FIGURE 53 Concentration-time curves of blood ( • -# , ug/ml) and brain (o--o, ug/g) 
concentrations of nifedipine after i.p. 60 mg/kg nifedipine (Tween). Vertical bars 
represent +SEM.
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FIGURE 54 Concentration-time curves of blood ( • - • ,  ug/ml) and brain (o -o , ug/g) 
concentrations of nimodipine after i.p. 60 mg/kg nimodipine (Tween). Vertical bars 
represent +SEM
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FIGURE 55 Nifedipine concentration in mouse blood and brain at all time-points after 
i.p. 60 mg/kg nifedipine (Tween).
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FIGURE 56 Nimodipine concentrations in mouse blood and brain at all time-points 
tfter i.p. 60 mg/kg nimodipine (Tween).
Figure 55), but no association was demonstrated with nimodipine (Figure 56).
PTZ seizure inhibition
EXPERIMENT 10A:
Mice treated with i.p. NIF (P<0.001), NIM (P<0.02) and CBZ (PcO.OOl) all exhibited 
increased seizure latency compared with controls (Figure 57). There were no significant 
differences between the drug groups.
EXPERIMENT 10B:
This experiment confirmed the beneficial effect of NIF (PcO.OOl) and CBZ (PcO.Ol) in 
this model (Figure 58). Combining NIF and NIM did not alter seizure latency 
significantly from control animals and was less effective than NIF given alone 
(P<0.005).
EXPERIMENT IOC:
Comparison o f the drug groups (Figure 59) showed that both oral NIF (P<0.002) and oral 
NIM (PcO.OOl) increased seizure latency compared with controls. Results with NIF and 
NIM were amalgamated and the effects of different doses analysed. Daily doses of lm g 
(PcO.OOl), 2mg (PcO.OOl) and 4mg (Pc0.02) were all effective but the highest dose 
showed the least impressive prolongation of seizure latency (Figure 60). Indeed, the 
anticonvulsant effect of 4mg daily was significantly less than that of lm g (Pc0.002) or 
2mg (PcO.05).
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DISCUSSION
In this study, NIF and NIM were effective intraperitoneally and orally in extending 
latency of PTZ-induced seizures. In our version of the model, i.p. CBZ also increased the 
time to fitting. This is unusual as the standard PTZ threshold test [Krall et al 1978] has 
been suggested as specific for drugs active against absence seizures. However, various 
alterations in the test, as discussed by Meldrum [1986], can change this supposed 
specificity [e.g. Kent & W ebster 1983, Sugaya et al 1986]. The procedure in the present 
study may allow for efficacy to be shown with CBZ and the other first-line AEDs.
It could be argued that the dihydropyridines were not acting as anticonvulsants per se, 
but were merely enhancing the action of ethanol present in the solvent. Dihydropyridines 
can prevent ethanol withdrawal seizures [Little et al 1986] and have been shown to 
augment its anaesthetic [Dolin & Little 1986] and psychomotor [Isaacson et al 1985] 
properties. However, they have not been shown to potentiate any anticonvulsant effect of 
ethanol, while nimodipine (although not nifedipine) is already known to possess an 
anticonvulsant action when given as a suspension [Dolin et al 1988] or in glycerol 
[Morocutti et al 1986] or Emulphor (5% alcohol) [O’Neill & Bolger 1989] preparations. 
In the present study, ethanol/water solutions were used to provide accurate 
pharmacokinetic data, as has been previously described for NIM in gerbils [Heffez et al 
1985]. EXPT. 9B demonstrates that this would not be feasible with a Tween preparation. 
The alcohol/water vehicle was also used for EXP 10A and 10B. Any "synergism" with 
ethanol would not explain the efficacy of CBZ, nor the detrimental interaction between 
CBZ and NIF, and clearly, any effect o f ethanol was not an issue in the oral experiment.
Nimodipine has been shown to be active against PTZ seizures both parenterally [Meyer 
et al 1986a] and orally [Meyer et al 1987]. This drug is known to cross the BBB [Heffez 
et al 1985], but after the publication of EXPT 8 , doubts were expressed over whether the 
less lipophilic NIF possesses this ability [Wen 1988]. Recently it has been shown to do
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so in the rat [Janicki et al 1988] and the results of the present study confirm that this is 
also the case in the mouse. Both dihydropyridines entered the brain freely, reaching peak 
levels in approximately 5 minutes. NIM was particularly efficient in crossing the BBB 
following i.p. injection. However,in the present study NIF was as effective as NIM in 
delaying seizures. NIM concentrations in blood were much lower than those of NIF 
suggesting a larger apparent volume of distribution - and this concurs with the findings in 
man [Ramsch et al 1986].
It has been suggested, following preliminary communication of this work, that alcohol 
may be acting as a "carrier" across the BBB. EXPERIMENT 9B was subsequently 
performed using the Tween preparation in the high doses required for anticonvulsant 
efficacy [Dolin et al 1988]. It demonstrates that both NIF and NIM are able to cross the 
BBB without the assistance of alcohol in the vehicle. Blood:brain ratios were similar to 
those with the alcohol/water preparation. Absorption of the dihydropyridines in the latter 
solution, however, seems much faster and more consistent than the suspension in Tween, 
allowing the accurate determination of pharmacokinetic parameters not previously 
described. The relationship between blood and brain levels is more easily seen, as the 
erratic absorption and short half-life of the dihydropyridines conspire to render much of 
the Tween data uninterpretable.
The correlation between brain and blood levels of the dihydropyridines (alcohol/water) 
was close, particularly at the early time points. Those at one minute were "flatter" than 
the rest which suggests that equilibration between blood and brain had not yet taken 
place. The association becomes less obvious around 20-30 minutes presumably owing to 
the added complexity of drug elimination from the brain. Both dihydropyridines had 
longer elimination half-lives in brain than in blood.
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The short half-life of NIF may explain a recent failure to demonstrate its efficacy against 
electroshock seizures when given 60 minutes before testing [Wong & Rahwan 1989], 
although NIF (prepared in 7.5% polyethylene glycol/7.5% alcohol) was active against 
PTZ seizures in that study. Their choice of a 60 minute delay probably relates to previous 
work showing protection from seizures over some hours with nimodipine [e.g. Dolin et 
al 1988], but such studies used suspensions and not solutions. The difference in 
absorption demonstrated in the present study explains why their solution may have had a 
shorter effect. The authors’ inference that N IF’s failure against electroshock seizures 
means that it might only be useful in absence seizures is perhaps less valid in view of the 
short half-life of NIF. The apparent efficacy of CBZ in the present study, using a model 
very similar to theirs, also argues against their results constituting proof of N IF’s 
selectivity o f effect. This demonstrates the importance of doing pharmacokinetic studies 
before performing and interpreting trials of efficacy.
The apparent loss of benefit when NIF was given with CBZ remains unexplained. Any 
pharmacokinetic interaction is presumably not due to an effect on CBZ concentrations, 
since such an interaction was virtually excluded (though in man) in the pilot study of NIF 
in epileptic patients (EXPT. 8 ). A pharmacodynamic interaction is another possibility, 
particularly as CBZ itself has calcium channel blocking properties [Crowder & Bradford
1987]. The possible involvement of adenosine receptors is discussed in EXPT. 13. 
Whatever the mechanism, if this lack of additional benefit is confirmed, it may be of 
some importance, since the major use of calcium antagonists in clinical practice is likely 
to be as adjuvant AEDs. It should be noted, however, that a recent study using 
electroshock seizures in mice [Czuczwar et al 1990] showed an enhancement of the 
anticonvulsant effects of CBZ and PHT when NIF was added. In this study, the 
dihydropyridine was used in subtherapeutic doses and appeared to act synergistically 
with the AEDs. Further dose-ranging studies using the dihydropyridines and AEDs are 
required to define the nature and extent of any interactions at different dosages.
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Dose-ranging studies of the CAs in isolation are also indicated, particularly in view of 
the apparent diminishing effect with increasing dosage in the present study. It may be 
that the CAs exhibit a "therapeutic window" similar to that tentatively postulated for PHT 
[Troupin & Ojemann 1975, Osorio et al 1989] and this could have implications for their 
clinical use. Clinical trials must be carefully designed to allow for such dose-response 
relationships. Preliminary studies of a dose-ranging nature again may be required.
Both CAs were effective orally and parenterally against PTZ seizures. Both entered the 
brain freely and there were close correlations between brain and blood levels. This study 
further supported their consideration as AEDs for use in clinical practice, while warning 
of possible dose-response difficulties and pharmacological interactions. Placebo- 
controlled trials of these drugs in a clinical setting was the logical next step.
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EXPT. 11 NIFEDIPINE IN EPILEPSY - A PLACEBO-CONTROLLED TRIAL
AIM
To assess the efficacy of nifedipine as an adjunctive anticonvulsant in epileptic patients 
in a double-blind crossover study.
PATIENTS AND METHODS
Twenty-two students (12 male, 10 female; aged 17-22 years) with refractory epilepsy 
attending Lingfield Hospital School, Surrey, England, were recruited into the study. 
Clinical details are shown in Table 24.
The trial was conducted as a balanced, placebo-controlled, crossover study with an eight 
week run-in period and an eight-week wash-out period between treatment phases, each of 
which also lasted eight weeks. Participants took either NIF tablets (Adalat Retard, Bayer) 
20mg twice daily for four weeks, then 40mg twice daily for a further four weeks; or 
matched placebo in a similar fashion. Previous AEDs were continued throughout the 
study in unchanged timing and dosage. Partial and generalised tonic-clonic seizures were 
recorded by staff at the school for the duration of the trial.
At baseline and at 2 weekly intervals during the treatment phases, erect and supine blood 
pressures and heart rates were measured at 0900h and 1600h. Students also completed a 
side-effect profile. This consisted of questions on 15 specific symptoms either associated 
with NIF administration (e.g. flushing, headache, palpitations) or unassociated "dummy" 
symptoms (e.g. itching, dry mouth). These were graded as absent (0), mild (1), moderate 
(2), or severe (3).
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TABLE 24 E x p .ll Clinical details of patients in nifedipine-placebo study
No Sex Age 
M /F(years)
Type of Epilepsy D rugs T rial
D rug
O rd er
O utcom e
1 M 19 CxP + 2°Gen. CBZ P/A Completed
2 M 19 CxP + 2°Gen. CBZ+VPA+PHT P/A Completed
3 M 17 CxP + 2°Gen. CBZ,VPA,ETHOSUX. A/P * 8  weeks 
(irritability)
4 F 18 CxP + 2°Gen. CBZ+PHT P/A Completed
5 M 19 CxP + 2°Gen. CBZ+PHT+E1HOSUX. P/A Completed
6 M 19 CxP + 2°Gen. CBZ+ETHOSUX. A/P Completed
7 F 19 CxP CBZ+VPA+PHT+ACET. P/A Completed
8 M 2 0 CxP + 2°Gen. CBZ+VPA+ETHOSUX. A/P * end of study 
(poor compliance)
9 M 2 2 CxP + 2°Gen. CBZ+VPA+ETHOSUX. A/P Completed
1 0 M 19 GTCS CBZ+VPA A/P Completed
1 1 M 19 CxP + 2°Gen. CBZ+CLOBAZAM P/A Completed
1 2 F 19 CxP + 2°Gen. CBZ+VPA A/P Completed
13 F 18 GTCS CBZ+VPA+ACET. P/A Completed
14 F 18 GTCS CBZ,ACET,CLOBAZAM P/A Completed
15 F 17 CxP CBZ,ACET,CLOBAZAM P/A Completed
16 F 2 1 CxP + 2°Gen. CBZ,PHT A/P Completed
17 F 19 GTCS CBZ,VPA,ETHOSUX. A/P Completed
18 M 18 CxP + 2°Gen. CBZ,ETHOSUX. A/P Completed
19 M 19 GTCS CBZ,PHT P/A Completed
2 0 F 18 CxP CBZ,VPA A/P Completed
2 1 M 17 CxP + 2°Gen. CBZ,VPA P/A Completed
2 2 F 2 0 CxP + 2°Gen. CBZ,VPA,ACET A/P Completed
Cxp - Complex partial seizures ACET - Acetazolamide
2°Gen - Secondary generalised seizures ETHOSUX - Ethosuximide
GTCS - Generalised tonic-clonic seizures P - Placebo
* - Withdrawn from study A - Active nifedipine
Every two weeks, blood was withdrawn approximately 1 hour after the morning dose by 
venepuncture for assay of NIF concentrations. Samples were centrifuged immediately 
and the serum stored in black bags at -25°C until batch analysis. Nifedipine was 
measured by capillary gas chromatography using electron captive detection with 
nicardipine as internal standard by Dr. John Williams at the Department of 
Pharmacology & Therapeutics, University of Wales, Cardiff. All procedures involved in 
the extraction were performed under sodium light. The limit of detection was 1 ng/ml 
and inter-assay coefficients of variation at 2.5 ng/ml, 10 ng/ml and 20 ng/ml were 22.7%, 
5% and 4.3% respectively.
A surface EEG was also performed every 2 weeks. These were graded by an experienced 
neurophysiologist in a blinded manner with reference to a "baseline" EEG for each 
student (+ 1 / + 2  = slight/definite improvement; - 1 / - 2  = slight/definite deterioration; 0  = no 
change). These were summed to produce an overall score for the active and placebo 
phases of the trial.
Statistical comparisons between placebo and NIF phases of the trial were made using the 
Wilcoxon Rank Pairs test. Power calculations using the equivalent parametric test - the 
paired Student’s t-test - suggested a power of 0.95 to pick up a fall in total seizure 
numbers (at P<0.05) of 50%, which was the figure recorded in the pilot study (EXPT. 8 ). 
The power to detect a 25% fall was 0.6. Calculations were also made to identify a 25% 
fall in GTCS (0.5), partial seizures (0.95) and seizure-days (0.95).
As this trial was performed at Lingfield, I did not take part in its day-to-day running. I 
was, however, involved in its conception and design, and was responsible for all of the 
collation, analysis and interpretation of data.
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RESULTS
Twenty-one students completed the study. Eleven took placebo in the first leg, and ten 
received NIF first. One student was withdrawn after five weeks of treatment because of 
aggressive outbursts. He was found to have been receiving placebo. Another had very 
poor recording of seizures while on holiday and his data were omitted from the analysis 
of seizure frequency.
Total numbers of seizures in the two treatment groups are shown in Figure 61. Only in 
the first two weeks of the trial was seizure control better with NIF (P<0.05). Sub-group 
analysis suggested that this was due to a fall in the number of partial seizures (Figure 62), 
which was lost by the second month. There were fewer seizure days in the NIF phase 
during the first month of treatment (from a mean of 13.2 to 11.6, P<0.05) but this did not 
carry through to the second month of the trial. The number of patients reporting a 50% 
fall in seizures on each treatment is shown in Table 25. There were no differences 
between treatments for any seizure type. Blood pressure showed a small drop after two 
weeks of NIF and also after two weeks of placebo. This effect had settled by four weeks 
in both phases. There was no evidence of a significant postural drop in blood pressure in 
any of the students. Heart rate was not affected by either treatment.
"Severe" side-effects reported included headache in two students (both on active drug), 
dry mouth in two (one active, one placebo), drowsiness (one placebo) and poor memory 
(one active). Overall scores for all specific or all dummy side-effects did not differ 
between the NIF and placebo treatment phases. Scores for headache, however, were 
significantly higher with NIF (P<0.02).
Nifedipine concentrations are shown in Table 26. Students with maximum levels greater 
than 1 0  ng/ml (n=l 1 ) did no better in terms of seizure control than those with 
concentrations below this arbitrary figure. A weak correlation, however, was shown
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TABLE 25 Students reporting a 50% reduction in seizures following treatment 
with nifedipine and matched placebo for 2 months each
FIRST SECOND TWO
MONTH MONTH MONTHS
*Partial 
(n = 17)
Placebo 1 2 O
Nifedipine 3 5 2
*Tonic-Clonic 
(n = 17)
Placebo 1 0 7 8
Nifedipine 6 4 3
Total 
(n = 2 1 )
Placebo 3 2 2
Nifedipine 4 3 2
Each includes 4 students who had no seizures in this category and so 
could not have a 50% reduction
TABLE 26 Nifedipine concentrations (ug/L) in students with refractory 
epilepsy taking 20mg and 40mg of the drug twice daily for 
4 weeks
n Mean (SD) Median Range
20mg nifedipine twice daily 20 4.3±(5.3) 1.9 0-16.6
(at 4 weeks)
40mg nifedipine twice daily 19 9.8+(11.3) 5.7 0-47
(at 8  weeks)
Maximum concentration 2 1  13.1±(10.4) 11.3 2.1-49
No of
SEIZURES
7 0 - |
5 0 -
3 0 -  p<0.05
10-
TotalFirst two weeks First month Second month
FIGURE 61 Total number of seizures in 20 students with refractory epilepsy taking 
nifedipine and placebo. Values are mean + SEM.
PARTIAL SEIZURES
7 0 - i
H U  Nifedipine 
Placebo5 0 -
3 0 -
p<0.05
10-
TotalSecond monthFirst two weeks First month
FIGURE 62 Number of partial seizures in 20 students with refractory epilepsy taking 
nifedipine and placebo. Values are mean + SEM.
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Total EEG scores
p<0.05 NIFEDIPINE 
BETTER
PLACEBO
BETTER
FIGURE 65 Comparison of summed ’EEG scores’ during nifedipine and placebo 
phases of study in 19 students with refractory epilepsy.
between seizure improvement on NIF (seizure count on placebo - seizure count on NIF) 
and NIF concentrations at week 8 for total seizures (r = 0.443, P<0.05 one-tailed; Figure 
63) and partial seizures (r = 0.455, P<0.025; Figure 64).
Total EEG scores for the four tracings during NIF treatment were compared with those 
on placebo. More students had improved scores while receiving the active drug (P<0.05, 
Figure 65)
DISCUSSION
The results from this study are not particularly promising. Although one or two 
"significant" improvements were seen with NIF, a large number of comparisons were 
made, and allowance for this makes their clinical relevance doubtful. M inor favourable 
changes were seen early in treatment, largely as a consequence of a decreased number of 
partial seizures. The EEG findings also suggest a positive pharmacological response to 
NIF.
If there is a genuine effect which is lost in the second month of treatment despite higher 
NIF doses, this may suggest the rapid development of tolerance. This could be receptor- 
mediated. Down-regulation of ^H-nitrendipine sites in mice has been reported following 
treatment with NIF for 28 days [Panza et al 1985], due to a decrease in receptor numbers 
with no change in receptor affinity. Seizures themselves have also been shown to 
decrease [^H]nimodipine binding in rat brain [Gleiter et al 1989] and to have variable 
effects on the cortex or the cerebellum of the cat [Bolger et al 1987]. The relevance of 
these findings to the clinical situation is unclear. Another possibility is the "therapeutic 
window" which was suggested in EXPT. 10C. This is, perhaps, unlikely, as there are
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very few situations in clinical medicine where a true "window" exists. I have already 
mentioned that it has been postulated to occur with PHT [Gruber et al 1940, Troupin & 
Ojemann 1975], but others consider the phenomenon of doubtful significance [Osorio
1989]. In the present case, the particularly low concentrations of NIF may also argue 
against this explanation.
This disappointing study leaves an inconsistency which also requires an explanation. 
Why are CAs so impressive in animal models of epilepsy, yet apparently ineffective in 
epileptic patients? One possibility, of course, is that the models are inappropriate, but 
CAs have been effective in a large variety of animal seizures which have, over the years, 
been successful in predicting clinical activity [Meldrum 1986]. Another problem relates 
to the screening of potential AEDs in individuals with poorly controlled epilepsy despite 
treatment with multiple AEDs. The students in the present trial reported an average of 
nearly 30 seizures per month in the baseline period and were receiving, in the main, two 
or three established antiepileptic agents. It is, perhaps, not surprising that results with 
NIF are disappointing in such a population.
Next, the NIF dose must be taken into consideration. Circulating NIF concentrations in 
this study were low. Information on an "effective blood concentration" of NIF is limited, 
but single dose (10mg-20mg) studies usually achieve peak concentrations of 60-80 ng/ml 
[Taburet et al 1983, Renwick et al 1988] while a study of adjuvant NIF in angina 
suggested that effective levels were in the 30-40 ng/ml range [Challenor et al 1989].
Very few of our patients achieved these levels (Table 26 and Figure 63), as all were 
taking enzyme-inducing drugs which are likely to accelerate the break-down of NIF 
[Schellens et al 1989] which is extensively metabolised in the liver [Challenor et al 
1987]. Half-life following a single dose of NIF is approximately 2.5 hours in healthy 
subjects [Ramsch et al 1986, Renwick et al 1988], and while this increases at steady-state 
[Ramsch et al 1986], it is likely that in induced patients the short half-life will make it
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very difficult to maintain effective concentrations. This is true despite using the "Retard" 
preparation which we deliberately utilised in this study. A marked decrease in circulating 
concentrations of felodipine - another dihydropyridine - has been demonstrated in similar 
circumstances [Capewell et al 1988]. The slight correlation between seizure 
improvement and attained NIF concentrations also suggests that higher NIF 
concentrations may have improved the results, but one should be wary of reading too 
much into this correlation which depended largely on one or two results. Arguably, the 
significantly increased incidence of headache in patients taking NIF does hint at 
pharmacologically active concentrations in many individuals.
Pharmacological interactions, as suggested by EXPT. IOC would be another possible 
reason for failure of the nifedipine. Many of these factors also relate to nimodipine, the 
controlled study of which was taking place in our unit at the same time as the above.
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EXPT. 12 NIMODIPINE IN EPILEPSY - A PLACEBO-CONTROLLED TRIAL
AIM
To assess the aniconvulsant efficacy of adjuvant nimodipine therapy in epileptic patients 
using a placebo-controlled crossover study.
PATIENTS AND METHODS
Twenty-two patients (8 male, 14 female; aged 18-53 years) attending the epilepsy clinic 
with refractory epilepsy ( each averaging > 3 seizures/month) were recruited into the 
study. Clinical details are shown in Table 27.
The trial was conducted as a balanced, placebo-controlled crossover study with a 4 week 
run-in period and a four week wash-out period after each treatment phase, both of which 
lasted 12 weeks. During each treatment phase, patients took nimodipine tablets 30mg tds 
(0800h, 1500h and 2300h) for four weeks, 60mg tds for the next four weeks, and 90mg 
tds for a further 4 weeks, or matched placebo in a similar fashion. During the washout 
period, patients took 60mg tds for one week followed by 30mg tds for a further week 
before stopping therapy (Figure 66). Twelve patients had placebo in the first treatment 
phase, and ten were given the active drug in the first phase. Previous anticonvulsant 
therapy was continued unchanged throughout the study.
Patients attended for review at weeks -4 ,0 , 4, 8 ,1 2 ,1 6 ,2 0 , 24 ,28  and 32. At each visit, 
drug compliance was checked by way of a tablet count, and patients were supplied with a 
seizure chart (cf. Figure 44) which they used for recording each individual seizure during 
the subsequent month. At each visit, patients also completed a "tolerability profile"
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TABLE 27 Exp.12 Clinical details of patients in nimodipine-placebo study
No Sex Age 
M /F (years)
D uration  Type of Epilepsy D rugs T rial
D rug
O rd er
O utcom e
1 F 29 7 CxP + 2°Gen. CBZ,PHT P/A Completed
2 M 26 18 CxP + 2°Gen. CBZ,VPA A/P Completed
3 F 19 5 SCxP VPA,PHT A/P Completed
4 M 41 10 CxP + 2°Gen. CBZ P/A Completed
5 F 27 20 CxP + 2°Gen. PHT P/A Completed
6 F 33 23 CxP + 2°Gen. CBZ,VPA A/P * 16 weeks 
(weight loss)
7 M 38 10 CxP + 2°Gen. CBZ P/A Completed
8 M 22 19 CxP + 2°Gen. CBZ,PHT A/P Completed
9 F 33 24 CxP + 2°Gen. CBZ,PRIM A/P Completed
10 M 25 13 CxP + 2°Gen. CBZ P/A Completed
11 F 31 30 SCxP CBZ,PRIM A/P Completed
12 F 19 19 GTCS CBZ P/A Completed
13 F 37 12 CxP PHT P/A Completed
14 M 26 26 CxP PHT A/P Completed
15 F 32 21 CxP + 2°Gen. CBZ P/A * 8 weeks 
(Nausea)
16 F 35 22 CxP + 2°Gen. CBZ,VPA A/P Completed
17 F 42 23 CxP + 2°Gen. VPA,PHT A/P * 20 weeks
(Intercurrent
pneumonia)
18 M 42 30 GTCS PHT.PB P/A Completed
19 F 24 16 CxP + 2°Gen. VPA A/P * 8 weeks 
(Headaches O.C.)
20 M 24 4 CxP CBZ,VPA P/A Completed
21 F 30 17 CxP + 2°Gen. CBZ,PB P/A * Completed study 
but non-compliant
22 F 53 46 CxP + 2°Gen. CBZ P/A Completed
Cxp - Complex partial seizures
SCxp - Simple and complex partial seizures
2°Gen - Secondary generalised seizures
PRIM
P
A
-
Primidone
Placebo
Active nimodipine
GTCS - Generalised tonic-clonic seizures 
* - W ithdrawn from study
WEEKS
FIGURE 66 Schematic outline of balanced crossover trial o f nimodipine in epilepsy 
(EXPT. 12) showing drug dosage, including during "washout" periods (weeks 16-20 and 
32-36)
consisting of 10 "visual analogue scale" lines of 10 cm length citing specific symptoms 
either associated with nimodipine administration (e.g. flushing, headache) or 
unassociated "dummy" symptoms (e.g. itching) and including possible side-effects from 
concomitant AEDs (e.g. sedation, double vision). A brief general medical examination 
was also performed. Erect and supine pulse and blood pressure were measured at 0900h, 
1200h, and 1600h. Blood was withdrawn from an antecubital vein for nimodipine assay 
at 0900h (’peak’), 1500h (’trough’) and 1600h (’peak’), and also for assay of other AEDs 
at 0900h and 1600h. Blood samples were centrifuged and the serum stored at -20°C  for 
batch analysis. Haematological and biochemical parameters were also checked at each 
hospital visit.
Drug Assays
Carbamazepine, phenytoin and valproate were assayed by enzyme immunoassay as 
previously described. Nimodipine assays were performed in a blinded fashion by Bayer 
Laboratories using gas chromatography.
Statistics
Comparisons of seizure frequency between the nimodipine and placebo phases were 
performed using Wilcoxon rank pairs testing for non-parametric data. Power calculations 
(revised to allow for "drop-outs") performed as if using the equivalent parametric test - 
paired Student’s t-test - suggested a power of >0.99 to pick up a fall o f 50% in partial 
seizures, total seizures or seizure days in this group of patients. The power calculations to 
detect a 25% improvement were 0.79, 0.85 and 0.75 respectively. A 50% or 25% fall in 
GTCS had power calculations of 0.54 and 0.18.
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RESULTS
Seventeen patients satisfactorily completed the study. Two were withdrawn because of 
possible side-effects while taking the active drug (1 weight loss, 1 nausea and vomiting) 
and one patient had an intercurrent pneumonia unrelated to therapy. Two patients were 
withdrawn because of inadequate compliance, one with drug therapy and one with 
seizure monitoring (see Table 27).
Median (range) numbers of GTCS and partial seizures at each stage of the trial are shown 
in Table 28. Median numbers of total seizures and seizure days are shown in Figures 67 
and 68. There were no differences between nimodipine and the placebo preparation at 
any stage. The numbers of patients achieving a 50% or 25% drop in GTCS, partial 
seizures or seizure-days on either preparation is shown in Table 29. Again, there were no 
differences between active drug and placebo. Patient-preference was ascertained before 
coding was broken. Nine preferred nimodipine, 3 preferred placebo and 5 expressed no 
preference. This difference is not statistically significant (P=0.073, binomial test).
Mean concentrations of concomitant AEDs are shown in Table 30. Although all three 
drugs exhibited slightly higher concentrations while patients were taking nimodipine, no 
statistically significant differences were seen.
Nimodipine concentrations were generally low throughout the study. Afternoon peak 
concentrations on 60 mg tds were 6.77 + 3.0 ug/L (mean + SD, range 2.6 - 13.9 ug/L) 
while those at 90 mg tds were only marginally higher at 7.83 + 2.0 ug/L (range 4.8 - 11.5 
ug/L). There was no correlation between nimodipine concentrations and seizure control.
Mean systolic blood pressures were slightly lower at peak nimodipine concentrations 
(0900h, 1600h) than at similar times on placebo (difference = 3mm mercury) or at 
baseline (5-7 mm mercury), but these differences were not significant. There were no
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TABLE 28 NIMODIPINE TRIAL
Median seizure frequency (range) in 17 patients on active 
drug and placebo
PARTIAL 
1st month 
2nd month 
3rd month 
TOTAL
TONIC-CLONIC 
1st month 
2nd month 
3rd month 
TOTAL
ACTIVE
4 (0 - 48)
5 (0 - 75) 
7 (0 - 43)
1 8 (0 -1 6 5 )
1 (0 - 26) 
2 (0 - 19) 
0 (0 - 44)
5 (0 - 100)
PLACEBO 
4 (0 - 42)
4 (0 - 43)
6 (0 - 40) 
1 4 (0 -1 1 9 )
0 (0 - 15)
0 (0 - 30)
1 (0 - 14)
2 (0 - 48)
Active drug (nimodipine 20mg tds, 60mg tds, 90mg tds each for a month) 
and matched placebo in ransom order for 12 weeks
TA BLE 29 P atien ts achieving 25%  (50% ) fall in seizure frequency 
from  baseline
1ST M ON TH 2ND M O N TH 3RD M O N TH TO TA L
Active Placebo Active Placbo Active Placebo Active Placi
PARTIAL* 10 7 6 8 10 8 9 6
SEIZURES (6) (6) (6) (5) (7) (4) (7) (5)
TONIC-** 4 3 4 4 4 4 5 4
CLONIC (4) (3) (1) (3) (2) (1) (1) (1)
SEIZURE*** 9 7 5 6 7 6 7 7
DAYS (6) (4) (2) (2) (2) (1) (3) (2)
* 15 appropriate patients finished study
** 12 appropriate patients finished study
*** 20 appropriate patients finished study
TABLE 30 Anticonvulsant concentrations in 17 patients treated with 
adjuvant nimodipine or matched placebo
b Nimodipine Placebo
CBZ 13 10.6 ±  3.6 9.2 ±  3.9
PHT 7 21.9 ±  8.5 19.3 ±  8.9
VPA 4 71.1 ±  35 61.6 ±  28
Results are from the 3rd month of treatment with the highest nimodipine dose.
TABLE 31 Tolerability Scores during baseline and high dose therapy 
of nimodipine and placebo
Complaint Baseline Active high dose Placebo high dose
Sedation 5.96 5.75 4.94
Impaired concentration 6.68 5.55 6.78
Nausea 1.86 1.79 2.28
Headache 3.27 3.65 5.50
Itching 2.09 1.65 3.11
Agitation 3.27 3.00 3.67
Unsteadiness 2.27 3.20 3.11
Flushing 1.64 1.65 2.94
Palpitations 1.86 1.65 1.89
Double vision 2.91 3.00 1.56
Values are means of results on a scale from 1.0 to 20.0. Higher 
values suggest presence of side effect. There are no significant 
differences between drugs or between drug and baseline.
MEDIAN SEIZURE 
NUMBER
20- |
12-
4 -
Totat1st month 2nd month 3rd month
30mg tds 60mg Ids 90mg Ids
FIGURE 67 Comparison of total seizure numbers in 17 patients during nimodipine 
phase and placebo phase o f the study. Values are medians.There are no significant 
differences.
MEDIAN SEIZURE 
DAYS 
!5- |
(S im odip lno
1st month 2nd month 3rd month Total
30mg tds 60mg tds 90mg tds
FIGURE 68 Comparison o f seizure-days in 17 patients during nimodipine and placebo 
phases o f the study. Values are medians. There are no significant differences.
incidences of postural hypotension. Haematological and biochemical indices were 
unchanged on nimodipine therapy, and "tolerability scores" did not reveal any signicant 
side-effects (Table 31).
DISCUSSION
The dihydropyridines have been a particularly effective group of CAs in a wide variety 
of animal models of epilepsy [Morocutti et al 1986, M eyer et al 1987, De Sarro et al 
1988, Dolin et al 1988 etc.], and nimodipine has been prominent in most of these reports. 
In the present study, however, it failed to show any usefulness as an adjunctive therapy 
in a clinical setting. The power of this study, even allowing for withdrawals, was such 
that we would expect to detect an important action by NIM in this situation, but the 
results gave no suggestion of any effect, and indeed were more negative than those with 
nifedipine in EXPT. 11.
Again, there are many possible reasons for this disparity between efficacy in seizure 
models and in clinical practice. Firstly, the models may be inappropriate. Secondly, the 
dose regimen of NIM may not be optimal. Thirdly, there may be an interaction between 
NIM and other AEDs. Lastly, the anticonvulsant effect may be present, but insufficient 
to make a clinical impact as an adjuvant therapy in patients with refractory epilepsy.
With regard to the first possibility, it must be noted that NIM  has been effective in a wide 
range of seizure models, including those chemically induced with PTZ [Meyer et al 
1987, Dolin et al 1988, Moron et al 1989, O ’Neill & Bolger 1989], cefazolin [Morocutti 
et al 1986], picritoxin [Thomas 1990], kainic acid [Paczynski et al 1990] and strychnine 
[O’Neill & Bolger 1989]. Other models include electroshock seizures [Meyer et al 1990]
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and audiogenic seizures in DBA/2 mice [De Sarro et al 1988]. These and similar models 
have proven useful in investigating anticonvulsant activity with other drugs [Meldrum 
1986] and it seems unlikely that they are so inappropriate as to explain N IM ’s failure in 
this study.
As with NIF, the pharmacokinetics may be a more likely explanation. The elimination 
half-life of NIM in healthy subjects is only two hours [Ramsch et al 1986]. It has been 
used as a 4-hourly regimen in the successful treatment of subarachnoid haemorrhage 
[Allen GS et al 1983, Pickard et al 1989], but this would not be feasible in the long-term 
management of epilepsy. Thrice-daily dosage, however, has been used successfully 
following ischaemic stroke [Paci et al 1989] at a dosage of 40mg tds despite evidence 
that very little accumulation occurs at this dosage [Ramsch et al 1985]. In the present 
study, an attempt was made to overcome the rapid elimination o f NIM by increasing the 
dosage to the uppermost range of previous studies. However, even this manouevre seems 
not to have achieved its aims. All patients were taking enzyme-inducing drugs along with 
NIM. Since this drug undergoes hepatic metabolism with a large first-pass effect 
[Ramsch et al 1986], enzyme induction would be likely to reduce circulating 
concentrations in a similar fashion to the reported effects of AED induction on nifedipine 
[Breimer et al 1989] and felodipine [Capewell et al 1988]. Patients with subarachnoid 
haemorrhage who are given I-V infusions of NIM have been shown to run serum 
concentrations of 36-72 ug/L [Ramsch et al 1985], while oral dosing (60 mg tds) gave 
peak levels around 17-42 ug/L in the same study. Our subjects failed to achieve such 
levels, with maximum concentrations approximating 12 ug/L. There was no correlation 
between concentration and seizure control as was found with nifedipine in EXPT. 11, but 
the circulating concentrations may have been too low in all patients to achieve any effect.
A more fanciful suggestion would be that the doses were perhaps too high. Both EXPT. 
10C and another animal study [Thomas 1990] have shown some decrease in efficacy of
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NIM with increasing dosage. Such an event could conceivably be related to an effect on 
receptors - dihydropyridine binding sites in mice are downregulated by chronic NIF 
therapy [Panza et al 1985] - but it seems an unlikely explanation.
In addition to the pharmacokinetic interactions with AEDs, a pharmacodynamic 
interaction is also a possibility. Phenytoin [Sohn & Ferrendelli 1976, Ferrendelli & 
Daniels-McQueen 1982] and CBZ [Ferrendelli & Daniels-McQueen 1982, Crowder & 
Bradford 1987] both have calcium antagonist activity, and a detrimental interaction - 
again perhaps receptor-mediated - cannot be excluded. This would be in keeping with the 
failure of the CBZ-NIF combination therapy in EXPT. 10B.
The final possibilty again refers to the present study as well as EXPT. 11. These patients 
were taking appropriate doses of established AEDs and achieving adequate serum 
concentrations (Table 30), yet were suffering an average of 18 seizures per month. It is 
very possible that a drug with genuine anticonvulsant activity might fail to impress in 
this situation.
In summary, this trial did not suggest that NIM will be a useful adjuvant anticonvulsant, 
at least not in these doses. Failure to achieve effective circulating concentrations seems 
the most likely explanation. Further dose increments may improve its efficacy, but there 
are obvious drawbacks in using such an approach to counteract the effects of enzyme 
induction from other AEDs. A slow-release preparation could be an alternative approach, 
but the disappointing results in EXPT. 11 using the nifedipine tablet which enhances its 
bioavailability, do not support a prediction of success.
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EXPT. 13 ADENOSINE A 1 RECEPTORS IN MOUSE BRAIN: EFFECT OF 
ORAL CARBAMAZEPINE AND DIHYDROPYRIDINES
AIM
To investigate the effects of nifedipine, nimodipine and carbamazepine on adenosine A  ^
receptors in mouse cortex, cerebellum and mid-brain, and assess the likely relevance of 
any effects to their anticonvulsive properties.
METHODS
CF1 mice (Bantin & Kingman, Hull) weighing 25g were used. Each was individually 
caged and given free access to food and water. They were allocated to one o f four 
schedules -1 )  normal feed (control); 2) added NIF: 0.3 g/kg per day; 3) added NIM: 0.3 
g/kg per day; 4) added CBZ: 1 g/kg daily for three days followed by 2.25 g/kg for four 
days. These doses are similar to those effective against PTZ seizures in EXPT. 10C.
At the end of seven days’ oral treatment, the animals were killed by decapitation and 
their brains removed and dissected as outlined by Glowinski & Iverson [1966]. Brain 
stem, cerebellum and cortex were stored separately at -70 °C. Samples from two animals 
were pooled for each assay to ensure adequate protein. As all tissues could not be 
processed simultaneously, compensation for day-to-day variation was achieved by 
matching each treated pair o f animals with a pair from each other group and a control 
pair.
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Binding Assay
This was the first time that receptor assays had been performed in our laboratory. The 
assays were established "from scratch" by George Thompson (Senior Technician) and 
myself, from first principles of binding assays [Bennett & Yamamura 1985] and 
published papers. These principles, along with the mathematical theory behind them, are 
outlined in Appendix A. On occasions during the development of the assay and during 
the present study, I personally undertook each of the procedures involved in the assay. 
However, in general the assays were performed by Mr. Thompson and his staff - except 
for the computerised Scatchard and saturation isotherm analysis which I performed on all 
results.
Adenosine binding was assessed by a modification o f the method of Marangos et al 
[1987] using tritiated cyclohexyladenosine ([^H]CHA) 34.4 Ci/mmol (New England 
Nuclear). Brain tissue was thawed and homogenised (polytron setting 5) for 10 seconds 
in 25 volumes of 50 mM Tris-HCl buffer at pH 7.5. After centrifugation (30,000g at 4°C  
for 20 min), the pellet was suspended in buffer and incubated with adenosine deaminase 
(2u/ml) at 22°C  for 30 min) before further centrifugation. The pellet was finally 
resuspended in approximately 25 volumes of buffer so that the protein concentration 
(measured by a modified method of Lowrie [Peterson 1977]) was 0.6-1.5 mg/L (final 
assay concentration 0.4-1 mg/L).
The receptor assay was performed by incubating 500 ul of protein solution and 150 ul 
[%I]CHA with 100 uL buffer for total binding or with lOOul 37.5 uM "cold" CHA for 
non-specific binding.
Incubations at 6 different concentrations of [JH]CHA (0.2 nM - 29 nM) were performed 
in duplicate for estimation of dissociation constant (Kd) and receptor numbers (Bmax).
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The highest concentration (29nM) was included to ensure a suitable range [Bennett & 
Yamamura 1985] in the event of a marked increase in Kd in the treated groups, but was 
generally unneccessary. Assays were incubated for 2h at 22°C  and the reaction was 
terminated by vaccuum filtration through GF-B filters using a Brandel cell harvester (3 
washes with 4ml ice-cold buffer). Filters were dried overnight before counting in 3ml 
Emulsifier Safe Scintillin (Packard). Kd and Bmax were estimated using both Scatchard 
and Saturation isotherm analyses (Packard CA 2000 Combicept 1.1; see Appendix A).
Results were considered acceptable if correlation co-efficient on the Scatchard line was 
>0.85 and Scatchard and saturation isotherm analysis did not differ by >25%. The mean 
of Scatchard and isotherm analysis results was taken as the Kd or Bmax on each 
occasion. Preliminary experiments included eight separate assays performed on pooled 
control homogenised mouse brain which produced Kd (SD) values of 2.89 (0.24) nM 
(co-efficient of variance 8%) and Bmax (SD) of 661 (81) fmol/mg protein (co-efficient 
of variance 12%).
Statistics
Wilcoxon-Rank matched pairs analysis was used.
RESULTS
Despite tiered dosing, mice in the CBZ group were slightly lighter (mean 30.7 + SD 
1.2g, P<0.05) at the end o f one week compared with the other groups (control 32.6 + 
3.6g, NIF 32.8 + 2.3g, NIM 33.1 ±  1.6g).
In all, 120 assays were prepared, 10 from each anatomical area - brain stem, cerebellum 
and cortex - in each of the four treatment groups. O f these, 111 led to satisfactory results
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by the criteria outlined. Most unsatisfactory assays (n=7) were in brain stem where 
protein concentration was sometimes too low.
Scatchard plot correlation co-efficients ranged from 0.902 to 0.999 (mean 0.983 +
0.014). Correlation between Scatchard analysis and saturation isotherm analysis was also 
close for both Kd (r=0.96) and Bmax (r=0.99) results (Figures 69 & 70). Figure 71 
shows the Scatchard and saturation isotherm analysis of the three brain areas in the 
control mice of the tenth and final run, while an actual print-out is shown as Figure 72.
Adenosine receptors were present in much higher numbers in the cortex than the 
cerebellum (P<0.02), which in turn contained more binding sites than brain stem 
(P<0.02). These differences are illustrated for the control mice in Figure 73, although 
they were present in all treated groups. The Kds were more closely matched, but the 
mean Kd in the cortex (P<0.05) was higher than in the other areas (Figure 73).
Table 32 shows the KDs and Bmax of all three brain areas in the four treatment groups, 
and these are shown graphically in Figures 74 and 75. The increased Kd with NIM in 
brain stem failed to reach statistical significance, but both NIF (P<0.005) and NIM 
(P<0.02) increased Kd in the cerebellum. There was a trend for CBZ to increase Kd in 
the cerebellum (0.05<P<0.1) while no effect was seen in the cortex. The increased Bmax 
in brain stem with NIM also failed to reach conventional levels of statistical significance. 
Treatment with CBZ produced an increase in receptor numbers but only in the 
cerebellum (P<0.02).
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TABLE 32 Adenosine receptor Kd and Bmax in different brain areas in control mice 
and those treated with oral nifedipine, nimodipine and carbamazepine
BRAIN STEM CERERBELLUM CORTEX
Kd Bmax Kd Bmax Kd Bmax
CARBAMAZEPINE 2.09 188 2.39 280 3.12 449
(0.31) (26) (0.2) (24) (0.28) (54)
NIFEDIPINE 2.43 179 3.69** 317 3.22 371
(0.36) (27) (0.35) (24) (0.29) (54)
Values are means (SEM) of at least 7 animals.
Kd (nM) and Bmax (fmol/mg protein) were calculated using Scatchard and saturation 
isotherm analyses of [^H]CHA binding at 0.2 - 29 nM concentrations.
* P<0.02 ** P<0.005 vs controls
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FIGURE 69 Adenosine A j receptors. Graph o f dissociation constant (Kd) as calculated 
using saturation isotherm analysis vs. Scatchard analysis in 111 assays o f mouse brain 
(line o f identity shown). Results from cortex, cerebellum and brain stem o f control mice 
and those treated with nifedipine, nimodipine or carbamazepine are shown.
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FIGURE 70 Adenosine A j receptors. Graph o f total receptor number (Bmax) as 
calculated using saturation isotherm and Scatchard analysis as in Figure 69.
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single control mouse brain stem (o—o), cerebellum and cortex ( • - • ) .  Saturation
isotherm analysis Kds respectively 1.16,1.35 and 3.02nM; Bmax: 166, 337 and 430 
fmol/mg protein. Scatchard analysis Kds 1.15,1.15 and 2.73 nM; Bmax: 163,298 and 
391 fmol/mg protein.
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FIGURE 73 Adenosine A j receptor Kd and Bmax assayed by [^H]CHA binding at 
0.2-29nM. Mean o f Scatchard and saturation isotherm analyses taken as result. Results 
from control mouse brain stem, cerebellum and cortex. Vertical bars represent +SEM. 
* P<0.05; ** P<0.01; *** P<0.001 - vs. brain stem.
+ P<0.05; ++ P<0.01 - vs. cerebellum.
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FIGURE 74 Adenosine A i receptor Kd assayed by [ H]CHA binding at 0.2-29nM. 
Results from areas of mouse Drain after treatment with nifedipine, nimodipine, 
carbamazepine or control feed. Vertical bars represent +SEM.
* P<0.05; ** P<0.01 - vs. controls.
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FIGURE 75 Adenosine A j receptor Bmax in areas of mouse brain assayed after 
treatment as in Figure 74.
DISCUSSION
Interaction with the adenosine receptor in vitro has been repeatedly shown with both 
CBZ [Marangos et al 1983, Skerritt et al 1982, W eir et al 1984] and CAs, particularly the 
dihydropyridines [Murphy & Snyder 1982, Morgan et al 1987, Cheung et al 1987, Hu et 
al 1987]. In vivo, chronic treatment with CBZ increases adenosine binding in rat cortex, 
cerebellum and brain stem [Marangos et al 1985, Marangos et al 1987] with Scatchard 
analysis suggesting that this was due to an increased Bmax rather than an alteration in 
Kd. Increased receptor numbers after CBZ in various brain regions have been confirmed 
by autoradiography [Daval et al 1989].
All o f the above studies were performed in rat brain. Many used "specific binding" 
results at a single ligand concentration for comparisons between groups, with only the 
occasional Scatchard calculation of Kd or Bmax [Marangos et al 1985, Marangos et al 
1987, Cheung et al 1987, Sanders & Murray 1989]. In the present study, Kd and Bmax 
for CHA binding in mice were calculated in all cases using the two outlined methods. 
Results obtained were in a similar range to those found in rats when Scatchard analysis 
has been performed. In particular, mean Bmax in cerebellum (297 fmol/mg protein) was 
comparable to the results of Marangos et al, 1987 (251 fmol/mg protein) and to the 
recent reports of Sanders & Murray (250 fmol/mg protein) and Daval et al (325 fmol/mg 
protein). The low receptor numbers in the brain stem are also similar to previous reports 
[Marangos et al 1985, Fastbom et al 1987]. The high adenosine receptor density in 
mouse cortex differs from one binding study [Marangos et al 1987], but agrees with 
autoradiographic findings [Fastbom et al 1987]. This may be explained by the higher Kd 
(lower affinity) in the cortex, as a single-point binding assay may underestimate the 
receptor density in this site relative to the cerebellum, as can be seen from the sample 
saturation curves in Figure 71. Calculation of Bmax, as in the present study, avoids this 
problem.
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The effect of CBZ and calcium antagonists on receptor numbers seems less marked than 
in studies of rat brain. Only CBZ showed any significant effect on Bmax and then only 
on receptors in the cerebellum. Kd in this region, however, was altered by both NIF and 
NIM, and the "trend" with CBZ suggests that this drug may also produce this effect. The 
relevance of these changes is uncertain. Although only NIF is known to inhibit CHA 
binding in vitro [Morgan et al 1987], both dihydropyridines in the present study were 
seen to affect Kd in the cerebellum. Previous work would predict a change in Bmax 
rather than Kd [Marangos et al 1985]. However, adenosine agonists are known to induce 
a high-affinity receptor [Lohse et al 1984], and so the decrease in affinity which we have 
shown could possibly be associated with the antagonist action of CBZ, and an as yet 
unclassified action of the dihydropyridines.
Since the doses of the drugs used in the present study inhibit PTZ seizures in mice 
[EXPT IOC], the minimal changes in adenosine receptors suggest that such an effect is 
an incidental feature of these drugs and is not related to their anticonvulsant action. It is 
worth noting that Bay K 8644 - the calcium agonist which exacerbates seizure activity 
[Walden et al 1986] and antagonises some adenosine effects [Fredholm et al 1986] - has 
the same effect at the A^ receptor as dihydropyridine antagonists which have the 
opposite pharmacological actions [Hu et al 1987]. This argues against the drugs’ effects 
on A j receptors as being of major relevance to their main pharmacological actions. 
However, when we consider EXPT. IOC, where combination therapy of NIF an CBZ 
was poorer than either alone, and note the clinical failure of NIF and NIM in EXPTS. 11 
and 12, it is interesting to speculate that any anticonvulsant effect of CBZ which is due to 
an increase in adenosine receptor numbers might be counteracted by a decreased affinity 
induced by the dihydropyridines.
It is also possible that our global assessment of cortical binding may miss important
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localised changes. Daval et al [1989] have shown possible differentiation of CBZ effects 
on different areas of rat brain, but analysis of multiple small groups may have over­
interpreted normal experimental variation. Further autoradiographic studies may confirm 
genuine differences in different brain regions and show a relationship between effects on 
adenosine receptors in electrophysiologically important brain areas and anticonvulsant 
efficacy. However, at present the association of adenosine receptor activity and 
anticonvulsant effect remains unproven.
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CONCLUSION CHAPTER 4
CALCIUM ANTAGONISTS AND EPILEPSY
The role of calcium antagonists in the drug management of epilepsy remains uncertain. 
There is certainly a place for new AEDs, particularly if sedative side-effects can be 
shown to be reduced, thus opening up the prospect of multiple drug therapy. Small doses 
of "synergistic" drugs may increase efficacy while reducing toxicity. A long and barren 
period for new AEDs is now ending with a clutch of potential anticonvulsants trying to 
establish a place in the limited armamentarium. I have already mentioned the GABA 
transaminase inhibitor vigabatrin, but other "designer drugs" have been successful in 
early trials. Gabapentin is a further attempt to make use of the natural anticonvulsant 
effects of GABA, although it now seems that its action may not be due to GABA effects 
[Brodie & Porter 1990]. Lamotrigine attacks the other side of the excitation-inhibition 
balance by blocking the release of excitatory neurotransmitters [Brodie & Porter 1990] 
and a number of other such drugs are waiting in the wings.
As with these other drugs, there are good theoretical reasons why calcium antagonists 
should be effective in epilepsy. The arguments for calcium involvement in the release of 
excitatory neurotransmitters, with subsequent synchronisation of the "burst firing" of 
neurones are persuasive [Meyer 1989]. The abolition of such events in vitro by the 
calcium antagonists further enhances their prospects as logical anticonvulsants. It has to 
be admitted, however, that the widespread and continuing [De Sarro et al 1990] success 
of these drugs in animal models of epilepsy, including EXPT. 10, has not yet led to any 
convincing application in the clinical setting. During the work of this thesis, a number of 
clinical trials have been performed to assess the efficacy of flunarizine, the drug which 
had shown such promise in the early work of Overweg and others [e.g. Overweg et al
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1986]. One double-blind crossover study did show a small but significant drop in the 
seizure frequency of around 35% [Starreveld et al 1989], but other controlled studies 
have been less successful. Keene and his colleagues have studied young patients with 
refractory epilepsy [1989], and found more patients to have a 50% decrease in seizures 
on placebo than on the active drug. Similarly negative results were obtained in adult 
patients by Alving et al [1989]. An open study in Japan [Nakane et al 1989] also failed to 
show a convincing overall benefit, although two out of 64 patients apparently had an 
abolition of their seizures.
These findings do not necessarily mean that flunarizine has no effect on epilepsy. One of 
the negative trials [Keene et al 1989] suggested that the drug may be more effective 
against partial seizures, and the results do not exclude a small anticonvulsant effect from 
the drug. The trial of Alving and his colleagues, however, did exclude (at the 2.5% level) 
a 29% drop in seizure numbers being caused by the drug. It is likely that flunarizine does 
have some anticonvulsant efficacy, but in refractory patients it seems unable to make 
much impact on the disease.
The situation with the currently used dihydropyridines may well be similar. Following 
our successful open study of nifedipine in refractory epilepsy [EXPT. 8], other workers 
found little help from the drug in similar circumstances [Sander & Trevisol-Bittencourt
1990]. The results in the placebo-controlled trials of nifedipine [EXPT. 11] and 
nimodipine [EXPT. 12] in this thesis are also far from convincing. One might even be 
tempted to dismiss the open study as a manifestation of the placebo effect. As mentioned 
in the prologue, Esquirol in the 1840s showed similar results for up to three months with 
such remedies as bloodletting and cauterisation [Esquirol 1845]. Yet, there are one or 
two encouraging aspects of the placebo-controlled study of nifedipine. The possible 
short-term effect and the correlation between improved seizure control and serum
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concentrations of the drug, taken together with the generally low levels of nifedipine 
measured in the study, might propose a failure to achieve adequate circulating 
concentrations as the reason for the drug’s failure to significantly affect seizure control.
Nimodipine may have suffered to an even greater extent from this problem in EXPT. 12. 
Both dihydropyridines have short half-lives of well under ten hours. The enzyme 
induction caused by concomitant AEDs further reduces these, and will hinder attempts to 
achieve adequate levels. The high presystemic elimination of nimodipine may make its 
bioavailability particularly vulnerable to the effects of increased hepatic enzyme activity, 
and it is worth noting that the drug has been used successfully as an intravenous 
preparation in partial status epilepticus [Brandt et al 1988]. Using higher and higher 
doses of the dihydropyridine seems a simplistic approach to the problem of oral use.
Even if peak levels could reach those required, the short half-life will result in a rapid fall 
from these levels, causing violent swings in concentrations during the day unless very 
frequent dosing is used. A slow-release preparation might possibly be expected to offset 
this effect, but the nifedipine retard preparation used in EXPT. 11 was, at best, only 
partially successful. However, the dosage of nifedipine used was not particularly high.
The question of whether these drugs will work as useful anticonvulsants requires an 
answer. Perhaps studies of high-dose slow-release nifedipine need to be tackled. 
Alternatively, the drugs may be more successful if used along with the non-inducing 
AEDs such as sodium valproate or oxcarbazepine. Another option is the use of 
dihydropyridines with a longer half-life, and such a drug - amlodipine - has recently been 
marketed by Pfizer.
Amlodipine has a half-life in man of approximately 35 hours [Reid et al 1988]. It appears 
to be efficacious in hypertension, with a duration of action of more than 24 hours 
[Webster et al 1987]. We have performed some preliminary studies in mice using our
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PTZ model, and so far amlodipine (alcohol/water) does appear to be effective up to 6h 
after dosing. A very recent paper [O’Neill & Bolger 1990] also suggests that this drug 
may have similar anticonvulsant properties to the other dihydropyridines in animal 
models. We are in the process of setting up an h.p.l.c. assay for amlodipine, so that 
pharmacokinetic studies can be carried out in mice, and the relationship of blood and 
brain levels to any anticonvulsant effect ascertained. Hopefully, brief, dose-ranging 
pharmacokinetic studies in induced patients will presage a placebo-controlled study of 
this drug in a group of epileptic patients from our clinic. This should answer whether a 
simple pharmacokinetic interaction with inducing drugs is the reason for the relative 
failure of CAs as anticonvulsants in patients.
It is, however, possible that the problem is more complicated. The loss of efficacy with 
the combination of nifedipine and carbamazepine in EXPT. 10B (Figure 58) could not 
have been caused by enzyme induction as it was an acute study. A deliterious 
pharmacodynamic interaction may be taking place, which could involve the known 
calcium antagonist actions of CBZ [Crowder & Bradford 1987] or could involve the 
effects of the drugs on various neuroreceptors. In EXPT. 13, we were able to make a 
brief investigation of the effects of these drugs on adenosine receptors in mouse brain. 
While the importance of the CBZ effect on these receptors is only speculative, it is 
interesting to note that the effects of dihydropyridines differ from those of CBZ, and that 
the decrease in affinity caused by the calcium antagonists may go some way towards 
offsetting the increased numbers induced by CBZ.
Other receptors may be involved. The dihydropyridine receptor itself is, as expected, 
altered by chronic dihydropyridine therapy, which decreases its numbers [Panza et al 
1985]. Electroshock seizures also alter these receptors [Bolger et al 1987], and it would
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not be too fanciful to suggest that CBZ, with its calcium antagonist activity, might also 
alter the configuration or numbers of these binding sites, and thus influence the effects of 
the drugs. Studies are required o f the effects produced by each of the line AEDs on these 
binding sites, both when used alone and when used in combination with a 
dihydropyridine. There may be a selective interaction between dihydropyridines and the 
AEDs known to have calcium antagonist properties (CBZ, PHT) but not with VPA - 
another reason why this drug might turn out to be the best co-therapy with calcium 
antagonists.
Clearly, much work has still to be done, to ensure that a potential major advance in 
epilepsy therapy is not discarded because of the indifferent performance of these drugs in 
early controlled clinical trials. It may be that the initial promise of the drugs will indeed 
come to naught. However, there are clear indications from the clinical and animal studies 
in the second part of this thesis that specific problems can be identified. By manipulating 
the drugs’ pharmacokinetic profiles, or by considering the effects of concomitant AEDs, 
it is possible that these may be overcome. New dihydropyridines may be produced with 
the right pharmacokinetic profile, and provide an advance similar to that of 
oxcarbazepine over CBZ where innovations were made to improve one particular aspect 
of the drug’s profile. Amlodipine is first in line for assessment in epilepsy.
The gains which could be made in the life-style of epileptic patients by the discovery of a 
new group of non-sedative AEDs are enormous. Investigations must continue to establish 
whether calcium antagonists will fit the bill.
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GENERAL CONCLUSIONS
Epilepsy is a potentially debilitating disease. While it is only rarely life-threatening, its 
impact on the "quality of life" of the sufferer is severe - not only through the physical 
problems and the social stigma which unquestionably remains, but also through damage 
to the patient’s self-image.
Advances in understanding and treating epilepsy have been slow. A small group of drugs 
are in clinical use, and they only partially control the disease in a large minority of 
patients. In this thesis, many aspects of the pharmacology and therapeutics of epilepsy 
have been considered.
Therapeutic drug monitoring
Therapeutic drug monitoring is an attempt to rationalise the use of current antiepileptic 
drugs. However, care must be taken to avoid the thoughtless mechanisation of chasing 
"therapeutic ranges" which might paradoxically make dosage selection more irrational. 
An approach based on the concept that each patient has his own individual "therapeutic 
range", to which population studies can supply guidelines, is gaining ground, and this is 
reflected in EXPT. 1. However, the question of whether TDM improves control remains 
unanswered. No-one seems willing to tackle the necessary ’placebo’-controlled study, 
perhaps understandably in view of the inherent logistic difficulties. The attitudes of 
individual physicians, measures of outcome, financial aspects and drug toxicity are all 
problems requiring attention. Ethical considerations also make such a study difficult to 
design. It is perhaps for these reasons that we ourselves are simply following up our 
patients and comparing subsequent years with the original data presented, and have not 
undertaken a placebo-controlled trial.
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Cognitive function
Impairment of cognitive function is ubiquitous with the currently used AEDs. The more 
recent drugs, such as CBZ and VPA, appear less troublesome on formal testing, but is 
this a true reflection of their effects? Five years’experience in the epilepsy clinic would 
suggest that many patients do suffer from increased tiredness, impaired memory, or 
slowness of thought and action while taking these drugs. As demonstrated earlier [EXPT. 
2], the effect of the disease itself is a complicating factor, and the placebo side-effects of 
a patient expecting drug-induced drowsiness also requires consideration.
It may be, however, that the psychomotor tests we employ are rather stylised, 
unrepresentative of real life, and fail to detect subtle changes in patients’ abilities to 
perform daily activities. While CBZ does not significantly alter one’s appreciation of 
flickering diodes, it may convert the making of a plate of chips into a complicated and 
potentially hazardous procedure. A move towards "quality of life" testing is more than 
welcome and might show up some of the AEDs in a less favourable light. Newer drugs 
such as vigabatrin, lamotrigine, or possibly the calcium antagonists have hopefully even 
less neurotoxic side-effects than CBZ or VPA. Their use in combination may produce an 
improvement in seizure control at present unattainable in many patients.
The degree of cognitive impairment caused by the individual AEDs in epileptic patients 
remains difficult to ascertain. The proper placebo group of untreated epileptic patients 
with frequent seizures is ethically unachievable. Instead, various designs of study, each 
controlling for one aspect at a time, are performed, such as those in this thesis. Such 
studies should continue. They should include untreated epilepsy control groups as far as 
possible. They should also use patients as their own controls, changing therapies and 
allowing adequate time on each, so that short term effects (as in EXPT. 3) are not over­
interpreted. The introduction of new tests, more relevant to everyday life, is also
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advisable. One of our volunteers in the controlled-release CBZ study [EXPT. 4] 
performed all of his psychomotor testing beautifully, then rode his bicycle into the back 
of a parked car while returning home from the hospital.
Gradually, a "league-table" of cognitive impairment with AEDs could be built up. 
However, the lesson learned from TDM should be remembered. Each patient is different, 
and the least neurotoxic drug on a population basis might be the most toxic in any one 
individual, or vice-versa.
Enzyme induction
The enzyme induction caused by many AEDs is well known. The question here concerns 
its clinical relevance. Obviously, interactions with other drugs such as the contraceptive 
pill are worth avoiding, e.g. by using VPA or perhaps, in the future, oxcarbazepine. The 
effect of the latter drug when used long term in conjunction with the contraceptive pill 
requires assessment. The results of EXPT. 7 suggest that there may be no interaction, but 
specific confirmation that it does not induce oestrogen metabolism is needed before 
oxcarbazepine might be proposed as an ideal substitute for CBZ in many young female 
patients.
More doubtful is the importance of inducing AED s’ effects on the patients’ endogenous 
hormones. It seems unlikely that thyroid function is affected to any appreciable extent, 
but the accumulating reports of hyposexuality in epileptic patients may indeed relate to 
AED usage. Although a preponderance of TLE patients amongst hyposexual epileptics 
has often been reported - including a few taking no therapy - we have shown no 
biochemical hormonal upset in untreated patients. The drugs, however, certainly decrease 
the effective circulating concentrations of many hormones, and it seems likely that the 
anecdotal report of the occasional patient in the clinic "having problems" does, in some
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way, relate to AED therapy.
Our ongoing study of sexual function, mentioned in the conclusion to Chapter 3, does 
show that there are many complicating factors, including possible differences in the 
upbringing and education of people with epilepsy. This large study should pinpoint many 
of these factors, supplying new information per se, and perhaps facilitating a controlled 
study of the effects of AEDs on sexual function. Meantime, it is worth considering the 
substitution of VPA (or possibly oxcarbazepine) in patients complaining of sexual 
difficulties while taking one of the inducing drugs.
Calcium Antagonists
My conclusions concerning the calcium antagonists have been outlined in the previous 
section. It would be surprising if a group of drugs with such a good hypothetical basis, 
impressive record in animal seizures, and established clinical safety profile, did not 
produce one useful anticonvulsant. For various reasons, mainly pharmacokinetic, 
nifedipine and nimodipine may not be viable as AEDs, but the dihydropyridines remain a 
promising group, and amlodipine will be receiving close scrutiny in our unit in the near 
future.
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APPENDIX A
RECEPTOR BINDING ASSAYS 
T heory
The principle behind receptor binding assays is that the kinetics of ligand-receptor 
binding are similar to those of enzyme-substrate reactions i.e.
k+l
[L] + [R] _______* [LR]
k-1 .............................................................. (!)
where [L] = free ligand concentration
[R] = unoccupied receptor concentration
[LR] = ligand-receptor complex concentration
At equilibrium :
k+i [L] [R] = k.l [LR] -----------------------------------------------(2)
A measure of the affinity of the receptor can be defined as the equilibrium 
association binding constant = Ka
K a  =  K + J _  =  [LR]
K - 1  [L] [R]
or more usually as the dissociation constant = Kd
Kd = J L i  = [LI 1111---------------- -----------------------------------------------(3)
K +1 [LR]
Kd thus refers to the tendency for the ligand-receptor complex to come apart and 
from equation (3) we see that it will possess the units of concentration e.g. nM. We 
also see that a higher Kd (e.g. lOOnM as vs. lOnM) suggests a receptor of lower affinity.
By measuring bound ligand [LR] at equilibrium using different ligand concentrations [L], 
we can essentially set up a series of simultaneous equations from which the Kd and the finite 
number of receptors which a tissue has (Bmax) can be derived viz :
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Clearly [LR] + [R] = Bmax
Multiply by [L] ===> [L] [LR] + [L] [R] = Bmax [L]
Multiply segment ===> [L] [LR] + rLRl [L] [R] = Bmax [L]
b yL R  = 1 [LR]
LR
[ ]
===> [LR] [ [L] + fLl TR1 ] = Bmax [L]
[ [LR] ]
Substitute (3) ===> [LR] [ [L] + Kd] = Bmax [L]
===> [LR] = Bmax TL1  (4)
[L] + KD
More conventional terms for LR = bound ligand = B
L = free ligand = F
. ’ . B = Bmax F
F + Kd
Multiply out ===> BF + BKd = Bmax F
Divide by F ===> B + B/p Kd = Bmax
===> B/F = Bmax - B  (5)
Kd
This is the Scatchard Equation. If the bound ligand is now assayed at, for example, six
different concentrations of free ligand, then a graph of B/F (Y axis) vs B (x axis) can be
constructed. By paraphrasing equation 5 we g e t :
B/F = - 1/Kd B + 1/Kd Bmax
which, since Bmax is a relative constant, conforms to the general equation 
y = ax + b which is a straight line with slope a. Therefore, the slope of the 
straight line formed by these points is - 1/Kd (see Figure 71).
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Further, where the line crosses the x axis y = 0, i.e. B/p = 0, and by substitution in (5).
O = Bmax - B 
Kd
i.e. Bmax = B so the line crosses the x axis at Bmax.
Such Scatchard analysis has been the standard approach to interpreting binding assays to 
produce values for Kd and Bmax. There are obvious drawbacks, not least that ‘B ’ is 
present on both sides of the equation, and that variations in the assay values at low ligand 
concentration (the most difficult assays) have a disproportionately large effect on the 
calculated Kd and Bmax.
An alternative approach correlates bound ligand at equilibrium directly with free ligand 
concentrations. As the latter increases, B also increases, but not in a straight line. The 
number o f receptor sites is finite, so as ligand concentration increases, the percentage 
bound at equilibrium decreases as the dissociation reaction [L] ---> [L] + [R] be 
comes more prominent.
The curve of this ‘Saturation Isotherm ’ therefore resembles those shown in Figure 71, 
where the slope of the curve at the origin is proportional to 1/Kd (steep slope = high 
affinity, low Kd) and the B at F = infinity, is equal to Bmax. The mathematics of 
fitting such a curve to experimental points is outwith the scope of this thesis, but can be 
performed by computer programmes such as that we have available with the Packard 
2000 CA.
Assay
Experimental results which may be analysed as above are obtained using radioactive 
ligands which bind to receptors, such as tritiated cyclohexyladenosine ([3H]CHA) which 
binds to adenosine A j receptors. The tissue to be assayed is homogenised, prepared, 
then incubated with a known concentration of the ligand to allow equilibration. At 
equilibrium, the reaction is abruptly stopped by centrifugation and washing, or by rapid 
filtration and washing. The pellet or filtered remnants are then assayed, e.g. using a 
liquid scintillation counter, to measure the amount of ligand which has become bound to
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the tissue. When this has been performed at 6 different ligand concentrations under 
identical conditions (usually simultaneously) Scatchard and isotherm analysis can be 
carried out as outlined above.
A mention should be made of ‘non-specific binding’ (NSB). As well as binding to 
genuine tissue receptors, the [3H]CHA may bind non-specifically to glass, tissue 
binding sites or simply collect in various ‘holes’ in the tissue preparation. Such binding 
sites are clearly of low affinity, but are theoretically infinite so NSB increases in a linear 
fashion with increasing ligand concentration. To compensate for NSB, each reaction is 
duplicated but with the addition of ‘cold’ ligand i.e. non-tritiated CHA which being of 
much higher concentration (n x 1,000) than the [3H]CHA displaces the radioligand from 
the receptors. However, the binding of [3H]CHA to the ‘lim itless’ NSB sites is 
relatively unaffected. This gives a result which is a measure of the NSB and can be 
subtracted from the assay reaction results to give a truer estimate of ‘specific 
binding’. This final estimate is the one used in Scatchard and saturation isotherm 
analysis.
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APPENDIX B
As the work o f this thesis has progressed over four to five years, many extracts have 
been presented to learned societies, or published in scientific journals.
Presentations to Learned Societies EXPT.
1. Anticonvulsant monitoring at the epilepsy clinic. A 1 
prospective study.
Larkin JG*, McGuire GM, Percy-Robb I, Brodie MJ 
British Pharmacol Soc December 1987 
Abs. Brit J Clin Pharmacol 1988: 25; 627p
2. Anticonvulsants and psychomotor function. 2
Brodie MJ, McPhail E, Macphee GJA, Larkin JG*, Grey JMB 
British Pharmacol Soc December 1986
3. Comparison of conventional and sustained-release 4
carbamazepine in healthy subjects.
Larkin JG*, McLellan AR, Munday A, Sutherland M,
Butler E, Brodie MJ
International League Against Epilepsy May 1987
4. Hormonal abnormalities in male epileptic patients taking 5
anticonvulsants.
M acphee GJA*, Larkin JG, Beastall G, Brodie MJ 
Scottish Soc Exp Medicine May 1987
5. Effects of antiepileptic drugs on thyroid hormones. 6
Larkin JG*, Macphee GJA, Beastall GH, Brodie MJ
British Pharmacol Soc December 1988 (Poster)
Abs. Brit J Clin Pharmacol 1989: 27; 668p
6. Evidence of lack of auto- and hetero-induction with the 7
novel anticonvulsant oxcarbazepine in healthy volunteers.
Larkin JG*, McKee PJW, Thompson GG et al 
British Pharmacol Soc January 1990 (Poster)
Abs. Brit J Clin Pharmac 1990: 29; 643p
7. Nifedipine in epilepsy - a preliminary report. 8
Larkin JG*, Butler E, Brodie MJ
Scottish Soc Exp Medicine February 1987
8. Calcium antagonists and epilepsy. 8, lOabc
Larkin JG*, Thompson GG, Brodie MJ
Scottish Society of Physicians
9. Nifedipine and nimodipine are effective against pentylene- lOabc
tetrazol induced seizures in mice.
Larkin JG*, Thompson GG, Brodie MJ 
British Pharmacol Soc December 1988 
Abs. Brit J Pharmacol 1989: 96; 138p
2 0 7
Blood and brain pharmacokinetics of nifedipine and 9ab, lOabc
nimodipine in CF1 mice: efficacy against pentylenetetrazol 
(PTZ) seizures.
Larkin JG*, Thompson GG, Brodie MJ 
Medical Research Soc January 1990 (Poster)
A double-blind crossover, placebo-controlled trial of 11
adjuvant nifedipine in refractory epilepsy.
Brodie MJ*, Larkin JG, Cox A, Besag FM 
British Pharmacol Soc January 1990
Placebo-controlled trial o f nimodipine in refracyory epilepsy. 12
Larkin JG, McKee PJW, Thompson GG, Brodie MJ*
North Europe Epilepsy Symposium September 1990
* denotes presenter
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Publications EXPT.
1. Larkin JG, McGuire GM, Herrick A, Percy-Robb I, 1
Brodie MJ
Therapeutic drug monitoring at the epilepsy clinic 
Epilepsia 1991 (in press)
2. Brodie MJ, McPhail E, M acphee GJA, Larkin JG, 2
Gray JMB
Psychomotor impairment and anticonvulsant therapy in adult 
epilepsy patients.
Eur J Clin Pharmacol 1987: 31; 655-660
3. Larkin JG, McLellan A, Munday A, Sutherland M, 4
Butler E, Brodie MJ
A double-blind comparison of conventional and controlled- 
release carbamazepine in healthy subjects.
Brit J Clin Pharmacol 1989: 27; 313-322
4. Macphee GJA, Larkin JG, Butler E, Beastall GH, Brodie MJ 5
Circulating hormones and pituitary responsiveness in young 
epileptic men receiving long-term antiepileptic medication. 
Epilepsia 1988: 29; 468-475
5. Larkin JG, Macphee GJA, Beastall GH, Brodie MJ 6
Thyroid hormone concentrations in epileptic patients.
Eur J Clin Pharmacol 1989: 36; 213-216
6. Larkin JG, McKee PJW, Forrest G et al 7
Lack of enzyme induction with oxcarbazepine (600mg daily)
in healthy subjects.
Brit J Clin Pharmacol 1991: 31; 65-71
7. Larkin JG, Butler E, Brodie MJ 8
Nifedipine for epilepsy? A pilot study.
Brit Med J 1988: 296; 530-531
8. Larkin JG, Thompson GG, Scobie G, Drennan JE, Brodie MJ 13 
Lack of major effects on mouse brain adenosine A j 
receptors of oral carbamazepine and calcium antagonists.
Epilepsia 1991 (in press)
Reprints of those papers published before the submission of this thesis are enclosed.
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APPENDIX C
Some of my colleagues who helped to perform some of the work of this thesis have 
themselves presented their work for higher degrees.
EM McPhail
Effects of chronically administered anticonvulsants on psychomotor performance in 
epileptic subjects (alternative analysis of EXPT. 2)
M.Sc. University of Glasgow 1985
PA Milligan
Circulating androgens and sexual function in male epileptics (first 50 male subjects in 
Sexual function study  p. 108)
M.Sc. University of Glsagow 1987
VC MacKay
Circulating oestrogens and sexual function in female epileptics (first 50 female subjects 
in Sexual function study p. 108)
M.Sc. University of Strathclyde 1988
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